{"4e14cd688f83bf362a74659f8c02a1e01956dad9": [["Introduction:The coronavirus disease 2019 pandemic has led to a number of challenges in provision of patient care, performance of clinical assessment and communication with families [1] .Introduction:Protocols have been developed to prioritize safety, maximize efficiency, and focus on judicious use of resources without compromising quality of care [1] .Introduction:Covid-19 is currently a prominent cause of death worldwide, with a death toll of over 320,000 reported as of May 22, 2020 [2] .", [["coronavirus disease", "DISEASE", 17, 36], ["death", "DISEASE", 411, 416], ["death", "DISEASE", 435, 440], ["coronavirus", "ORGANISM", 17, 28], ["patient", "ORGANISM", 101, 108], ["patient", "SPECIES", 101, 108], ["The coronavirus disease", "PROBLEM", 13, 36], ["clinical assessment", "TEST", 130, 149], ["Protocols", "TREATMENT", 200, 209], ["death", "PROBLEM", 411, 416], ["coronavirus disease", "OBSERVATION", 17, 36]]], ["Although Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has been associated with conditions that can lead to brain death such as multi-organ damage, anoxic brain injury, and ischemic and hemorrhagic stroke [3, 4] , the unique considerations associated with catastrophic brain injury and death by neurologic criteria in this patient population have not been examined.Introduction:Here, we discuss our experience assessing patients with Covid-19 with catastrophic brain injuries and declaring brain death.Methods:We describe the evaluation of six patients hospitalized at New York University Langone Health associated hospitals in April 2020 who had Covid-19, were comatose and had absent brainstem reflexes.Methods:Of note, two of these patients were previously described by Carroll and Lewis in a case series on multifocal intracerebral hemorrhage in patients with Covid-19 who were treated with empiric anticoagulation [5] .Description of cases:Four men and two women with a median age of 58.5 (IQR 47-68) were admitted to the hospital for respiratory distress secondary to Covid-19 and were intubated (see Table) .", [["brain", "ANATOMY", 133, 138], ["multi-organ", "ANATOMY", 153, 164], ["brain", "ANATOMY", 180, 185], ["brain", "ANATOMY", 294, 299], ["neurologic", "ANATOMY", 320, 330], ["brain", "ANATOMY", 486, 491], ["brain", "ANATOMY", 515, 520], ["brainstem", "ANATOMY", 711, 720], ["intracerebral", "ANATOMY", 847, 860], ["respiratory", "ANATOMY", 1065, 1076], ["Acute Respiratory Syndrome", "DISEASE", 16, 42], ["infection", "DISEASE", 70, 79], ["brain death", "DISEASE", 133, 144], ["multi-organ damage", "DISEASE", 153, 171], ["brain injury", "DISEASE", 180, 192], ["ischemic and hemorrhagic stroke", "DISEASE", 198, 229], ["brain injury", "DISEASE", 294, 306], ["death", "DISEASE", 311, 316], ["brain injuries", "DISEASE", 486, 500], ["brain death", "DISEASE", 515, 526], ["comatose", "DISEASE", 687, 695], ["intracerebral hemorrhage", "DISEASE", 847, 871], ["respiratory distress", "DISEASE", 1065, 1085], ["SARS-CoV-2", "ORGANISM", 58, 68], ["brain", "ORGAN", 133, 138], ["multi-organ", "ORGAN", 153, 164], ["brain", "ORGAN", 180, 185], ["brain", "ORGAN", 294, 299], ["patient", "ORGANISM", 348, 355], ["patients", "ORGANISM", 445, 453], ["brain", "ORGAN", 486, 491], ["brain", "ORGAN", 515, 520], ["patients", "ORGANISM", 569, 577], ["brainstem", "ORGANISM_SUBDIVISION", 711, 720], ["patients", "ORGANISM", 760, 768], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 847, 860], ["patients", "ORGANISM", 875, 883], ["men", "ORGANISM", 975, 978], ["women", "ORGANISM", 987, 992], ["patient", "SPECIES", 348, 355], ["patients", "SPECIES", 445, 453], ["patients", "SPECIES", 569, 577], ["patients", "SPECIES", 760, 768], ["patients", "SPECIES", 875, 883], ["men", "SPECIES", 975, 978], ["women", "SPECIES", 987, 992], ["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2", "SPECIES", 9, 68], ["Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 9, 54], ["SARS", "PROBLEM", 58, 62], ["CoV", "TEST", 63, 66], ["infection", "PROBLEM", 70, 79], ["brain death", "PROBLEM", 133, 144], ["multi-organ damage", "PROBLEM", 153, 171], ["anoxic brain injury", "PROBLEM", 173, 192], ["ischemic and hemorrhagic stroke", "PROBLEM", 198, 229], ["catastrophic brain injury", "PROBLEM", 281, 306], ["death", "PROBLEM", 311, 316], ["neurologic criteria", "TEST", 320, 339], ["catastrophic brain injuries", "PROBLEM", 473, 500], ["brain death", "PROBLEM", 515, 526], ["the evaluation", "TEST", 547, 561], ["Covid", "TEST", 672, 677], ["absent brainstem reflexes", "PROBLEM", 704, 729], ["multifocal intracerebral hemorrhage", "PROBLEM", 836, 871], ["Covid", "TEST", 889, 894], ["empiric anticoagulation", "TREATMENT", 920, 943], ["respiratory distress", "PROBLEM", 1065, 1085], ["Covid", "TEST", 1099, 1104], ["intubated", "TREATMENT", 1117, 1126], ["Severe", "OBSERVATION_MODIFIER", 9, 15], ["Acute", "OBSERVATION_MODIFIER", 16, 21], ["Respiratory Syndrome", "OBSERVATION", 22, 42], ["multi-organ", "ANATOMY", 153, 164], ["damage", "OBSERVATION", 165, 171], ["anoxic brain injury", "OBSERVATION", 173, 192], ["ischemic", "OBSERVATION_MODIFIER", 198, 206], ["hemorrhagic", "OBSERVATION_MODIFIER", 211, 222], ["stroke", "OBSERVATION", 223, 229], ["considerations associated with", "UNCERTAINTY", 250, 280], ["catastrophic", "OBSERVATION_MODIFIER", 281, 293], ["brain", "ANATOMY", 294, 299], ["injury", "OBSERVATION", 300, 306], ["brain", "ANATOMY", 486, 491], ["injuries", "OBSERVATION", 492, 500], ["brain", "ANATOMY", 515, 520], ["death", "OBSERVATION", 521, 526], ["brainstem reflexes", "OBSERVATION", 711, 729], ["multifocal", "OBSERVATION_MODIFIER", 836, 846], ["intracerebral", "OBSERVATION_MODIFIER", 847, 860], ["hemorrhage", "OBSERVATION", 861, 871], ["respiratory", "ANATOMY", 1065, 1076], ["distress", "OBSERVATION", 1077, 1085]]], ["Neurology was consulted J o u r n a l P r e -p r o o f for catastrophic brain injury at a median of 14 days (IQR 13-18) after admission due to 1) global anoxic injury after cardiac arrest (n=2); 2) multifocal intracerebral hemorrhage with diffuse cerebral edema and brain compression (n=2); 3) global anoxic injury after cardiac arrest and catastrophic cerebellar hemorrhage with diffuse cerebral edema and brain compression (n=1); and 4) brainstem and cerebellar infarction followed by global hypoxic-ischemic injury (n=1).", [["brain", "ANATOMY", 72, 77], ["cardiac", "ANATOMY", 173, 180], ["intracerebral", "ANATOMY", 209, 222], ["cerebral", "ANATOMY", 247, 255], ["brain", "ANATOMY", 266, 271], ["cardiac", "ANATOMY", 321, 328], ["cerebellar", "ANATOMY", 353, 363], ["cerebral", "ANATOMY", 388, 396], ["brain", "ANATOMY", 407, 412], ["brainstem", "ANATOMY", 439, 448], ["cerebellar", "ANATOMY", 453, 463], ["brain injury", "DISEASE", 72, 84], ["cardiac arrest", "DISEASE", 173, 187], ["intracerebral hemorrhage", "DISEASE", 209, 233], ["cerebral edema", "DISEASE", 247, 261], ["brain compression", "DISEASE", 266, 283], ["anoxic injury", "DISEASE", 301, 314], ["cardiac arrest", "DISEASE", 321, 335], ["cerebellar hemorrhage", "DISEASE", 353, 374], ["cerebral edema", "DISEASE", 388, 402], ["brain compression", "DISEASE", 407, 424], ["cerebellar infarction", "DISEASE", 453, 474], ["hypoxic-ischemic injury", "DISEASE", 494, 517], ["brain", "ORGAN", 72, 77], ["cerebral edema", "PATHOLOGICAL_FORMATION", 247, 261], ["brain", "ORGAN", 266, 271], ["cerebellar", "ORGAN", 353, 363], ["cerebral edema", "PATHOLOGICAL_FORMATION", 388, 402], ["brain", "ORGAN", 407, 412], ["brainstem", "ORGAN", 439, 448], ["cerebellar", "ORGAN", 453, 463], ["catastrophic brain injury", "PROBLEM", 59, 84], ["IQR", "TEST", 109, 112], ["global anoxic injury", "PROBLEM", 146, 166], ["cardiac arrest", "PROBLEM", 173, 187], ["multifocal intracerebral hemorrhage", "PROBLEM", 198, 233], ["diffuse cerebral edema", "PROBLEM", 239, 261], ["brain compression", "PROBLEM", 266, 283], ["global anoxic injury", "PROBLEM", 294, 314], ["cardiac arrest", "PROBLEM", 321, 335], ["catastrophic cerebellar hemorrhage", "PROBLEM", 340, 374], ["diffuse cerebral edema", "PROBLEM", 380, 402], ["brain compression (n=1); and 4) brainstem and cerebellar infarction", "PROBLEM", 407, 474], ["global hypoxic-ischemic injury", "PROBLEM", 487, 517], ["brain", "ANATOMY", 72, 77], ["injury", "OBSERVATION", 78, 84], ["anoxic", "OBSERVATION_MODIFIER", 153, 159], ["injury", "OBSERVATION", 160, 166], ["cardiac", "ANATOMY", 173, 180], ["arrest", "OBSERVATION", 181, 187], ["multifocal", "OBSERVATION_MODIFIER", 198, 208], ["intracerebral", "ANATOMY", 209, 222], ["hemorrhage", "OBSERVATION", 223, 233], ["diffuse", "OBSERVATION_MODIFIER", 239, 246], ["cerebral", "ANATOMY", 247, 255], ["edema", "OBSERVATION", 256, 261], ["brain", "ANATOMY", 266, 271], ["compression", "OBSERVATION", 272, 283], ["anoxic", "OBSERVATION_MODIFIER", 301, 307], ["injury", "OBSERVATION", 308, 314], ["cardiac", "ANATOMY", 321, 328], ["arrest", "OBSERVATION", 329, 335], ["catastrophic", "OBSERVATION_MODIFIER", 340, 352], ["cerebellar", "ANATOMY", 353, 363], ["hemorrhage", "OBSERVATION", 364, 374], ["diffuse", "OBSERVATION_MODIFIER", 380, 387], ["cerebral", "ANATOMY", 388, 396], ["edema", "OBSERVATION", 397, 402], ["brain", "ANATOMY", 407, 412], ["compression", "OBSERVATION", 413, 424], ["brainstem", "ANATOMY", 439, 448], ["cerebellar", "ANATOMY", 453, 463], ["infarction", "OBSERVATION", 464, 474], ["global", "OBSERVATION_MODIFIER", 487, 493], ["hypoxic", "OBSERVATION_MODIFIER", 494, 501], ["ischemic", "OBSERVATION_MODIFIER", 502, 510], ["injury", "OBSERVATION", 511, 517]]], ["All patients had been on sedatives or narcotics due to ventilator dyssynchrony and these had been discontinued for a median of 2.5 days (IQR 1-4) at the time of neurology consultation.", [["ventilator dyssynchrony", "DISEASE", 55, 78], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["sedatives", "TREATMENT", 25, 34], ["narcotics", "TREATMENT", 38, 47], ["ventilator dyssynchrony", "PROBLEM", 55, 78], ["neurology consultation", "TEST", 161, 183]]], ["Five patients had received paralytics previously, but no paralytics had been administered for a median of 8 days (IQR 5-8) prior to the consult.", [["paralytics", "DISEASE", 57, 67], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["paralytics", "TREATMENT", 27, 37], ["paralytics", "TREATMENT", 57, 67]]], ["All patients were on vasopressors at the time of the consult.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["vasopressors", "TREATMENT", 21, 33]]], ["Labs were notable for a median creatinine of 2.17mg/dL (IQR 1.5-4.8), pH of 7.35 (IQR 7.26-7.38), PaO 2 of 125 mm Hg (IQR 106-148) and PaCO 2 of 41.5 mmHg (IQR 40-43.5).", [["creatinine", "CHEMICAL", 31, 41], ["creatinine", "CHEMICAL", 31, 41], ["Hg", "CHEMICAL", 114, 116], ["Labs", "GENE_OR_GENE_PRODUCT", 0, 4], ["creatinine", "SIMPLE_CHEMICAL", 31, 41], ["Labs", "TEST", 0, 4], ["a median creatinine", "TEST", 22, 41], ["IQR", "TEST", 56, 59], ["pH", "TEST", 70, 72], ["IQR", "TEST", 82, 85], ["PaO", "TEST", 98, 101], ["Hg", "TEST", 114, 116], ["IQR", "TEST", 118, 121], ["PaCO", "TEST", 135, 139], ["mmHg", "TEST", 150, 154], ["IQR", "TEST", 156, 159]]], ["All patients were unresponsive; had absent pupillary, corneal, oculovestibular, cough, and gag reflexes; and did not move their extremities to any stimuli.", [["corneal", "ANATOMY", 54, 61], ["oculovestibular", "ANATOMY", 63, 78], ["extremities", "ANATOMY", 128, 139], ["cough", "DISEASE", 80, 85], ["patients", "ORGANISM", 4, 12], ["corneal", "TISSUE", 54, 61], ["extremities", "ORGANISM_SUBDIVISION", 128, 139], ["patients", "SPECIES", 4, 12], ["unresponsive", "PROBLEM", 18, 30], ["cough", "TEST", 80, 85], ["gag reflexes", "TEST", 91, 103], ["any stimuli", "TEST", 143, 154], ["pupillary", "OBSERVATION", 43, 52], ["corneal", "ANATOMY", 54, 61]]], ["Non-contrast computed tomography (CT) of the head was obtained in five patients, but one patient who had anoxic injury after cardiac arrest was too unstable to be transported for brain imaging.", [["head", "ANATOMY", 45, 49], ["cardiac", "ANATOMY", 125, 132], ["brain", "ANATOMY", 179, 184], ["anoxic injury", "DISEASE", 105, 118], ["cardiac arrest", "DISEASE", 125, 139], ["head", "ORGAN", 45, 49], ["patients", "ORGANISM", 71, 79], ["patient", "ORGANISM", 89, 96], ["brain", "ORGAN", 179, 184], ["patients", "SPECIES", 71, 79], ["patient", "SPECIES", 89, 96], ["Non-contrast computed tomography (CT) of the head", "TEST", 0, 49], ["anoxic injury", "PROBLEM", 105, 118], ["cardiac arrest", "PROBLEM", 125, 139], ["brain imaging", "TEST", 179, 192], ["head", "ANATOMY", 45, 49], ["cardiac", "ANATOMY", 125, 132], ["arrest", "OBSERVATION", 133, 139]]], ["Formal apnea testing was performed for only one patient and was aborted due to hypoxia and hypotension; it was not attempted for the remaining 5 patients due to concern for inability to tolerate testing (n=2), decision to withdraw support (n=2) and observation of spontaneous respirations (n=1).", [["apnea", "DISEASE", 7, 12], ["hypoxia", "DISEASE", 79, 86], ["hypotension", "DISEASE", 91, 102], ["respirations", "DISEASE", 276, 288], ["patient", "ORGANISM", 48, 55], ["patients", "ORGANISM", 145, 153], ["patient", "SPECIES", 48, 55], ["patients", "SPECIES", 145, 153], ["Formal apnea testing", "TEST", 0, 20], ["hypoxia", "PROBLEM", 79, 86], ["hypotension", "PROBLEM", 91, 102], ["testing", "TEST", 195, 202], ["spontaneous respirations", "PROBLEM", 264, 288], ["hypoxia", "OBSERVATION", 79, 86], ["hypotension", "OBSERVATION", 91, 102]]], ["Ancillary testing was performed in three patients after which death by neurological criteria was declared.", [["death", "DISEASE", 62, 67], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["Ancillary testing", "TEST", 0, 17]]], ["Death was declared by cardiopulmonary criteria in the other three patients (two of whom had support withdrawn and one of whom had a cardiopulmonary arrest).", [["Death", "DISEASE", 0, 5], ["cardiopulmonary arrest", "DISEASE", 132, 154], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["a cardiopulmonary arrest", "TREATMENT", 130, 154], ["cardiopulmonary", "ANATOMY", 132, 147], ["arrest", "OBSERVATION", 148, 154]]], ["Despite pandemic conditions, a family member was able to visit five of the six patients prior to cardiopulmonary arrest/discontinuation of organ support.Discussion:Assessment of patients with catastrophic brain injuries and determination of brain death can be challenging under ordinary conditions, but the unique medical and social circumstances of the Covid-19 J o u r n a l P r e -p r o o f Journal Pre-proof pandemic exacerbate this further.", [["cardiopulmonary", "ANATOMY", 97, 112], ["organ", "ANATOMY", 139, 144], ["brain", "ANATOMY", 205, 210], ["brain", "ANATOMY", 241, 246], ["cardiopulmonary arrest", "DISEASE", 97, 119], ["brain injuries", "DISEASE", 205, 219], ["brain death", "DISEASE", 241, 252], ["patients", "ORGANISM", 79, 87], ["organ", "ORGAN", 139, 144], ["patients", "ORGANISM", 178, 186], ["brain", "ORGAN", 205, 210], ["brain", "ORGAN", 241, 246], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 178, 186], ["cardiopulmonary arrest", "TREATMENT", 97, 119], ["organ support", "TREATMENT", 139, 152], ["catastrophic brain injuries", "PROBLEM", 192, 219], ["brain death", "PROBLEM", 241, 252], ["cardiopulmonary", "ANATOMY", 97, 112], ["arrest", "OBSERVATION", 113, 119], ["brain", "ANATOMY", 205, 210], ["injuries", "OBSERVATION", 211, 219], ["brain", "ANATOMY", 241, 246]]], ["Here, we discuss the issues we faced in assessing six patients with Covid-19 who developed catastrophic brain injuries.", [["brain", "ANATOMY", 104, 109], ["brain injuries", "DISEASE", 104, 118], ["patients", "ORGANISM", 54, 62], ["brain", "ORGAN", 104, 109], ["patients", "SPECIES", 54, 62], ["catastrophic brain injuries", "PROBLEM", 91, 118], ["catastrophic", "OBSERVATION_MODIFIER", 91, 103], ["brain", "ANATOMY", 104, 109], ["injuries", "OBSERVATION", 110, 118]]], ["While only 3 of these patients were ultimately declared dead based on neurologic criteria, the other 3 had catastrophic irreversible brain damage prompting us to carefully consider whether they could be declared dead using neurologic criteria.Determination of irreversible brain damage:A prerequisite to the determination of brain death is the identification of the proximate cause and irreversibility of injury.", [["brain", "ANATOMY", 133, 138], ["neurologic", "ANATOMY", 223, 233], ["brain", "ANATOMY", 273, 278], ["brain", "ANATOMY", 325, 330], ["brain damage", "DISEASE", 133, 145], ["brain damage", "DISEASE", 273, 285], ["brain death", "DISEASE", 325, 336], ["patients", "ORGANISM", 22, 30], ["brain", "ORGAN", 133, 138], ["brain", "ORGAN", 273, 278], ["brain", "ORGAN", 325, 330], ["patients", "SPECIES", 22, 30], ["dead", "PROBLEM", 56, 60], ["neurologic criteria", "TEST", 70, 89], ["catastrophic irreversible brain damage", "PROBLEM", 107, 145], ["irreversible brain damage", "PROBLEM", 260, 285], ["brain death", "PROBLEM", 325, 336], ["injury", "PROBLEM", 405, 411], ["catastrophic", "OBSERVATION_MODIFIER", 107, 119], ["irreversible", "OBSERVATION_MODIFIER", 120, 132], ["brain", "ANATOMY", 133, 138], ["damage", "OBSERVATION", 139, 145], ["irreversible", "OBSERVATION_MODIFIER", 260, 272], ["brain", "ANATOMY", 273, 278], ["damage", "OBSERVATION", 279, 285], ["brain", "ANATOMY", 325, 330], ["death", "OBSERVATION", 331, 336], ["injury", "OBSERVATION", 405, 411]]], ["The exact mechanism by which Covid-19 affects the central nervous system remains largely unknown, but direct and indirect pathways of injury have been proposed.", [["central nervous system", "ANATOMY", 50, 72], ["Covid-19", "CHEMICAL", 29, 37], ["Covid-19", "CHEMICAL", 29, 37], ["Covid-19", "GENE_OR_GENE_PRODUCT", 29, 37], ["central nervous system", "ANATOMICAL_SYSTEM", 50, 72], ["Covid-19", "PROTEIN", 29, 37], ["Covid", "TEST", 29, 34], ["injury", "PROBLEM", 134, 140], ["central", "ANATOMY_MODIFIER", 50, 57], ["nervous system", "ANATOMY", 58, 72], ["injury", "OBSERVATION", 134, 140]]], ["SARS-CoV-2 enters cells using ACE2 receptors, which are expressed in the brain and may facilitate direct damage to the cardiorespiratory center in the brainstem through trans-synaptic migration of the virus from the respiratory system [6, 7] .", [["cells", "ANATOMY", 18, 23], ["brain", "ANATOMY", 73, 78], ["brainstem", "ANATOMY", 151, 160], ["synaptic", "ANATOMY", 175, 183], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["cells", "CELL", 18, 23], ["ACE2", "GENE_OR_GENE_PRODUCT", 30, 34], ["brain", "ORGAN", 73, 78], ["brainstem", "ORGAN", 151, 160], ["ACE2 receptors", "PROTEIN", 30, 44], ["SARS", "TEST", 0, 4], ["ACE2 receptors", "TREATMENT", 30, 44], ["direct damage to the cardiorespiratory center", "PROBLEM", 98, 143], ["brain", "ANATOMY", 73, 78], ["synaptic migration", "OBSERVATION", 175, 193], ["respiratory system", "ANATOMY", 216, 234]]], ["Indirect damage to the central nervous system may occur from induction of proinflammatory cytokines in the glial cells of the brain and spinal cord, disruption to the coagulation cascade or cerebral hypoxic and ischemic injury secondary to prolonged shock and refractory hypoxia [8, 9] .", [["central nervous system", "ANATOMY", 23, 45], ["glial cells", "ANATOMY", 107, 118], ["brain", "ANATOMY", 126, 131], ["spinal cord", "ANATOMY", 136, 147], ["cerebral", "ANATOMY", 190, 198], ["ischemic injury", "DISEASE", 211, 226], ["shock", "DISEASE", 250, 255], ["hypoxia", "DISEASE", 271, 278], ["central nervous system", "ANATOMICAL_SYSTEM", 23, 45], ["glial cells", "CELL", 107, 118], ["brain", "ORGAN", 126, 131], ["spinal cord", "ORGAN", 136, 147], ["cerebral", "ORGAN", 190, 198], ["proinflammatory cytokines", "PROTEIN", 74, 99], ["glial cells", "CELL_TYPE", 107, 118], ["Indirect damage to the central nervous system", "PROBLEM", 0, 45], ["proinflammatory cytokines in the glial cells of the brain and spinal cord", "PROBLEM", 74, 147], ["the coagulation cascade", "PROBLEM", 163, 186], ["cerebral hypoxic and ischemic injury", "PROBLEM", 190, 226], ["prolonged shock", "PROBLEM", 240, 255], ["refractory hypoxia", "PROBLEM", 260, 278], ["damage", "OBSERVATION", 9, 15], ["central", "ANATOMY_MODIFIER", 23, 30], ["nervous system", "ANATOMY", 31, 45], ["proinflammatory cytokines", "OBSERVATION", 74, 99], ["glial cells", "OBSERVATION", 107, 118], ["brain", "ANATOMY", 126, 131], ["spinal cord", "ANATOMY", 136, 147], ["coagulation", "OBSERVATION", 167, 178], ["cerebral", "ANATOMY", 190, 198], ["hypoxic", "OBSERVATION_MODIFIER", 199, 206], ["ischemic", "OBSERVATION_MODIFIER", 211, 219], ["prolonged", "OBSERVATION_MODIFIER", 240, 249], ["shock", "OBSERVATION", 250, 255], ["refractory", "OBSERVATION_MODIFIER", 260, 270], ["hypoxia", "OBSERVATION", 271, 278]]], ["All of our patients had some component of anoxic injury; four also had severe edema and brain compression due to ischemic or hemorrhagic stroke.", [["edema", "ANATOMY", 78, 83], ["brain", "ANATOMY", 88, 93], ["anoxic injury", "DISEASE", 42, 55], ["edema", "DISEASE", 78, 83], ["brain compression", "DISEASE", 88, 105], ["ischemic or hemorrhagic stroke", "DISEASE", 113, 143], ["patients", "ORGANISM", 11, 19], ["edema", "PATHOLOGICAL_FORMATION", 78, 83], ["brain", "ORGAN", 88, 93], ["patients", "SPECIES", 11, 19], ["anoxic injury", "PROBLEM", 42, 55], ["severe edema", "PROBLEM", 71, 83], ["brain compression", "PROBLEM", 88, 105], ["ischemic or hemorrhagic stroke", "PROBLEM", 113, 143], ["component", "OBSERVATION_MODIFIER", 29, 38], ["anoxic injury", "OBSERVATION", 42, 55], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["edema", "OBSERVATION", 78, 83], ["brain", "ANATOMY", 88, 93], ["compression", "OBSERVATION", 94, 105], ["ischemic", "OBSERVATION_MODIFIER", 113, 121], ["hemorrhagic", "OBSERVATION_MODIFIER", 125, 136], ["stroke", "OBSERVATION", 137, 143]]], ["Notably, while knowledge of the mechanism for catastrophic brain injury is required to make a determination of brain death, neuroimaging is not mandated [10] .", [["brain", "ANATOMY", 59, 64], ["brain", "ANATOMY", 111, 116], ["brain injury", "DISEASE", 59, 71], ["brain death", "DISEASE", 111, 122], ["brain", "ORGAN", 59, 64], ["brain", "ORGAN", 111, 116], ["catastrophic brain injury", "PROBLEM", 46, 71], ["brain death", "PROBLEM", 111, 122], ["neuroimaging", "TEST", 124, 136], ["brain", "ANATOMY", 59, 64], ["injury", "OBSERVATION", 65, 71]]], ["Due to hemodynamic instability, we were only able to obtain imaging in five of the six patients; one patient had anoxic injury after cardiac arrest and was too unstable to be transported for brain imaging.Determination of irreversible brain damage:Prior to the assessment of catastrophic brain injury and determination of brain death, it is necessary to ensure the condition is irreversible by excluding confounding factors such as hypothermia, drug intoxication, neuromuscular blockade, or metabolic abnormalities.", [["cardiac", "ANATOMY", 133, 140], ["brain", "ANATOMY", 191, 196], ["brain", "ANATOMY", 235, 240], ["brain", "ANATOMY", 288, 293], ["brain", "ANATOMY", 322, 327], ["neuromuscular", "ANATOMY", 464, 477], ["anoxic injury", "DISEASE", 113, 126], ["cardiac arrest", "DISEASE", 133, 147], ["brain damage", "DISEASE", 235, 247], ["brain injury", "DISEASE", 288, 300], ["brain death", "DISEASE", 322, 333], ["hypothermia", "DISEASE", 432, 443], ["neuromuscular blockade", "DISEASE", 464, 486], ["metabolic abnormalities", "DISEASE", 491, 514], ["patients", "ORGANISM", 87, 95], ["patient", "ORGANISM", 101, 108], ["brain", "ORGAN", 191, 196], ["brain", "ORGAN", 235, 240], ["brain", "ORGAN", 288, 293], ["brain", "ORGAN", 322, 327], ["patients", "SPECIES", 87, 95], ["patient", "SPECIES", 101, 108], ["hemodynamic instability", "PROBLEM", 7, 30], ["imaging", "TEST", 60, 67], ["anoxic injury", "PROBLEM", 113, 126], ["cardiac arrest", "PROBLEM", 133, 147], ["brain imaging", "TEST", 191, 204], ["irreversible brain damage", "PROBLEM", 222, 247], ["the assessment", "TEST", 257, 271], ["catastrophic brain injury", "PROBLEM", 275, 300], ["brain death", "PROBLEM", 322, 333], ["confounding factors", "PROBLEM", 404, 423], ["hypothermia", "PROBLEM", 432, 443], ["drug intoxication", "PROBLEM", 445, 462], ["neuromuscular blockade", "PROBLEM", 464, 486], ["metabolic abnormalities", "PROBLEM", 491, 514], ["hemodynamic instability", "OBSERVATION", 7, 30], ["injury", "OBSERVATION", 120, 126], ["cardiac", "ANATOMY", 133, 140], ["arrest", "OBSERVATION", 141, 147], ["irreversible brain damage", "OBSERVATION", 222, 247], ["catastrophic", "OBSERVATION_MODIFIER", 275, 287], ["brain", "ANATOMY", 288, 293], ["injury", "OBSERVATION", 294, 300], ["hypothermia", "OBSERVATION", 432, 443], ["metabolic abnormalities", "OBSERVATION", 491, 514]]], ["Although patients with Covid-19 are often febrile, hypothermia is uncommon and less likely to be a confounding factor [11] .", [["febrile", "DISEASE", 42, 49], ["hypothermia", "DISEASE", 51, 62], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["Covid", "TEST", 23, 28], ["febrile", "PROBLEM", 42, 49], ["hypothermia", "PROBLEM", 51, 62], ["hypothermia", "OBSERVATION", 51, 62]]], ["In contrast, the impact of drugs on patients with Covid-19 is an important consideration; a large proportion of Covid-J o u r n a l P r e -p r o o f 19 patients have unusually high sedation requirements and receive multiple sedating agents for prolonged periods of time [12] .", [["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 152, 160], ["drugs", "TREATMENT", 27, 32], ["unusually high sedation requirements", "PROBLEM", 166, 202], ["multiple sedating agents", "TREATMENT", 215, 239], ["high sedation", "OBSERVATION", 176, 189]]], ["There are no uniform recommendations for the use of toxicology tests in patients who have previously received sedating drugs to ensure these medications are no longer impacting the neurologic assessment, but the American Academy of Neurology advises clinicians to wait at least 5 halflives (assuming normothermia and normal hepatic and renal function) after discontinuation of sedation prior to evaluating a patient for brain death [10] .", [["neurologic", "ANATOMY", 181, 191], ["hepatic", "ANATOMY", 324, 331], ["renal", "ANATOMY", 336, 341], ["brain", "ANATOMY", 420, 425], ["brain death", "DISEASE", 420, 431], ["patients", "ORGANISM", 72, 80], ["hepatic", "MULTI-TISSUE_STRUCTURE", 324, 331], ["renal", "ORGAN", 336, 341], ["patient", "ORGANISM", 408, 415], ["brain", "ORGAN", 420, 425], ["patients", "SPECIES", 72, 80], ["patient", "SPECIES", 408, 415], ["toxicology tests", "TEST", 52, 68], ["sedating drugs", "TREATMENT", 110, 124], ["these medications", "TREATMENT", 135, 152], ["the neurologic assessment", "TEST", 177, 202], ["normothermia", "TREATMENT", 300, 312], ["sedation", "TREATMENT", 377, 385], ["brain death", "PROBLEM", 420, 431], ["no", "UNCERTAINTY", 10, 12], ["uniform", "OBSERVATION_MODIFIER", 13, 20], ["hepatic", "ANATOMY", 324, 331], ["renal", "ANATOMY", 336, 341]]], ["Similarly, patients with Covid-19 often require paralytics to manage ventilator dyssynchrony.", [["ventilator dyssynchrony", "DISEASE", 69, 92], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["Covid", "TEST", 25, 30], ["paralytics", "TREATMENT", 48, 58], ["ventilator dyssynchrony", "PROBLEM", 69, 92], ["ventilator dyssynchrony", "OBSERVATION", 69, 92]]], ["The ongoing effects of paralytics can be excluded using train-of-four testing or by assessing for the presence of deep tendon reflexes [13] .", [["tendon", "ANATOMY", 119, 125], ["paralytics", "DISEASE", 23, 33], ["tendon", "ORGANISM_SUBDIVISION", 119, 125], ["paralytics", "TREATMENT", 23, 33], ["four testing", "TEST", 65, 77], ["deep tendon reflexes", "PROBLEM", 114, 134], ["deep", "ANATOMY_MODIFIER", 114, 118], ["tendon", "ANATOMY", 119, 125]]], ["Patients with Covid-19 also develop multiorgan failure which must be considered prior to assessment for catastrophic brain injury and determination of brain death [14] .", [["multiorgan", "ANATOMY", 36, 46], ["brain", "ANATOMY", 117, 122], ["brain", "ANATOMY", 151, 156], ["multiorgan failure", "DISEASE", 36, 54], ["brain injury", "DISEASE", 117, 129], ["brain death", "DISEASE", 151, 162], ["Patients", "ORGANISM", 0, 8], ["multiorgan", "ORGAN", 36, 46], ["brain", "ORGAN", 117, 122], ["brain", "ORGAN", 151, 156], ["Patients", "SPECIES", 0, 8], ["Covid", "TEST", 14, 19], ["multiorgan failure", "PROBLEM", 36, 54], ["assessment", "TEST", 89, 99], ["catastrophic brain injury", "PROBLEM", 104, 129], ["brain death", "PROBLEM", 151, 162], ["multiorgan", "ANATOMY", 36, 46], ["failure", "OBSERVATION", 47, 54], ["brain", "ANATOMY", 117, 122], ["injury", "OBSERVATION", 123, 129]]], ["Alterations in hepatic and renal function can change the pharmacokinetics of drugs resulting in protracted effects of sedative and paralytic agents [15] .", [["hepatic", "ANATOMY", 15, 22], ["renal", "ANATOMY", 27, 32], ["hepatic", "MULTI-TISSUE_STRUCTURE", 15, 22], ["renal", "ORGAN", 27, 32], ["Alterations in hepatic and renal function", "PROBLEM", 0, 41], ["the pharmacokinetics of drugs", "TREATMENT", 53, 82], ["sedative", "TREATMENT", 118, 126], ["paralytic agents", "TREATMENT", 131, 147], ["hepatic", "ANATOMY", 15, 22], ["renal", "ANATOMY", 27, 32], ["function", "OBSERVATION", 33, 41]]], ["Moreover, metabolic acidosis and hyperkalemia secondary to kidney injury increase the likelihood for hemodynamic instability and cardiac arrhythmias during apnea testing [16] .Neurological examinationThe diagnosis of brain death is primarily clinical, and consists of three essential findings:Neurological examinationirreversible coma, absence of brainstem reflexes, and apnea [17].", [["kidney", "ANATOMY", 59, 65], ["cardiac", "ANATOMY", 129, 136], ["brain", "ANATOMY", 217, 222], ["brainstem", "ANATOMY", 347, 356], ["metabolic acidosis", "DISEASE", 10, 28], ["hyperkalemia", "DISEASE", 33, 45], ["kidney injury", "DISEASE", 59, 72], ["cardiac arrhythmias", "DISEASE", 129, 148], ["apnea", "DISEASE", 156, 161], ["brain death", "DISEASE", 217, 228], ["coma", "DISEASE", 330, 334], ["absence of brainstem reflexes", "DISEASE", 336, 365], ["apnea", "DISEASE", 371, 376], ["kidney", "ORGAN", 59, 65], ["cardiac", "ORGAN", 129, 136], ["brain", "ORGAN", 217, 222], ["brainstem", "ORGANISM_SUBDIVISION", 347, 356], ["metabolic acidosis", "PROBLEM", 10, 28], ["hyperkalemia", "PROBLEM", 33, 45], ["kidney injury", "PROBLEM", 59, 72], ["hemodynamic instability", "PROBLEM", 101, 124], ["cardiac arrhythmias", "PROBLEM", 129, 148], ["apnea testing", "TEST", 156, 169], ["Neurological examination", "TEST", 176, 200], ["brain death", "PROBLEM", 217, 228], ["Neurological examinationirreversible coma", "TEST", 293, 334], ["brainstem reflexes", "PROBLEM", 347, 365], ["apnea", "PROBLEM", 371, 376], ["metabolic acidosis", "OBSERVATION", 10, 28], ["hyperkalemia", "OBSERVATION", 33, 45], ["kidney", "ANATOMY", 59, 65], ["injury", "OBSERVATION", 66, 72], ["hemodynamic instability", "OBSERVATION", 101, 124], ["cardiac", "ANATOMY", 129, 136], ["arrhythmias", "OBSERVATION", 137, 148], ["brain", "ANATOMY", 217, 222], ["death", "OBSERVATION", 223, 228]]], ["Although we were able to perform the neurological examination of our patients, it should be noted that, in the setting of the pandemic, performance of a neurological examination may be impacted by limitations in personal protective equipment and fear of spreading infection.Apnea testThe apnea test is used to assess for loss of function of the medullary chemoreceptors when performing a determination of brain death.", [["neurological", "ANATOMY", 153, 165], ["medullary chemoreceptors", "ANATOMY", 345, 369], ["brain", "ANATOMY", 405, 410], ["infection", "DISEASE", 264, 273], ["Apnea", "DISEASE", 274, 279], ["apnea", "DISEASE", 288, 293], ["brain death", "DISEASE", 405, 416], ["patients", "ORGANISM", 69, 77], ["medullary chemoreceptors", "MULTI-TISSUE_STRUCTURE", 345, 369], ["brain", "ORGAN", 405, 410], ["patients", "SPECIES", 69, 77], ["the neurological examination", "TEST", 33, 61], ["the pandemic", "PROBLEM", 122, 134], ["a neurological examination", "TEST", 151, 177], ["personal protective equipment", "TREATMENT", 212, 241], ["spreading infection", "PROBLEM", 254, 273], ["Apnea test", "TEST", 274, 284], ["The apnea test", "TEST", 284, 298], ["loss of function of the medullary chemoreceptors", "PROBLEM", 321, 369], ["brain death", "PROBLEM", 405, 416], ["spreading", "OBSERVATION_MODIFIER", 254, 263], ["infection", "OBSERVATION", 264, 273], ["medullary", "ANATOMY", 345, 354]]], ["In a positive apnea test, there is no respiratory response to hypercarbia, defined as a PaCO2 >60 mmHg or 20 mmHg greater than baseline [10] .", [["respiratory", "ANATOMY", 38, 49], ["apnea", "DISEASE", 14, 19], ["hypercarbia", "DISEASE", 62, 73], ["a positive apnea test", "TEST", 3, 24], ["respiratory response", "PROBLEM", 38, 58], ["hypercarbia", "PROBLEM", 62, 73], ["a PaCO2", "TEST", 86, 93], ["positive apnea", "OBSERVATION", 5, 19], ["no", "UNCERTAINTY", 35, 37], ["respiratory response", "OBSERVATION", 38, 58], ["hypercarbia", "OBSERVATION", 62, 73]]], ["Although there is J o u r n a l P r e -p r o o f Journal Pre-proof no international consensus on the apnea test procedure, most protocols require disconnection of a patient from the ventilator prior to observation for spontaneous respirations.", [["apnea", "DISEASE", 101, 106], ["patient", "ORGANISM", 165, 172], ["patient", "SPECIES", 165, 172], ["the apnea test procedure", "TREATMENT", 97, 121], ["the ventilator", "TREATMENT", 178, 192], ["spontaneous respirations", "PROBLEM", 218, 242], ["respirations", "OBSERVATION", 230, 242]]], ["This procedure is safe if a patient has a normal pH, is preoxygenated well, is euvolemic and is normotensive [18] .Apnea testThere are two major concerns when considering performance of the apnea test in patients with Covid-19.", [["Apnea", "DISEASE", 115, 120], ["apnea", "DISEASE", 190, 195], ["patient", "ORGANISM", 28, 35], ["patients", "ORGANISM", 204, 212], ["patient", "SPECIES", 28, 35], ["patients", "SPECIES", 204, 212], ["This procedure", "TREATMENT", 0, 14], ["normotensive", "PROBLEM", 96, 108], ["Apnea test", "TEST", 115, 125], ["the apnea test", "TEST", 186, 200], ["Covid", "TEST", 218, 223], ["normal", "OBSERVATION", 42, 48], ["euvolemic", "OBSERVATION", 79, 88]]], ["First, many patients with acute respiratory failure due to Covid-19 require high positive endexpiratory pressures (PEEP) to maintain adequate alveolar recruitment and oxygen exchange.Apnea testDisconnecting the ventilator can lead to de-recruitment of alveoli leading to hypoxia and hypotension and may even result in lung collapse.", [["respiratory", "ANATOMY", 32, 43], ["alveolar", "ANATOMY", 142, 150], ["alveoli", "ANATOMY", 252, 259], ["lung", "ANATOMY", 318, 322], ["acute respiratory failure", "DISEASE", 26, 51], ["oxygen", "CHEMICAL", 167, 173], ["Apnea", "DISEASE", 183, 188], ["hypoxia", "DISEASE", 271, 278], ["hypotension", "DISEASE", 283, 294], ["lung collapse", "DISEASE", 318, 331], ["oxygen", "CHEMICAL", 167, 173], ["patients", "ORGANISM", 12, 20], ["alveolar", "MULTI-TISSUE_STRUCTURE", 142, 150], ["oxygen", "SIMPLE_CHEMICAL", 167, 173], ["alveoli", "MULTI-TISSUE_STRUCTURE", 252, 259], ["lung", "ORGAN", 318, 322], ["patients", "SPECIES", 12, 20], ["acute respiratory failure", "PROBLEM", 26, 51], ["Covid", "TEST", 59, 64], ["high positive endexpiratory pressures", "TREATMENT", 76, 113], ["PEEP", "TREATMENT", 115, 119], ["oxygen exchange", "TREATMENT", 167, 182], ["Apnea", "PROBLEM", 183, 188], ["the ventilator", "TREATMENT", 207, 221], ["alveoli", "PROBLEM", 252, 259], ["hypoxia", "PROBLEM", 271, 278], ["hypotension", "PROBLEM", 283, 294], ["lung collapse", "PROBLEM", 318, 331], ["acute", "OBSERVATION_MODIFIER", 26, 31], ["respiratory failure", "OBSERVATION", 32, 51], ["pressures", "OBSERVATION_MODIFIER", 104, 113], ["adequate", "OBSERVATION_MODIFIER", 133, 141], ["alveolar recruitment", "OBSERVATION", 142, 162], ["oxygen exchange", "OBSERVATION", 167, 182], ["hypoxia", "OBSERVATION", 271, 278], ["hypotension", "OBSERVATION", 283, 294], ["lung", "ANATOMY", 318, 322], ["collapse", "OBSERVATION", 323, 331]]], ["Second, the primary method of transmission of SARS-CoV-2 is by droplet spread, and disconnection of the ventilator system generates aerosols, thus increasing the risk of transmission of viral particles [19] .", [["SARS", "DISEASE", 46, 50], ["SARS-CoV", "SPECIES", 46, 54], ["SARS", "PROBLEM", 46, 50], ["CoV", "TEST", 51, 54], ["droplet spread", "PROBLEM", 63, 77], ["disconnection of the ventilator system", "PROBLEM", 83, 121], ["viral particles", "PROBLEM", 186, 201], ["droplet spread", "OBSERVATION", 63, 77], ["ventilator system", "OBSERVATION", 104, 121]]], ["A modified apnea test that does not require disconnection from the ventilator system, such as the one proposed by Ahlawat et al., is therefore preferred in these patients, as it prevents high-risk aerosolization of viral particles during this procedure [20] .Apnea testDue to concern for hemodynamic instability, apnea testing was deferred in two of the three patients who were determined dead by neurologic criteria.", [["neurologic", "ANATOMY", 397, 407], ["apnea", "DISEASE", 11, 16], ["Apnea", "DISEASE", 259, 264], ["hemodynamic instability", "DISEASE", 288, 311], ["apnea", "DISEASE", 313, 318], ["patients", "ORGANISM", 162, 170], ["patients", "ORGANISM", 360, 368], ["patients", "SPECIES", 162, 170], ["patients", "SPECIES", 360, 368], ["A modified apnea test", "TEST", 0, 21], ["the ventilator system", "TREATMENT", 63, 84], ["viral particles", "PROBLEM", 215, 230], ["this procedure", "TREATMENT", 238, 252], ["Apnea test", "TEST", 259, 269], ["hemodynamic instability", "PROBLEM", 288, 311], ["apnea testing", "TEST", 313, 326], ["apnea", "OBSERVATION", 11, 16], ["viral particles", "OBSERVATION", 215, 230]]], ["In the third, apnea testing was attempted using a t-piece and PEEP valve, but it needed to be aborted after 90 seconds because the patient developed hypoxia and hypotension, likely caused by de-recruitment of alveoli after disconnecting the ventilator.Ancillary testsAn ancillary test is not routinely required for brain death determination, but it may be indicated to supplement the clinical examination and apnea test when extenuating circumstances preclude performance of a complete brain death examination.", [["alveoli", "ANATOMY", 209, 216], ["brain", "ANATOMY", 315, 320], ["brain", "ANATOMY", 486, 491], ["apnea", "DISEASE", 14, 19], ["hypoxia", "DISEASE", 149, 156], ["hypotension", "DISEASE", 161, 172], ["death", "DISEASE", 321, 326], ["apnea", "DISEASE", 409, 414], ["brain death", "DISEASE", 486, 497], ["patient", "ORGANISM", 131, 138], ["alveoli", "MULTI-TISSUE_STRUCTURE", 209, 216], ["brain", "ORGAN", 315, 320], ["brain", "ORGAN", 486, 491], ["patient", "SPECIES", 131, 138], ["apnea testing", "TEST", 14, 27], ["a t-piece", "TREATMENT", 48, 57], ["PEEP valve", "TREATMENT", 62, 72], ["hypoxia", "PROBLEM", 149, 156], ["hypotension", "PROBLEM", 161, 172], ["alveoli", "PROBLEM", 209, 216], ["disconnecting the ventilator", "TREATMENT", 223, 251], ["Ancillary tests", "TEST", 252, 267], ["An ancillary test", "TEST", 267, 284], ["brain death determination", "TEST", 315, 340], ["the clinical examination", "TEST", 380, 404], ["apnea test", "TEST", 409, 419], ["a complete brain death examination", "TEST", 475, 509], ["PEEP valve", "OBSERVATION", 62, 72], ["hypoxia", "OBSERVATION", 149, 156], ["hypotension", "OBSERVATION", 161, 172], ["likely caused", "UNCERTAINTY", 174, 187], ["alveoli", "OBSERVATION", 209, 216]]], ["The ancillary tests used in the confirmation of brain death represent two principles: confirmation of loss of bioelectrical activity of the brain using electroencephalography (EEG) or demonstration of cerebral circulatory arrest using neuroimaging (transcranial Doppler ultrasonography [TCD], 4-vessel diagnostic digital subtraction angiography [DSA], or cerebral scintigraphy [radionuclide brain scan]) [10, 21, 22] .", [["brain", "ANATOMY", 48, 53], ["brain", "ANATOMY", 140, 145], ["cerebral", "ANATOMY", 201, 209], ["cerebral", "ANATOMY", 355, 363], ["brain", "ANATOMY", 391, 396], ["brain death", "DISEASE", 48, 59], ["cerebral circulatory arrest", "DISEASE", 201, 228], ["brain", "ORGAN", 48, 53], ["brain", "ORGAN", 140, 145], ["vessel", "MULTI-TISSUE_STRUCTURE", 295, 301], ["cerebral", "ORGAN", 355, 363], ["brain", "ORGAN", 391, 396], ["The ancillary tests", "TEST", 0, 19], ["brain death", "PROBLEM", 48, 59], ["loss of bioelectrical activity of the brain", "PROBLEM", 102, 145], ["electroencephalography (EEG", "TEST", 152, 179], ["cerebral circulatory arrest", "PROBLEM", 201, 228], ["neuroimaging (transcranial Doppler ultrasonography", "TEST", 235, 285], ["TCD", "TEST", 287, 290], ["diagnostic digital subtraction angiography", "TEST", 302, 344], ["DSA", "TEST", 346, 349], ["cerebral scintigraphy", "TEST", 355, 376], ["radionuclide brain scan", "TEST", 378, 401], ["brain", "ANATOMY", 48, 53], ["brain", "ANATOMY", 140, 145], ["cerebral circulatory", "ANATOMY", 201, 221], ["vessel", "ANATOMY", 295, 301], ["cerebral", "ANATOMY", 355, 363]]], ["These tests require considerable technical J o u r n a l P r e -p r o o f expertise and are prone to artifact.", [["These tests", "TEST", 0, 11], ["artifact", "OBSERVATION", 101, 109]]], ["However, these tests are necessary to declare brain death in patients with Covid-19 who cannot complete apnea testing.Electro-diagnostic testsCerebral cortical inactivity can be confirmed when a 30-minute EEG recording of good quality shows complete electrocerebral silence, defined as no cerebral activity greater than 2 \uf06dV [23] .", [["brain", "ANATOMY", 46, 51], ["cortical", "ANATOMY", 151, 159], ["electrocerebral", "ANATOMY", 250, 265], ["cerebral", "ANATOMY", 289, 297], ["brain death", "DISEASE", 46, 57], ["apnea", "DISEASE", 104, 109], ["brain", "ORGAN", 46, 51], ["patients", "ORGANISM", 61, 69], ["cortical", "MULTI-TISSUE_STRUCTURE", 151, 159], ["cerebral", "ORGAN", 289, 297], ["patients", "SPECIES", 61, 69], ["these tests", "TEST", 9, 20], ["brain death", "PROBLEM", 46, 57], ["apnea testing", "TEST", 104, 117], ["Electro", "TEST", 118, 125], ["a 30-minute EEG", "TEST", 193, 208], ["cerebral activity", "TEST", 289, 306], ["no", "UNCERTAINTY", 286, 288], ["cerebral", "ANATOMY", 289, 297]]], ["There are several disadvantages to interpretation of an EEG in a critically ill patient with Covid-19.", [["critically ill", "DISEASE", 65, 79], ["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87], ["an EEG", "TEST", 53, 59], ["Covid", "TEST", 93, 98]]], ["Heavy sedation used in these patients to prevent ventilator dyssynchrony can produce unreliable false positive readings.", [["ventilator dyssynchrony", "DISEASE", 49, 72], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["Heavy sedation", "TREATMENT", 0, 14], ["ventilator dyssynchrony", "PROBLEM", 49, 72], ["unreliable false positive readings", "PROBLEM", 85, 119], ["positive readings", "OBSERVATION", 102, 119]]], ["Other factors which may lead to false positive readings in this population include toxic or metabolic abnormalities and electrical artifacts caused by ambient electromagnetic fields [22] .", [["Other factors", "PROBLEM", 0, 13], ["false positive readings", "PROBLEM", 32, 55], ["toxic or metabolic abnormalities", "PROBLEM", 83, 115], ["electrical artifacts", "PROBLEM", 120, 140], ["toxic", "OBSERVATION_MODIFIER", 83, 88]]], ["EEG has also been criticized due to the potential failure to detect subcortical and brainstem activity resulting in a flat EEG in patients with preserved brainstem function [22] .", [["subcortical", "ANATOMY", 68, 79], ["brainstem", "ANATOMY", 84, 93], ["brainstem", "ANATOMY", 154, 163], ["subcortical", "MULTI-TISSUE_STRUCTURE", 68, 79], ["brainstem", "ORGAN", 84, 93], ["patients", "ORGANISM", 130, 138], ["brainstem", "ORGAN", 154, 163], ["EEG", "PROTEIN", 0, 3], ["patients", "SPECIES", 130, 138], ["EEG", "TEST", 0, 3], ["the potential failure", "PROBLEM", 36, 57], ["subcortical and brainstem activity", "PROBLEM", 68, 102], ["a flat EEG", "TEST", 116, 126], ["subcortical", "ANATOMY_MODIFIER", 68, 79], ["brainstem activity", "OBSERVATION", 84, 102]]], ["Additionally, care must be taken when bringing an EEG into the room of a patient who has COVID-19 due to the risk of contamination of equipment and nosocomial spread of disease.Electro-diagnostic testsDespite these deficiencies, an EEG can readily be obtained at the bedside and does not require transport of the patient out of the ICU.", [["patient", "ORGANISM", 73, 80], ["patient", "ORGANISM", 313, 320], ["patient", "SPECIES", 73, 80], ["patient", "SPECIES", 313, 320], ["an EEG", "TEST", 47, 53], ["COVID", "TEST", 89, 94], ["nosocomial spread of disease", "PROBLEM", 148, 176], ["these deficiencies", "PROBLEM", 209, 227], ["an EEG", "TEST", 229, 235], ["nosocomial", "OBSERVATION", 148, 158]]], ["As a result, an EEG was used as an ancillary test for brain death determination for two of our patients.NeuroimagingThe gold standard test to assess for cerebral blood flow is invasive 4-vessel angiography, but noninvasive modalities are available.", [["brain", "ANATOMY", 54, 59], ["cerebral", "ANATOMY", 153, 161], ["blood", "ANATOMY", 162, 167], ["vessel", "ANATOMY", 187, 193], ["brain death", "DISEASE", 54, 65], ["brain", "ORGAN", 54, 59], ["patients", "ORGANISM", 95, 103], ["cerebral blood", "MULTI-TISSUE_STRUCTURE", 153, 167], ["vessel", "MULTI-TISSUE_STRUCTURE", 187, 193], ["patients", "SPECIES", 95, 103], ["an EEG", "TEST", 13, 19], ["an ancillary test", "TEST", 32, 49], ["brain death determination", "TEST", 54, 79], ["Neuroimaging", "TEST", 104, 116], ["The gold standard test", "TEST", 116, 138], ["cerebral blood flow", "TEST", 153, 172], ["vessel angiography", "TEST", 187, 205], ["noninvasive modalities", "TEST", 211, 233], ["vessel", "ANATOMY", 187, 193]]], ["Patients with Covid-19 are frequently too hemodynamically unstable to be out of the ICU for a protracted period, if at all.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["Covid", "TEST", 14, 19], ["hemodynamically unstable", "PROBLEM", 42, 66]]], ["TCD can conveniently be performed at the bedside, so this test was utilized for one of our patients.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["this test", "TEST", 53, 62]]], ["Other imaging modalities such as computed tomography perfusion (CTP) or angiography (CTA) are sometimes used to assess for cerebral blood flow, but these studies have pitfalls so they are not included in the American Academy of Neurology Practice Parameter J o u r n a l P r e -p r o o f on Determination of Death by Neurologic Criteria; however, CTA is included in the New York State Department of Health Guidelines for Determining Brain Death [10, 24] .", [["cerebral blood", "ANATOMY", 123, 137], ["Brain", "ANATOMY", 433, 438], ["Death", "DISEASE", 308, 313], ["Brain Death", "DISEASE", 433, 444], ["cerebral blood", "MULTI-TISSUE_STRUCTURE", 123, 137], ["Brain", "ORGAN", 433, 438], ["Other imaging modalities", "TEST", 0, 24], ["computed tomography perfusion (CTP)", "TEST", 33, 68], ["angiography (CTA)", "TEST", 72, 89], ["cerebral blood flow", "TEST", 123, 142], ["these studies", "TEST", 148, 161], ["CTA", "TEST", 347, 350]]], ["One of our patients had a CTA and a CTP.Communication with families about catastrophic brain injuryIn ordinary circumstances, it can be daunting to discuss catastrophic brain injury and introduce the potential for brain death determination with a patient's family.", [["brain", "ANATOMY", 87, 92], ["brain", "ANATOMY", 169, 174], ["brain", "ANATOMY", 214, 219], ["CTP", "DISEASE", 36, 39], ["brain injury", "DISEASE", 87, 99], ["brain injury", "DISEASE", 169, 181], ["brain death", "DISEASE", 214, 225], ["CTP", "CHEMICAL", 36, 39], ["patients", "ORGANISM", 11, 19], ["brain", "ORGAN", 87, 92], ["brain", "ORGAN", 169, 174], ["brain", "ORGAN", 214, 219], ["patient", "ORGANISM", 247, 254], ["patients", "SPECIES", 11, 19], ["patient", "SPECIES", 247, 254], ["a CTA", "TEST", 24, 29], ["a CTP", "TEST", 34, 39], ["catastrophic brain injury", "PROBLEM", 74, 99], ["catastrophic brain injury", "PROBLEM", 156, 181], ["brain", "ANATOMY", 87, 92], ["injury", "OBSERVATION", 93, 99]]], ["A family's acceptance of brain death is dependent upon their understanding of brain death.", [["brain", "ANATOMY", 25, 30], ["brain", "ANATOMY", 78, 83], ["brain death", "DISEASE", 25, 36], ["brain death", "DISEASE", 78, 89], ["brain", "ORGAN", 25, 30], ["brain", "ORGAN", 78, 83], ["brain death", "PROBLEM", 25, 36], ["brain death", "PROBLEM", 78, 89], ["brain", "ANATOMY", 25, 30], ["death", "OBSERVATION", 31, 36], ["brain", "ANATOMY", 78, 83], ["death", "OBSERVATION", 84, 89]]], ["Clear effective communication is imperative; having a poor comprehension of brain death and the impact of catastrophic brain injuries can put families at increased risk for complicated grief [25, 26] .", [["brain", "ANATOMY", 76, 81], ["brain", "ANATOMY", 119, 124], ["brain death", "DISEASE", 76, 87], ["brain injuries", "DISEASE", 119, 133], ["grief", "DISEASE", 185, 190], ["brain", "ORGAN", 76, 81], ["brain", "ORGAN", 119, 124], ["brain death", "PROBLEM", 76, 87], ["catastrophic brain injuries", "PROBLEM", 106, 133], ["brain", "ANATOMY", 76, 81], ["catastrophic", "OBSERVATION_MODIFIER", 106, 118], ["brain", "ANATOMY", 119, 124], ["injuries", "OBSERVATION", 125, 133]]], ["Before the Covid-19 pandemic, these conversations were held face-to-face with a patient's family, and family members were allowed time to grieve with their loved one at the bedside.", [["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87]]], ["In response to the highly contagious nature of Covid-19, the New York State Department of Health established new security protocols which prohibited visitors to hospitalized patients as a disease containment measure except in the setting of imminent death [27] .", [["death", "DISEASE", 250, 255], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182], ["new security protocols", "TREATMENT", 109, 131], ["a disease containment measure", "TREATMENT", 186, 215], ["imminent death", "PROBLEM", 241, 255]]], ["Under normal circumstances, palliative care, social work and chaplaincy often mediate these discussions, but due to the surge of deaths during the pandemic, these services became strained and scarcely available.Communication with families about catastrophic brain injuryLimited interaction between the clinical staff and a patient's family, as well as between the family and the patient themselves, may result in delayed acceptance of catastrophic brain injury and brain death.Communication with families about catastrophic brain injuryFor the families of the three patients who were declared dead by cardiopulmonary criteria, education about catastrophic brain injury and the concern for brain death through serial conversations over the phone culminated in the decision to proceed with palliative extubation for two patients and to change code status to do-not-resuscitate and await cardiopulmonary arrest in the third patient who was still taking spontaneous respirations.", [["brain", "ANATOMY", 258, 263], ["brain", "ANATOMY", 448, 453], ["brain", "ANATOMY", 465, 470], ["brain", "ANATOMY", 524, 529], ["brain", "ANATOMY", 656, 661], ["brain", "ANATOMY", 689, 694], ["deaths", "DISEASE", 129, 135], ["brain injury", "DISEASE", 448, 460], ["brain death", "DISEASE", 465, 476], ["brain injury", "DISEASE", 524, 536], ["brain injury", "DISEASE", 656, 668], ["brain death", "DISEASE", 689, 700], ["cardiopulmonary arrest", "DISEASE", 885, 907], ["brain", "ORGAN", 258, 263], ["patient", "ORGANISM", 323, 330], ["patient", "ORGANISM", 379, 386], ["brain", "ORGAN", 448, 453], ["brain", "ORGAN", 465, 470], ["brain", "ORGAN", 524, 529], ["patients", "ORGANISM", 566, 574], ["brain", "ORGAN", 656, 661], ["brain", "ORGAN", 689, 694], ["patients", "ORGANISM", 818, 826], ["patient", "ORGANISM", 921, 928], ["patient", "SPECIES", 323, 330], ["patient", "SPECIES", 379, 386], ["patients", "SPECIES", 566, 574], ["patients", "SPECIES", 818, 826], ["patient", "SPECIES", 921, 928], ["catastrophic brain injuryLimited interaction", "PROBLEM", 245, 289], ["catastrophic brain injury", "PROBLEM", 435, 460], ["brain death", "PROBLEM", 465, 476], ["catastrophic brain injury", "PROBLEM", 511, 536], ["catastrophic brain injury", "PROBLEM", 643, 668], ["brain death", "PROBLEM", 689, 700], ["palliative extubation", "TREATMENT", 788, 809], ["resuscitate", "TREATMENT", 863, 874], ["cardiopulmonary arrest", "TREATMENT", 885, 907], ["normal", "OBSERVATION", 6, 12], ["catastrophic brain injury", "OBSERVATION", 435, 460], ["brain", "ANATOMY", 465, 470], ["brain", "ANATOMY", 524, 529], ["injury", "OBSERVATION", 530, 536], ["cardiopulmonary", "ANATOMY", 885, 900], ["arrest", "OBSERVATION", 901, 907]]], ["The families of the three patients who were declared dead by neurologic J o u r n a l P r e -p r o o f Journal Pre-proof criteria doubted the dismal neurological prognosis relayed to them over the phone, expressed that they did not believe this assessment and requested further testing prompting performance of ancillary testing and delay in discontinuation of organ support after brain death determination.Communication with families about catastrophic brain injuryComprehension can be improved by allowing families to observe the neurological examination on a patient with catastrophic brain injury [26, 28] , but in the current environment, this is not easy to facilitate.", [["neurologic", "ANATOMY", 61, 71], ["neurological", "ANATOMY", 149, 161], ["organ", "ANATOMY", 361, 366], ["brain", "ANATOMY", 381, 386], ["brain", "ANATOMY", 454, 459], ["neurological", "ANATOMY", 532, 544], ["brain", "ANATOMY", 588, 593], ["brain death", "DISEASE", 381, 392], ["brain injuryComprehension", "DISEASE", 454, 479], ["brain injury", "DISEASE", 588, 600], ["patients", "ORGANISM", 26, 34], ["organ", "ORGAN", 361, 366], ["brain", "ORGAN", 381, 386], ["brain", "ORGAN", 454, 459], ["patient", "ORGANISM", 562, 569], ["brain", "ORGAN", 588, 593], ["patients", "SPECIES", 26, 34], ["patient", "SPECIES", 562, 569], ["this assessment", "TEST", 240, 255], ["further testing", "TEST", 270, 285], ["ancillary testing", "TEST", 311, 328], ["organ support", "TREATMENT", 361, 374], ["brain death determination", "TEST", 381, 406], ["catastrophic brain injuryComprehension", "PROBLEM", 441, 479], ["the neurological examination", "TEST", 528, 556], ["catastrophic brain injury", "PROBLEM", 575, 600], ["brain", "ANATOMY", 588, 593], ["injury", "OBSERVATION", 594, 600]]], ["Of the three patients who were declared brain dead, the family was able to see two in-person before the brain death determination and one prior to discontinuation of organ support.", [["brain", "ANATOMY", 40, 45], ["brain", "ANATOMY", 104, 109], ["organ", "ANATOMY", 166, 171], ["brain death", "DISEASE", 104, 115], ["patients", "ORGANISM", 13, 21], ["brain", "ORGAN", 40, 45], ["brain", "ORGAN", 104, 109], ["organ", "ORGAN", 166, 171], ["patients", "SPECIES", 13, 21], ["person", "SPECIES", 86, 92], ["the brain death determination", "TEST", 100, 129], ["organ support", "TREATMENT", 166, 179]]], ["Of the three patients who were declared dead by cardiopulmonary criteria, the family was able to see two in-person before cardiopulmonary arrest.Organ DonationThe impetus for brain death determination, just like determination of death by cardiopulmonary criteria, is the need to make a distinction between whether a patient is alive or dead [29] .", [["Organ", "ANATOMY", 145, 150], ["brain", "ANATOMY", 175, 180], ["cardiopulmonary arrest", "DISEASE", 122, 144], ["brain death", "DISEASE", 175, 186], ["death", "DISEASE", 229, 234], ["patients", "ORGANISM", 13, 21], ["brain", "ORGAN", 175, 180], ["patient", "ORGANISM", 316, 323], ["patients", "SPECIES", 13, 21], ["person", "SPECIES", 108, 114], ["patient", "SPECIES", 316, 323], ["cardiopulmonary arrest", "PROBLEM", 122, 144], ["Organ Donation", "TREATMENT", 145, 159], ["brain death determination", "TEST", 175, 200], ["death", "PROBLEM", 229, 234], ["cardiopulmonary", "ANATOMY", 122, 137], ["arrest", "OBSERVATION", 138, 144]]], ["A determination of death eliminates the need for decision-making about withdrawal of treatment and instead provides a concrete finding which is followed by distinct next steps.", [["death", "DISEASE", 19, 24], ["treatment", "TREATMENT", 85, 94]]], ["There are numerous consequences of a determination of death including the initiation of mourning and performance of ritualistic procedures.Organ DonationAdditionally, determination of death impacts taxation and criminal prosecution.", [["Organ", "ANATOMY", 139, 144], ["death", "DISEASE", 54, 59], ["death", "DISEASE", 184, 189], ["death", "PROBLEM", 54, 59], ["ritualistic procedures", "TREATMENT", 116, 138], ["death impacts taxation", "TREATMENT", 184, 206]]], ["Following a determination of brain death, organ support is discontinued.", [["brain", "ANATOMY", 29, 34], ["organ", "ANATOMY", 42, 47], ["brain death", "DISEASE", 29, 40], ["brain", "ORGAN", 29, 34], ["organ", "ORGAN", 42, 47], ["brain death", "PROBLEM", 29, 40], ["organ support", "TREATMENT", 42, 55], ["brain", "ANATOMY", 29, 34], ["death", "OBSERVATION", 35, 40]]], ["This facilitates allocation of resources, including an ICU bed, a ventilator, medications, and nursing and clinician time, to living patients, in lieu of a dead patient.", [["patients", "ORGANISM", 133, 141], ["patient", "ORGANISM", 161, 168], ["patients", "SPECIES", 133, 141], ["patient", "SPECIES", 161, 168], ["an ICU bed", "TREATMENT", 52, 62], ["a ventilator", "TREATMENT", 64, 76], ["medications", "TREATMENT", 78, 89]]], ["However, it is worth noting that organ support is continued after brain death if a patient, or their surrogate, has indicated they would want to be an organ donor.Organ DonationIn March 2020, multiple national and international organizations issued recommendations against the use of organs from donors with SARS-CoV-2 based on the assumption that viral particles could be inadvertently transplanted from a positive donor and result in severe manifestations in immunosuppressed recipients [30] .", [["organ", "ANATOMY", 33, 38], ["brain", "ANATOMY", 66, 71], ["organ", "ANATOMY", 151, 156], ["organs", "ANATOMY", 284, 290], ["brain death", "DISEASE", 66, 77], ["SARS", "DISEASE", 308, 312], ["organ", "ORGAN", 33, 38], ["brain", "ORGAN", 66, 71], ["patient", "ORGANISM", 83, 90], ["organ", "ORGAN", 151, 156], ["organs", "ORGAN", 284, 290], ["donors", "ORGANISM", 296, 302], ["SARS-CoV-2", "ORGANISM", 308, 318], ["patient", "SPECIES", 83, 90], ["organ support", "TREATMENT", 33, 46], ["an organ donor", "TREATMENT", 148, 162], ["CoV", "TEST", 313, 316], ["viral particles", "PROBLEM", 348, 363], ["a positive donor", "PROBLEM", 405, 421], ["severe manifestations", "PROBLEM", 436, 457], ["immunosuppressed recipients", "TREATMENT", 461, 488], ["severe", "OBSERVATION_MODIFIER", 436, 442]]], ["Referral for organ donation of patients with COVID-19 to our organ procurement J o u r n a l P r e -p r o o f", [["organ", "ANATOMY", 13, 18], ["organ", "ANATOMY", 61, 66], ["organ", "ORGAN", 13, 18], ["patients", "ORGANISM", 31, 39], ["organ", "ORGAN", 61, 66], ["patients", "SPECIES", 31, 39], ["COVID", "TEST", 45, 50]]]], "4d7815df88eff129de3eb9c412b5f2d1712ef4d3": [], "cd8b69df63dfbc0221995dd9e0dab29c99e3d969": [["IntroductionPeople are going through a battle against novel coronavirus pneumonia (COVID-19) all over the world.", [["coronavirus pneumonia", "DISEASE", 60, 81], ["COVID-19", "CHEMICAL", 83, 91], ["coronavirus", "ORGANISM", 60, 71], ["novel coronavirus pneumonia", "PROBLEM", 54, 81], ["pneumonia", "OBSERVATION", 72, 81]]], ["By 3 April 2020, more than 1,010,000 people have been infected and more than 50,000 have died worldwide.", [["people", "ORGANISM", 37, 43], ["people", "SPECIES", 37, 43], ["infected", "OBSERVATION", 54, 62]]], ["The 2019 novel coronavirus (SARS-CoV-2) was confirmed as the pathogen of the COVID-19 and belongs to Beta coronavirus by the phylogenetic analysis, which is similar to severe acute respiratory syndrome coronavirus (SARS-CoV) and middle east respiratory syndrome coronavirus (MERS-CoV).", [["acute respiratory syndrome coronavirus", "DISEASE", 175, 213], ["SARS-CoV) and middle east respiratory syndrome coronavirus", "DISEASE", 215, 273], ["coronavirus", "ORGANISM", 15, 26], ["SARS-CoV-2", "ORGANISM", 28, 38], ["COVID-19", "ORGANISM", 77, 85], ["Beta coronavirus", "ORGANISM", 101, 117], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 168, 213], ["SARS-CoV", "ORGANISM", 215, 223], ["middle east respiratory syndrome coronavirus", "ORGANISM", 229, 273], ["MERS-CoV", "ORGANISM", 275, 283], ["COVID-19", "DNA", 77, 85], ["coronavirus", "SPECIES", 15, 26], ["Beta coronavirus", "SPECIES", 101, 117], ["COVID-19", "SPECIES", 77, 85], ["Beta coronavirus", "SPECIES", 101, 117], ["severe acute respiratory syndrome coronavirus", "SPECIES", 168, 213], ["SARS-CoV", "SPECIES", 215, 223], ["middle east respiratory syndrome coronavirus", "SPECIES", 229, 273], ["MERS-CoV", "SPECIES", 275, 283], ["SARS-CoV", "TEST", 28, 36], ["the COVID", "TEST", 73, 82], ["Beta coronavirus", "PROBLEM", 101, 117], ["the phylogenetic analysis", "TEST", 121, 146], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 168, 213], ["middle east respiratory syndrome coronavirus", "PROBLEM", 229, 273], ["severe", "OBSERVATION_MODIFIER", 168, 174], ["acute", "OBSERVATION_MODIFIER", 175, 180], ["respiratory syndrome coronavirus", "OBSERVATION", 181, 213], ["middle", "ANATOMY_MODIFIER", 229, 235], ["respiratory syndrome", "OBSERVATION", 241, 261]]], ["Respiratory symptoms, fever, dry cough, and panting, even acute respiratory distress syndrome (ARDS) and acute cardiac injury manifested in the COVID-19 patients [1] [2] [3] [4] .IntroductionSARS-CoV-2 can cause a series of disorders of the coagulation systems including endothelial damage, coagulation activation, and intravascular fibrin deposition.", [["Respiratory", "ANATOMY", 0, 11], ["respiratory", "ANATOMY", 64, 75], ["cardiac", "ANATOMY", 111, 118], ["endothelial", "ANATOMY", 271, 282], ["intravascular", "ANATOMY", 319, 332], ["Respiratory symptoms", "DISEASE", 0, 20], ["fever", "DISEASE", 22, 27], ["dry cough", "DISEASE", 29, 38], ["acute respiratory distress syndrome", "DISEASE", 58, 93], ["ARDS", "DISEASE", 95, 99], ["cardiac injury", "DISEASE", 111, 125], ["disorders of the coagulation", "DISEASE", 224, 252], ["cardiac", "ORGAN", 111, 118], ["patients", "ORGANISM", 153, 161], ["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 162, 177], ["IntroductionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 179, 201], ["endothelial", "TISSUE", 271, 282], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 319, 332], ["fibrin", "GENE_OR_GENE_PRODUCT", 333, 339], ["patients", "SPECIES", 153, 161], ["Respiratory symptoms", "PROBLEM", 0, 20], ["fever", "PROBLEM", 22, 27], ["dry cough", "PROBLEM", 29, 38], ["panting", "PROBLEM", 44, 51], ["acute respiratory distress syndrome", "PROBLEM", 58, 93], ["ARDS)", "PROBLEM", 95, 100], ["acute cardiac injury", "PROBLEM", 105, 125], ["the COVID", "TEST", 140, 149], ["IntroductionSARS", "TEST", 179, 195], ["disorders", "PROBLEM", 224, 233], ["the coagulation systems", "PROBLEM", 237, 260], ["endothelial damage", "PROBLEM", 271, 289], ["coagulation activation", "PROBLEM", 291, 313], ["intravascular fibrin deposition", "PROBLEM", 319, 350], ["fever", "OBSERVATION", 22, 27], ["cough", "OBSERVATION", 33, 38], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["respiratory distress", "OBSERVATION", 64, 84], ["ARDS", "OBSERVATION", 95, 99], ["acute", "OBSERVATION_MODIFIER", 105, 110], ["cardiac", "ANATOMY", 111, 118], ["injury", "OBSERVATION", 119, 125], ["endothelial", "ANATOMY", 271, 282], ["damage", "OBSERVATION", 283, 289], ["intravascular", "OBSERVATION", 319, 332], ["fibrin deposition", "OBSERVATION", 333, 350]]], ["For COVID-19 patients in severe, coagulation activation can be leading to the formation of thrombus and even disseminated intravascular coagulation (DIC) [5] .IntroductionAnd this coagulation activation is more common in patients with pre-existing coagulation disorders.", [["thrombus", "ANATOMY", 91, 99], ["intravascular", "ANATOMY", 122, 135], ["thrombus", "DISEASE", 91, 99], ["disseminated intravascular coagulation", "DISEASE", 109, 147], ["DIC", "DISEASE", 149, 152], ["coagulation disorders", "DISEASE", 248, 269], ["patients", "ORGANISM", 13, 21], ["thrombus", "PATHOLOGICAL_FORMATION", 91, 99], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 122, 135], ["patients", "ORGANISM", 221, 229], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 221, 229], ["COVID", "TEST", 4, 9], ["coagulation activation", "PROBLEM", 33, 55], ["thrombus", "PROBLEM", 91, 99], ["disseminated intravascular coagulation", "PROBLEM", 109, 147], ["this coagulation activation", "TEST", 175, 202], ["pre-existing coagulation disorders", "PROBLEM", 235, 269], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["thrombus", "OBSERVATION", 91, 99], ["disseminated", "OBSERVATION_MODIFIER", 109, 121], ["coagulation", "OBSERVATION", 248, 259]]], ["On the other side, although, most severe COVID-19 patients treated with extracorporeal membrane oxygenation (ECMO) to temporarily replaces cardiopulmonary function, the coagulation disorder is still one of the most common complications of ECMO, which is also a common cause of disruption of ECMO [6] [7] .IntroductionTherefore, it is significant to monitor the coagulation systems parameters in .", [["extracorporeal membrane", "ANATOMY", 72, 95], ["cardiopulmonary", "ANATOMY", 139, 154], ["COVID", "DISEASE", 41, 46], ["coagulation disorder", "DISEASE", 169, 189], ["ECMO [6]", "CHEMICAL", 291, 299], ["patients", "ORGANISM", 50, 58], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 72, 95], ["patients", "SPECIES", 50, 58], ["extracorporeal membrane oxygenation", "TREATMENT", 72, 107], ["ECMO", "TREATMENT", 109, 113], ["the coagulation disorder", "PROBLEM", 165, 189], ["ECMO", "TREATMENT", 239, 243], ["disruption of ECMO", "TREATMENT", 277, 295], ["the coagulation systems parameters", "TEST", 357, 391], ["cardiopulmonary function", "OBSERVATION", 139, 163], ["ECMO", "OBSERVATION", 239, 243]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["25.20077842 doi: medRxiv preprint COVID-19 patients to determine the coagulation function.(which was not certified by peer review)Previous studies have suggested that cytokine storms are typical abnormalities caused by SARS-CoV-2 [8] [9] .", [["patients", "ORGANISM", 43, 51], ["cytokine", "PROTEIN", 167, 175], ["patients", "SPECIES", 43, 51], ["the coagulation function", "TEST", 65, 89], ["Previous studies", "TEST", 130, 146], ["cytokine storms", "PROBLEM", 167, 182], ["typical abnormalities", "PROBLEM", 187, 208], ["SARS", "TEST", 219, 223], ["CoV", "TEST", 224, 227]]], ["And the underlying reason of the connection between the coagulation function and the disease severity was not completely clear.", [["the coagulation function", "TEST", 52, 76], ["the disease severity", "PROBLEM", 81, 101], ["clear", "OBSERVATION", 121, 126]]], ["Especially, the index related thrombus such as thrombin-antithrombin complex (TAT), \u03b12-plasmininhibitor-plasmin Complex (PIC), thrombomodulin (TM), t-PA/PAI-1 Complex (t-PAIC) are important markers in the process of venous thrombosis and significantly increased before thrombosis, which had not been reported.", [["thrombus", "ANATOMY", 30, 38], ["venous", "ANATOMY", 216, 222], ["thrombus", "DISEASE", 30, 38], ["venous thrombosis", "DISEASE", 216, 233], ["thrombosis", "DISEASE", 269, 279], ["thrombus", "PATHOLOGICAL_FORMATION", 30, 38], ["thrombin-antithrombin complex", "GENE_OR_GENE_PRODUCT", 47, 76], ["TAT", "GENE_OR_GENE_PRODUCT", 78, 81], ["\u03b12-plasmininhibitor-plasmin Complex", "GENE_OR_GENE_PRODUCT", 84, 119], ["PIC", "GENE_OR_GENE_PRODUCT", 121, 124], ["thrombomodulin", "GENE_OR_GENE_PRODUCT", 127, 141], ["t-PA", "GENE_OR_GENE_PRODUCT", 148, 152], ["PAI-1", "GENE_OR_GENE_PRODUCT", 153, 158], ["t-PAIC", "GENE_OR_GENE_PRODUCT", 168, 174], ["venous", "MULTI-TISSUE_STRUCTURE", 216, 222], ["thrombin", "PROTEIN", 47, 55], ["antithrombin complex", "PROTEIN", 56, 76], ["TAT", "PROTEIN", 78, 81], ["\u03b12", "PROTEIN", 84, 86], ["plasmininhibitor", "PROTEIN", 87, 103], ["plasmin Complex", "PROTEIN", 104, 119], ["PIC", "PROTEIN", 121, 124], ["thrombomodulin", "PROTEIN", 127, 141], ["TM", "PROTEIN", 143, 145], ["t-PA", "PROTEIN", 148, 152], ["PAI-1 Complex", "PROTEIN", 153, 166], ["PAIC", "PROTEIN", 170, 174], ["the index related thrombus", "PROBLEM", 12, 38], ["thrombin", "TEST", 47, 55], ["antithrombin complex", "PROBLEM", 56, 76], ["TAT", "TEST", 78, 81], ["\u03b12", "TEST", 84, 86], ["plasmininhibitor", "TEST", 87, 103], ["thrombomodulin (TM", "TEST", 127, 145], ["t-PA/PAI", "TEST", 148, 156], ["Complex (t-PAIC)", "TREATMENT", 159, 175], ["venous thrombosis", "PROBLEM", 216, 233], ["thrombosis", "PROBLEM", 269, 279], ["thrombus", "OBSERVATION", 30, 38], ["thrombin", "OBSERVATION", 47, 55], ["venous", "ANATOMY", 216, 222], ["thrombosis", "OBSERVATION", 223, 233], ["significantly", "OBSERVATION_MODIFIER", 238, 251], ["increased", "OBSERVATION_MODIFIER", 252, 261], ["thrombosis", "OBSERVATION", 269, 279]]], ["Therefore, this study was executed to evaluate the values of coagulation function for the prediction of severe COVID-19 patients .PatientsWe recruited 147 COVID patients and 18 health controls in Wuhan Leishenshan Hospital, Hubei, China.", [["COVID", "DISEASE", 111, 116], ["patients", "ORGANISM", 120, 128], ["Patients", "ORGANISM", 130, 138], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 120, 128], ["Patients", "SPECIES", 130, 138], ["patients", "SPECIES", 161, 169], ["this study", "TEST", 11, 21], ["coagulation function", "TEST", 61, 81], ["severe COVID", "PROBLEM", 104, 116]]], ["The patients were diagnosed and classified followed the New Coronavirus Pneumonia Prevention and Control Program (7th edition) published by the National Health Commission of China.", [["Pneumonia", "DISEASE", 72, 81], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["New Coronavirus Pneumonia", "PROBLEM", 56, 81], ["New", "OBSERVATION_MODIFIER", 56, 59], ["Coronavirus", "OBSERVATION_MODIFIER", 60, 71], ["Pneumonia", "OBSERVATION", 72, 81]]], ["Briefly, the controls were hospital employees who underwent the healthy examination.", [["the healthy examination", "TEST", 60, 83]]], ["The study was approved by the Ethics Committee of Zhongnan Hospital of Wuhan University.Standard of severe patientsSevere patients should have any of the following conditions: a.", [["patients", "ORGANISM", 107, 115], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 122, 130], ["The study", "TEST", 0, 9], ["severe", "OBSERVATION_MODIFIER", 100, 106]]], ["Respiratory distress, RR \u2265 30 times/minute;Standard of severe patients.", [["Respiratory", "ANATOMY", 0, 11], ["Respiratory distress", "DISEASE", 0, 20], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["Respiratory distress", "PROBLEM", 0, 20], ["RR", "TEST", 22, 24], ["distress", "OBSERVATION", 12, 20], ["severe", "OBSERVATION_MODIFIER", 55, 61]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Standard of severe patientsThe copyright holder for this preprint this version posted April 29, 2020.Statistical analysisStatistical analysis was performed with SPSS version 25.0 software and Graphpad Prism (version 7.0).", [["CC", "CHEMICAL", 0, 2], ["patients", "ORGANISM", 221, 229], ["patients", "SPECIES", 221, 229], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 229, 249], ["Statistical analysisStatistical analysis", "TEST", 303, 343], ["SPSS version", "TEST", 363, 375], ["software", "TEST", 381, 389], ["Graphpad Prism (version", "TEST", 394, 417], ["med", "ANATOMY", 105, 108], ["severe", "OBSERVATION_MODIFIER", 214, 220]]], ["All the measurement data were tested for normality, and non-normally distributed data were expressed as median (interquartile range), nonparametric Mann-Whitney test was used for comparison between the two groups.Statistical analysis.", [["All the measurement data", "TEST", 0, 24], ["Whitney test", "TEST", 153, 165], ["Statistical analysis", "TEST", 213, 233]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Statistical analysisThe copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["Statistical analysis", "TEST", 202, 222], ["The copyright holder", "TREATMENT", 222, 242], ["med", "ANATOMY", 105, 108]]], ["25.20077842 doi: medRxiv preprint Univariate and multivariate analysis using logistic regression analysis: calculate the odds ratio and 95% confidence interval.", [["multivariate analysis", "TEST", 49, 70], ["logistic regression analysis", "TEST", 77, 105]]], ["The prediction of various indicators for prognosis COVID-19 patients was analyzed by the receiver operating characteristic (ROC) curves, and the area under the ROC curve (AUC) was measured to evaluate the predictive ability.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["the ROC curve", "TEST", 156, 169], ["AUC", "TEST", 171, 174]]], ["For all statistical analysis, P<0.05 was considered statistically significant.Clinical CharacteristicsAmong the 147 COVID-19 patients, 76 were males and 71 were females, the median age was 64 years, while in the control group, 14 subjects were male and 4 subjects were females ( Table 1 ).", [["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["all statistical analysis", "TEST", 4, 28], ["P", "TEST", 30, 31]]], ["The age was not significantly different among groups.Clinical CharacteristicsThere were 105 mild patients, 18 severe patients and 24 critical patients, of which 37 patients with thrombotic disease and 110 patients without thrombotic disease.COVID-19 patientsThe levels of coagulation parameters at health controls and COVID-19 patients were demonstrated in Table 1 .", [["thrombotic disease", "DISEASE", 178, 196], ["thrombotic disease", "DISEASE", 222, 240], ["patients", "ORGANISM", 97, 105], ["patients", "ORGANISM", 117, 125], ["patients", "ORGANISM", 142, 150], ["patients", "ORGANISM", 164, 172], ["patients", "ORGANISM", 205, 213], ["patients", "ORGANISM", 250, 258], ["patients", "ORGANISM", 327, 335], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 117, 125], ["patients", "SPECIES", 142, 150], ["patients", "SPECIES", 164, 172], ["patients", "SPECIES", 205, 213], ["patients", "SPECIES", 250, 258], ["patients", "SPECIES", 327, 335], ["thrombotic disease", "PROBLEM", 178, 196], ["thrombotic disease", "PROBLEM", 222, 240], ["coagulation parameters", "TEST", 272, 294], ["COVID", "TEST", 318, 323], ["significantly different", "OBSERVATION_MODIFIER", 16, 39], ["mild", "OBSERVATION_MODIFIER", 92, 96], ["thrombotic", "OBSERVATION", 178, 188], ["without", "UNCERTAINTY", 214, 221], ["thrombotic", "OBSERVATION_MODIFIER", 222, 232], ["disease", "OBSERVATION", 233, 240]]], ["COVID-19 patients had significantly higher values of TAT, PIC, TM, t-PAIC, PT, INR, FIB, and DD than health controls, and there were no significant differences in APTT, TT, and PLT.Coagulation parameters of COVID-19 patients with thrombotic diseases vs patients without thrombotic diseases.", [["thrombotic diseases", "DISEASE", 230, 249], ["thrombotic diseases", "DISEASE", 270, 289], ["patients", "ORGANISM", 9, 17], ["TAT", "GENE_OR_GENE_PRODUCT", 53, 56], ["PIC", "GENE_OR_GENE_PRODUCT", 58, 61], ["t-PAIC", "GENE_OR_GENE_PRODUCT", 67, 73], ["PT", "GENE_OR_GENE_PRODUCT", 75, 77], ["INR", "GENE_OR_GENE_PRODUCT", 79, 82], ["APTT", "GENE_OR_GENE_PRODUCT", 163, 167], ["patients", "ORGANISM", 216, 224], ["patients", "ORGANISM", 253, 261], ["TAT", "PROTEIN", 53, 56], ["PIC", "PROTEIN", 58, 61], ["INR", "PROTEIN", 79, 82], ["FIB", "PROTEIN", 84, 87], ["APTT", "PROTEIN", 163, 167], ["TT", "PROTEIN", 169, 171], ["PLT", "PROTEIN", 177, 180], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 216, 224], ["patients", "SPECIES", 253, 261], ["COVID", "TEST", 0, 5], ["TAT", "TEST", 53, 56], ["PIC", "TREATMENT", 58, 61], ["TM", "TEST", 63, 65], ["PT", "TEST", 75, 77], ["INR", "TEST", 79, 82], ["FIB", "TEST", 84, 87], ["significant differences in APTT", "PROBLEM", 136, 167], ["TT", "TEST", 169, 171], ["PLT", "TEST", 177, 180], ["Coagulation parameters", "TEST", 181, 203], ["COVID", "TEST", 207, 212], ["thrombotic diseases", "PROBLEM", 230, 249], ["thrombotic diseases", "PROBLEM", 270, 289], ["FIB", "ANATOMY", 84, 87], ["no", "UNCERTAINTY", 133, 135], ["significant", "OBSERVATION_MODIFIER", 136, 147], ["thrombotic", "OBSERVATION_MODIFIER", 230, 240], ["diseases", "OBSERVATION", 241, 249], ["without", "UNCERTAINTY", 262, 269], ["thrombotic", "OBSERVATION_MODIFIER", 270, 280], ["diseases", "OBSERVATION", 281, 289]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["25.20077842 doi: medRxiv preprint Among the 147 patients, 37 patients with thrombotic disease, 110 were without the thrombotic disease.", [["thrombotic disease", "DISEASE", 75, 93], ["thrombotic disease", "DISEASE", 116, 134], ["patients", "ORGANISM", 48, 56], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 48, 56], ["patients", "SPECIES", 61, 69], ["thrombotic disease", "PROBLEM", 75, 93], ["the thrombotic disease", "PROBLEM", 112, 134], ["thrombotic", "OBSERVATION_MODIFIER", 75, 85], ["disease", "OBSERVATION", 86, 93], ["thrombotic", "OBSERVATION", 116, 126]]], ["There were 7 patients died among the thrombotic disease group, while 3 patients died in the non-thrombotic disease group ( Table 2 ).", [["thrombotic disease", "DISEASE", 37, 55], ["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 71, 79], ["the thrombotic disease group", "PROBLEM", 33, 61], ["thrombotic", "OBSERVATION_MODIFIER", 37, 47], ["disease", "OBSERVATION", 48, 55]]], ["The patients in thrombotic disease group had a higher case-fatality rate than the non-thrombotic disease group (p<0.05).", [["thrombotic disease", "DISEASE", 16, 34], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["thrombotic disease group", "PROBLEM", 16, 40], ["the non-thrombotic disease group", "PROBLEM", 78, 110], ["thrombotic", "OBSERVATION_MODIFIER", 16, 26], ["disease", "OBSERVATION", 27, 34]]], ["The levels of coagulation parameters at the thrombotic disease group and non-thrombotic disease group were demonstrated in There were no significant differences in levels of APTT, TT, and PLT.Coagulation parameters of three subgroups patientsAmong the 147 included patients, 105 patients belonged to mild group, 18 were severe, and 24 were critical.", [["thrombotic disease", "DISEASE", 44, 62], ["non-thrombotic disease", "DISEASE", 73, 95], ["APTT", "GENE_OR_GENE_PRODUCT", 174, 178], ["PLT", "GENE_OR_GENE_PRODUCT", 188, 191], ["patients", "ORGANISM", 234, 242], ["patients", "ORGANISM", 265, 273], ["patients", "ORGANISM", 279, 287], ["APTT", "PROTEIN", 174, 178], ["TT", "PROTEIN", 180, 182], ["PLT", "PROTEIN", 188, 191], ["patients", "SPECIES", 234, 242], ["patients", "SPECIES", 265, 273], ["patients", "SPECIES", 279, 287], ["The levels", "TEST", 0, 10], ["coagulation parameters", "TEST", 14, 36], ["the thrombotic disease group", "PROBLEM", 40, 68], ["non-thrombotic disease group", "PROBLEM", 73, 101], ["APTT", "TEST", 174, 178], ["TT", "TEST", 180, 182], ["PLT", "TEST", 188, 191], ["Coagulation parameters", "TEST", 192, 214], ["thrombotic", "OBSERVATION_MODIFIER", 44, 54], ["disease", "OBSERVATION", 55, 62], ["non-thrombotic disease", "OBSERVATION", 73, 95], ["no", "UNCERTAINTY", 134, 136], ["significant", "OBSERVATION_MODIFIER", 137, 148], ["mild", "OBSERVATION_MODIFIER", 300, 304]]], ["TM, t-PAIC, PT, INR, DD were significantly different among the three groups, while TT was no significant difference (Figs 2C-F, I, J).", [["INR", "PROTEIN", 16, 19], ["PT", "TEST", 12, 14], ["INR", "TEST", 16, 19], ["DD", "PROBLEM", 21, 23], ["TT", "TEST", 83, 85], ["significant difference", "PROBLEM", 93, 115]]], ["The more severe in COVID-19 patients , the higher the levels of TM, t-PAIC, PT, INR, and DD.", [["patients", "ORGANISM", 28, 36], ["TM", "GENE_OR_GENE_PRODUCT", 64, 66], ["t-PAIC", "GENE_OR_GENE_PRODUCT", 68, 74], ["PT", "GENE_OR_GENE_PRODUCT", 76, 78], ["TM", "PROTEIN", 64, 66], ["PAIC", "PROTEIN", 70, 74], ["PT", "PROTEIN", 76, 78], ["INR", "PROTEIN", 80, 83], ["patients", "SPECIES", 28, 36], ["The more severe in COVID", "PROBLEM", 0, 24], ["TM", "TEST", 64, 66], ["PT", "TEST", 76, 78], ["INR", "TEST", 80, 83], ["DD", "PROBLEM", 89, 91], ["more", "OBSERVATION_MODIFIER", 4, 8], ["severe", "OBSERVATION_MODIFIER", 9, 15]]], ["TAT and PLT were significantly different between the severe and critical groups or mild and critical group, and no significance were found between the mild and severe groups (Figs 2A, K) .", [["TAT", "GENE_OR_GENE_PRODUCT", 0, 3], ["PLT", "GENE_OR_GENE_PRODUCT", 8, 11], ["TAT", "PROTEIN", 0, 3], ["PLT", "PROTEIN", 8, 11], ["TAT", "TEST", 0, 3], ["PLT", "TEST", 8, 11], ["the severe and critical groups", "PROBLEM", 49, 79], ["mild and critical group", "PROBLEM", 83, 106], ["the mild and severe groups", "PROBLEM", 147, 173], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["mild", "OBSERVATION_MODIFIER", 83, 87], ["mild", "OBSERVATION_MODIFIER", 151, 155], ["severe", "OBSERVATION_MODIFIER", 160, 166]]], ["With regard to PIC and APTT, there were significant difference between mild and severe or mild and critical patients, and no significant difference in severe and critical group (Figs 2B, G).", [["PIC", "CHEMICAL", 15, 18], ["APTT", "GENE_OR_GENE_PRODUCT", 23, 27], ["patients", "ORGANISM", 108, 116], ["PIC", "PROTEIN", 15, 18], ["APTT", "PROTEIN", 23, 27], ["patients", "SPECIES", 108, 116], ["PIC", "TREATMENT", 15, 18], ["APTT", "TEST", 23, 27], ["significant difference between mild and severe or mild and critical patients", "PROBLEM", 40, 116], ["significant difference in severe", "PROBLEM", 125, 157], ["significant", "OBSERVATION_MODIFIER", 40, 51], ["mild", "OBSERVATION_MODIFIER", 71, 75], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["mild", "OBSERVATION_MODIFIER", 90, 94], ["no", "UNCERTAINTY", 122, 124], ["significant", "OBSERVATION_MODIFIER", 125, 136], ["difference", "OBSERVATION_MODIFIER", 137, 147], ["severe", "OBSERVATION_MODIFIER", 151, 157]]], ["In addition, there was a significant difference that the level of FIB in severe group and mild group, however no significant difference was found between severe and critical group or mild and critical patients (Fig 2H) .", [["patients", "ORGANISM", 201, 209], ["FIB", "PROTEIN", 66, 69], ["patients", "SPECIES", 201, 209], ["FIB in severe group and mild group", "PROBLEM", 66, 100], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["difference", "OBSERVATION", 37, 47], ["FIB", "OBSERVATION", 66, 69], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["mild", "OBSERVATION_MODIFIER", 90, 94], ["no", "UNCERTAINTY", 110, 112], ["significant", "OBSERVATION_MODIFIER", 113, 124], ["difference", "OBSERVATION", 125, 135], ["mild", "OBSERVATION_MODIFIER", 183, 187]]], ["The ROC curves and AUC (Fig 3) demonstrated that TM .", [["The ROC curves", "TEST", 0, 14], ["AUC", "TEST", 19, 22]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Further analysis using univariate and multivariate logistic regression also found that t-PAIC and DD were independent risk factors for patients death (Table 3) The sensitivity and specificity of t-PAIC in predicting death respectively were 90.0% and 91.2% with the cut-off of greater than 20.75 ng/mL; and those for DD were 100.0% and 86.0% with the cut-off of greater than 2.79 mg/L.DiscussionWe reported the coagulation function of COVID-19 patients in Wuhan Leishenshan Hospital of Hubei, China.", [["death", "DISEASE", 144, 149], ["death", "DISEASE", 216, 221], ["patients", "ORGANISM", 135, 143], ["patients", "ORGANISM", 443, 451], ["patients", "SPECIES", 135, 143], ["patients", "SPECIES", 443, 451], ["Further analysis", "TEST", 0, 16], ["univariate", "TREATMENT", 23, 33], ["multivariate logistic regression", "TEST", 38, 70], ["patients death", "PROBLEM", 135, 149], ["The sensitivity", "TEST", 160, 175], ["t-PAIC", "TEST", 195, 201], ["the cut-off", "TEST", 261, 272], ["DD", "TEST", 316, 318], ["the cut-off", "TEST", 346, 357], ["the coagulation function", "TEST", 406, 430]]], ["The world health organization had declared the COVID-19 was an international public health emergency at the end of January .", [["the COVID", "TEST", 43, 52]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Within a period of four months, more than 1,010,000 people have been infected and more than 50,000 people have died worldwide.", [["people", "ORGANISM", 52, 58], ["people", "ORGANISM", 99, 105], ["people", "SPECIES", 52, 58], ["people", "SPECIES", 99, 105], ["infected", "OBSERVATION", 69, 77]]], ["Although most of the COVID-19(which was not certified by peer review)patients have mild symptoms with good prognosis and the crude mortality rate was about 2.3%, for patients progressing to severe or critical, mortality rates have increased significantly with crude death rates reaching 49% for critically [11] [12] .(which was not certified by peer review)Early identification of severe patients will help improve recovery rates and reduce mortality.(which was not certified by peer review)Studies have shown that COVID-19 patients can develop a variety of secondary diseases that cause pathological changes such as hematology, immunity, biochemistry, etc. [13] [14] , but the changes in coagulopathy are not well understood.", [["death", "DISEASE", 266, 271], ["coagulopathy", "DISEASE", 689, 701], ["patients", "ORGANISM", 69, 77], ["patients", "ORGANISM", 166, 174], ["patients", "ORGANISM", 388, 396], ["patients", "ORGANISM", 524, 532], ["COVID-19", "DNA", 21, 29], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 166, 174], ["patients", "SPECIES", 388, 396], ["patients", "SPECIES", 524, 532], ["the COVID", "TEST", 17, 26], ["mild symptoms", "PROBLEM", 83, 96], ["the crude mortality rate", "TEST", 121, 145], ["severe or critical, mortality rates", "PROBLEM", 190, 225], ["crude death rates", "TEST", 260, 277], ["Studies", "TEST", 491, 498], ["COVID", "TEST", 515, 520], ["secondary diseases", "PROBLEM", 558, 576], ["pathological changes", "PROBLEM", 588, 608], ["the changes in coagulopathy", "PROBLEM", 674, 701], ["mild", "OBSERVATION_MODIFIER", 83, 87], ["severe", "OBSERVATION_MODIFIER", 381, 387], ["secondary diseases", "OBSERVATION", 558, 576], ["coagulopathy", "OBSERVATION", 689, 701]]], ["In this study, a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.", [["this study", "TEST", 3, 13], ["The copyright holder", "TREATMENT", 151, 171], ["med", "ANATOMY", 55, 58]]], ["25.20077842 doi: medRxiv preprint t-PAIC) can predict the possibility of thrombosis in the patients at an early stage.", [["thrombosis", "DISEASE", 73, 83], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["medRxiv preprint t-PAIC", "TREATMENT", 17, 40], ["thrombosis", "PROBLEM", 73, 83], ["thrombosis", "OBSERVATION", 73, 83]]], ["TAT as a marker for activation of the coagulation systems, to determine the optimal period of anticoagulation therapy and early diagnosis of thrombosis and pre-DIC [15] [16] .(which was not certified by peer review)PIC as a marker of fibrinolytic system activation, predicting the formation of thrombus, assisting the diagnosis of DIC, and guiding antifibrinolytic treatment [17] .(which was not certified by peer review)The elevated level of TM indicates an impaired vascular endothelial system [18] [19] .(which was not certified by peer review)t-PAIC, key marker of fibrinolytic system, suggesting thrombus progression [20] [21] .(which was not certified by peer review)Plasma levels of these sensitive biomarkers of endothelial injury in COVID-19 patients may be useful for evaluating the endothelial injury in COVID-19.", [["thrombus", "ANATOMY", 294, 302], ["vascular endothelial", "ANATOMY", 468, 488], ["thrombus", "ANATOMY", 601, 609], ["endothelial", "ANATOMY", 720, 731], ["endothelial", "ANATOMY", 793, 804], ["thrombosis", "DISEASE", 141, 151], ["thrombus", "DISEASE", 294, 302], ["DIC", "DISEASE", 331, 334], ["thrombus", "DISEASE", 601, 609], ["endothelial injury", "DISEASE", 720, 738], ["endothelial injury", "DISEASE", 793, 811], ["TAT", "GENE_OR_GENE_PRODUCT", 0, 3], ["thrombus", "PATHOLOGICAL_FORMATION", 294, 302], ["TM", "GENE_OR_GENE_PRODUCT", 443, 445], ["vascular endothelial", "TISSUE", 468, 488], ["thrombus", "PATHOLOGICAL_FORMATION", 601, 609], ["Plasma", "ORGANISM_SUBSTANCE", 673, 679], ["endothelial", "CELL", 720, 731], ["patients", "ORGANISM", 751, 759], ["endothelial", "CELL", 793, 804], ["TAT", "PROTEIN", 0, 3], ["TM", "PROTEIN", 443, 445], ["patients", "SPECIES", 751, 759], ["the coagulation systems", "TEST", 34, 57], ["anticoagulation therapy", "TREATMENT", 94, 117], ["thrombosis", "PROBLEM", 141, 151], ["pre-DIC", "TEST", 156, 163], ["PIC", "TREATMENT", 215, 218], ["fibrinolytic system activation", "PROBLEM", 234, 264], ["thrombus", "PROBLEM", 294, 302], ["DIC", "PROBLEM", 331, 334], ["guiding antifibrinolytic treatment", "TREATMENT", 340, 374], ["The elevated level of TM", "PROBLEM", 421, 445], ["an impaired vascular endothelial system", "PROBLEM", 456, 495], ["thrombus progression", "PROBLEM", 601, 621], ["Plasma levels", "TEST", 673, 686], ["endothelial injury", "PROBLEM", 720, 738], ["COVID", "TEST", 742, 747], ["the endothelial injury", "PROBLEM", 789, 811], ["COVID", "TEST", 815, 820], ["thrombosis", "OBSERVATION", 141, 151], ["thrombus", "OBSERVATION", 294, 302], ["elevated", "OBSERVATION", 425, 433], ["impaired", "OBSERVATION", 459, 467], ["vascular endothelial", "ANATOMY", 468, 488], ["fibrinolytic system", "ANATOMY", 569, 588], ["suggesting", "UNCERTAINTY", 590, 600], ["thrombus", "OBSERVATION", 601, 609], ["endothelial", "ANATOMY", 720, 731], ["injury", "OBSERVATION", 732, 738], ["endothelial", "ANATOMY", 793, 804], ["injury", "OBSERVATION", 805, 811]]], ["Besides, we also found the COVID-19 patients with thrombotic disease had a higher case-fatality rate.", [["thrombotic disease", "DISEASE", 50, 68], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["the COVID", "TEST", 23, 32], ["thrombotic disease", "PROBLEM", 50, 68], ["fatality rate", "TEST", 87, 100], ["thrombotic", "OBSERVATION", 50, 60]]], ["Therefore, it is a situation that requires our vigilance when the coagulation systems parameters are abnormal in COVID-19 patient, and it is likely to be accompanied by thrombosis, and the risk of death is greater.(which was not certified by peer review)TAT, PIC, TM, t-PAIC, PT, INR, APTT, FIB, DD, and PLT were also found correlated with disease severity, while the TT was no correlation (Fig 2) .", [["thrombosis", "DISEASE", 169, 179], ["death", "DISEASE", 197, 202], ["patient", "ORGANISM", 122, 129], ["TAT", "GENE_OR_GENE_PRODUCT", 254, 257], ["APTT", "GENE_OR_GENE_PRODUCT", 285, 289], ["PLT", "GENE_OR_GENE_PRODUCT", 304, 307], ["TAT", "PROTEIN", 254, 257], ["PIC", "PROTEIN", 259, 262], ["PAIC", "PROTEIN", 270, 274], ["INR", "PROTEIN", 280, 283], ["APTT", "PROTEIN", 285, 289], ["FIB", "PROTEIN", 291, 294], ["DD", "PROTEIN", 296, 298], ["PLT", "PROTEIN", 304, 307], ["patient", "SPECIES", 122, 129], ["the coagulation systems parameters", "TEST", 62, 96], ["thrombosis", "PROBLEM", 169, 179], ["death", "PROBLEM", 197, 202], ["TAT", "TEST", 254, 257], ["PIC", "TREATMENT", 259, 262], ["PT", "TEST", 276, 278], ["INR", "TEST", 280, 283], ["APTT", "TEST", 285, 289], ["FIB", "TEST", 291, 294], ["DD", "TEST", 296, 298], ["PLT", "TEST", 304, 307], ["disease severity", "PROBLEM", 340, 356], ["the TT", "TEST", 364, 370], ["likely to be", "UNCERTAINTY", 141, 153], ["thrombosis", "OBSERVATION", 169, 179], ["greater", "OBSERVATION_MODIFIER", 206, 213], ["FIB", "ANATOMY", 291, 294]]], ["TT is the time for plasma to coagulate after adding a prothrombin solution in the plasma, and reflects the presence of anticoagulants.", [["plasma", "ANATOMY", 19, 25], ["plasma", "ANATOMY", 82, 88], ["plasma", "ORGANISM_SUBSTANCE", 19, 25], ["prothrombin", "GENE_OR_GENE_PRODUCT", 54, 65], ["plasma", "ORGANISM_SUBSTANCE", 82, 88], ["plasma to coagulate", "TREATMENT", 19, 38], ["a prothrombin solution", "TREATMENT", 52, 74], ["anticoagulants", "TREATMENT", 119, 133], ["anticoagulants", "OBSERVATION", 119, 133]]], ["Based on clinical practice and ROC analysis between mild and non-mild patients (Fig 3) , some cut-off values of the test items were obtained.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["ROC analysis", "TEST", 31, 43], ["mild and non-mild patients (Fig", "PROBLEM", 52, 83], ["the test items", "TEST", 112, 126], ["mild", "OBSERVATION_MODIFIER", 52, 56]]], ["With TM >13.65 TU/mL, t-PAIC >15.25 ng/mL, PT >11.55 s, DD>1.03 mg/L, progress to severe illness should be closely observed and prevented.", [["illness", "DISEASE", 89, 96], ["TM", "TEST", 5, 7], ["t", "TEST", 22, 23], ["PAIC", "TEST", 24, 28], ["PT", "TEST", 43, 45], ["DD", "TEST", 56, 58], ["severe illness", "PROBLEM", 82, 96], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["illness", "OBSERVATION", 89, 96]]], ["Among them, the rise of DD concentration is most obvious, similar to Wang's [22] and Guan [23] study.", [["DD concentration", "PROBLEM", 24, 40], ["Wang's", "TEST", 69, 75], ["Guan [23] study", "TEST", 85, 100], ["most obvious", "OBSERVATION_MODIFIER", 44, 56]]], ["DD is elevated because inflammation causes coagulation activation.", [["inflammation", "DISEASE", 23, 35], ["inflammation", "PROBLEM", 23, 35], ["coagulation activation", "PROBLEM", 43, 65], ["elevated", "OBSERVATION_MODIFIER", 6, 14], ["inflammation", "OBSERVATION", 23, 35], ["coagulation activation", "OBSERVATION", 43, 65]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["25.20077842 doi: medRxiv preprint results suggest the value of coagulation systems parameters in patients, and more attention about these to avoid the COVID-19 progression.", [["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["coagulation systems parameters", "TEST", 63, 93], ["the COVID", "TEST", 147, 156]]], ["As reported, anticoagulant treatment is required in severe and critical patients, and DD \u2265 5 \u00b5g/mL is used as an indicator to adjust anticoagulant therapy, while improving the prognosis [24] .", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["anticoagulant treatment", "TREATMENT", 13, 36], ["anticoagulant therapy", "TREATMENT", 133, 154]]], ["To reverse intravascular coagulation, microthrombi formation, fibrin deposition, COVID-19 patients might need anticoagulant or fibrinolytic therapy.(which was not certified by peer review)Further, we found the COVID-19 patients in death group had significantly higher levels of TAT, TM, t-PAIC, PT, INR, APTT, and DD than the survival group, and the PLT decreased.", [["intravascular", "ANATOMY", 11, 24], ["microthrombi", "ANATOMY", 38, 50], ["intravascular coagulation", "DISEASE", 11, 36], ["death", "DISEASE", 231, 236], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 11, 24], ["microthrombi", "PATHOLOGICAL_FORMATION", 38, 50], ["fibrin", "GENE_OR_GENE_PRODUCT", 62, 68], ["patients", "ORGANISM", 90, 98], ["patients", "ORGANISM", 219, 227], ["TAT", "GENE_OR_GENE_PRODUCT", 278, 281], ["TM", "GENE_OR_GENE_PRODUCT", 283, 285], ["t-PAIC", "GENE_OR_GENE_PRODUCT", 287, 293], ["PT", "GENE_OR_GENE_PRODUCT", 295, 297], ["INR", "GENE_OR_GENE_PRODUCT", 299, 302], ["APTT", "GENE_OR_GENE_PRODUCT", 304, 308], ["TAT", "PROTEIN", 278, 281], ["TM", "PROTEIN", 283, 285], ["PAIC", "PROTEIN", 289, 293], ["INR", "PROTEIN", 299, 302], ["APTT", "PROTEIN", 304, 308], ["PLT", "PROTEIN", 350, 353], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 219, 227], ["reverse intravascular coagulation", "PROBLEM", 3, 36], ["microthrombi formation", "PROBLEM", 38, 60], ["fibrin deposition", "PROBLEM", 62, 79], ["COVID", "TEST", 81, 86], ["anticoagulant", "TREATMENT", 110, 123], ["fibrinolytic therapy", "TREATMENT", 127, 147], ["the COVID", "TEST", 206, 215], ["TAT", "TEST", 278, 281], ["TM", "TEST", 283, 285], ["t-PAIC", "TEST", 287, 293], ["PT", "TEST", 295, 297], ["INR", "TEST", 299, 302], ["APTT", "TEST", 304, 308], ["DD", "PROBLEM", 314, 316], ["the PLT", "TEST", 346, 353], ["intravascular coagulation", "OBSERVATION", 11, 36], ["microthrombi", "OBSERVATION", 38, 50], ["fibrin deposition", "OBSERVATION", 62, 79], ["decreased", "OBSERVATION_MODIFIER", 354, 363]]], ["It is shown that the patients have thrombocytopenia, elevated level of DD, and a prolonged APTT, suggesting that COVID-19 patients death may be associated with DIC [25] [26] .", [["thrombocytopenia", "DISEASE", 35, 51], ["death", "DISEASE", 131, 136], ["DIC", "DISEASE", 160, 163], ["patients", "ORGANISM", 21, 29], ["APTT", "GENE_OR_GENE_PRODUCT", 91, 95], ["patients", "ORGANISM", 122, 130], ["APTT", "PROTEIN", 91, 95], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 122, 130], ["thrombocytopenia", "PROBLEM", 35, 51], ["elevated level of DD", "PROBLEM", 53, 73], ["a prolonged APTT", "PROBLEM", 79, 95], ["COVID", "TEST", 113, 118], ["DIC", "PROBLEM", 160, 163], ["thrombocytopenia", "OBSERVATION", 35, 51]]], ["Most severe COVID-19 patients develop dyspnea or hypoxemia one week after the onset, and their lung is more serious and gas exchange cannot be performed.", [["lung", "ANATOMY", 95, 99], ["dyspnea", "DISEASE", 38, 45], ["hypoxemia", "DISEASE", 49, 58], ["patients", "ORGANISM", 21, 29], ["lung", "ORGAN", 95, 99], ["patients", "SPECIES", 21, 29], ["Most severe COVID", "PROBLEM", 0, 17], ["dyspnea", "PROBLEM", 38, 45], ["hypoxemia", "PROBLEM", 49, 58], ["gas exchange", "TEST", 120, 132], ["dyspnea", "OBSERVATION", 38, 45], ["hypoxemia", "OBSERVATION", 49, 58], ["lung", "ANATOMY", 95, 99], ["more", "OBSERVATION_MODIFIER", 103, 107], ["serious", "OBSERVATION_MODIFIER", 108, 115]]], ["When ventilator cannot restore lung function, ECMO has become an effective treatment to rescue critical patients, but it is only temporarily replacing cardiopulmonary function, and there are still many complications.", [["lung", "ANATOMY", 31, 35], ["cardiopulmonary", "ANATOMY", 151, 166], ["lung", "ORGAN", 31, 35], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["ventilator", "TREATMENT", 5, 15], ["ECMO", "TREATMENT", 46, 50], ["still many complications", "PROBLEM", 191, 215], ["cardiopulmonary function", "OBSERVATION", 151, 175], ["many", "OBSERVATION_MODIFIER", 197, 201], ["complications", "OBSERVATION", 202, 215]]], ["Among them, the coagulation systems disorder is still one of the most common complications of ECMO, which terminate the ECMO [27] [28] .", [["coagulation systems disorder", "DISEASE", 16, 44], ["ECMO [27]", "CHEMICAL", 120, 129], ["the coagulation systems disorder", "PROBLEM", 12, 44], ["ECMO", "TREATMENT", 94, 98]]], ["Therefore, safe and scientific monitoring of the ECMO loop and thrombosis in patients, then early intervention can further reduce the harm of these complications to promote effective circulation support for ECMO.", [["thrombosis", "DISEASE", 63, 73], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["scientific monitoring", "TEST", 20, 41], ["the ECMO loop", "TREATMENT", 45, 58], ["thrombosis", "PROBLEM", 63, 73], ["early intervention", "TREATMENT", 92, 110], ["these complications", "PROBLEM", 142, 161], ["effective circulation support", "TREATMENT", 173, 202], ["ECMO", "TREATMENT", 207, 211], ["thrombosis", "OBSERVATION", 63, 73]]], ["TAT, PIC, TM, and t-PAIC are the indicators of early prediction and monitoring of DIC, and DD is the indicator that a thrombus is occurring or ongoing.", [["thrombus", "ANATOMY", 118, 126], ["DIC", "DISEASE", 82, 85], ["thrombus", "DISEASE", 118, 126], ["PIC", "CHEMICAL", 5, 8], ["TAT", "GENE_OR_GENE_PRODUCT", 0, 3], ["PIC", "SIMPLE_CHEMICAL", 5, 8], ["t-PAIC", "GENE_OR_GENE_PRODUCT", 18, 24], ["thrombus", "PATHOLOGICAL_FORMATION", 118, 126], ["TAT", "PROTEIN", 0, 3], ["PIC", "PROTEIN", 5, 8], ["TM", "PROTEIN", 10, 12], ["t-PAIC", "PROTEIN", 18, 24], ["early prediction", "TEST", 47, 63], ["DIC", "PROBLEM", 82, 85], ["DD", "PROBLEM", 91, 93], ["a thrombus", "PROBLEM", 116, 126], ["thrombus", "OBSERVATION", 118, 126]]], ["What's more, our findings demonstrated that the prediction of the t-PAIC .", [["t-PAIC", "GENE_OR_GENE_PRODUCT", 66, 72], ["t-PAIC", "PROTEIN", 66, 72]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020.Corresponding AuthorCorrespondence and requests for materials should be addressed to Wen Xie. \u00b6 These authors contributed equally.Author ContributionsWen Xie had the idea for and designed the study.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["materials", "TREATMENT", 327, 336], ["the study", "TEST", 463, 472], ["med", "ANATOMY", 105, 108]]], ["Wen Xie, Xin Jin and Yongwei Duan had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.Wen Xie contributed to critical revision of the report.", [["the study", "TEST", 72, 81], ["the data analysis", "TEST", 156, 173], ["revision", "OBSERVATION", 206, 214]]], ["Xin Jin contributed to the statistical analysis.", [["Xin Jin", "TREATMENT", 0, 7], ["the statistical analysis", "TEST", 23, 47]]], ["All authors contributed to data acquisition, data analysis, or data interpretation, and reviewed and approved the final version.", [["data acquisition", "TEST", 27, 43], ["data analysis", "TEST", 45, 58], ["data interpretation", "TEST", 63, 82]]], ["Xin Jin and Yongwei Duan contributed equally to this article.Author Contributions.", [["Xin Jin and Yongwei Duan", "TREATMENT", 0, 24]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]]], "PMC7281885": [["Coronavirus disease 2019 (COVID-19), declared a pandemic by the World Health Organization onMarch 11, 2020, has currently overwhelmed the global health sector.", [["Coronavirus disease", "DISEASE", 0, 19], ["COVID-19", "CHEMICAL", 26, 34], ["Coronavirus disease 2019 (COVID-19", "SPECIES", 0, 34], ["Coronavirus disease", "PROBLEM", 0, 19], ["COVID", "TEST", 26, 31], ["global", "OBSERVATION_MODIFIER", 138, 144]]], ["This infectious disease,caused by severe acute respiratory syndrome\u2013associated coronavirus 2 (SARS-CoV-2), uses areceptor, ACE2, to gain entry into human cells with the help of an enzyme,1 TMPRSS2, and likely interferes with the body\u2019s normal protective response resulting ininfection.", [["cells", "ANATOMY", 154, 159], ["body", "ANATOMY", 229, 233], ["infectious disease", "DISEASE", 5, 23], ["SARS-CoV-2", "ORGANISM", 94, 104], ["ACE2", "GENE_OR_GENE_PRODUCT", 123, 127], ["human", "ORGANISM", 148, 153], ["cells", "CELL", 154, 159], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 189, 196], ["body", "ORGANISM_SUBDIVISION", 229, 233], ["ACE2", "PROTEIN", 123, 127], ["human cells", "CELL_TYPE", 148, 159], ["TMPRSS2", "PROTEIN", 189, 196], ["respiratory syndrome\u2013associated coronavirus", "SPECIES", 47, 90], ["human", "SPECIES", 148, 153], ["severe acute respiratory syndrome\u2013associated coronavirus", "SPECIES", 34, 90], ["SARS-CoV-2", "SPECIES", 94, 104], ["human", "SPECIES", 148, 153], ["This infectious disease", "PROBLEM", 0, 23], ["severe acute respiratory syndrome\u2013associated coronavirus", "PROBLEM", 34, 90], ["SARS", "TEST", 94, 98], ["CoV", "TEST", 99, 102], ["areceptor", "TREATMENT", 112, 121], ["ACE2", "TREATMENT", 123, 127], ["an enzyme", "TEST", 177, 186], ["infectious", "OBSERVATION", 5, 15], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["respiratory syndrome\u2013associated coronavirus", "OBSERVATION", 47, 90], ["protective response", "OBSERVATION", 243, 262]]], ["Depending on the course of the illness, patients may experience a range of problemsthat can manifest as physical, psychological, and/or cognitive impairments.", [["physical, psychological, and/or cognitive impairments", "DISEASE", 104, 157], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["cognitive impairments", "PROBLEM", 136, 157]]], ["The most commonsymptom of COVID-19 in critically ill patients is acute respiratory distress syndrome (ARDS).The majority of patients admitted to the hospital report symptoms of shortness of breath andcough, and many of them end up with invasive or noninvasive respiratory support in theintensive care unit (ICU).", [["respiratory", "ANATOMY", 71, 82], ["respiratory", "ANATOMY", 260, 271], ["COVID-19", "CHEMICAL", 26, 34], ["critically ill", "DISEASE", 38, 52], ["acute respiratory distress syndrome", "DISEASE", 65, 100], ["ARDS", "DISEASE", 102, 106], ["shortness of breath", "DISEASE", 177, 196], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 124, 132], ["COVID", "TEST", 26, 31], ["acute respiratory distress syndrome", "PROBLEM", 65, 100], ["ARDS", "PROBLEM", 102, 106], ["symptoms", "PROBLEM", 165, 173], ["shortness of breath", "PROBLEM", 177, 196], ["invasive or noninvasive respiratory support", "TREATMENT", 236, 279], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["respiratory distress", "OBSERVATION", 71, 91], ["ARDS", "OBSERVATION", 102, 106], ["respiratory support", "OBSERVATION", 260, 279]]], ["Among patients in the ICU, a frequent complication followingintubation and extubation is oropharyngeal dysphagia: a type of swallowing disorder thatarises due to \u22651 dysfunctions of the oral cavity, pharynx, larynx, or upper esophagealsphincter and is caused by certain health conditions associated with anatomic, respiratory, orneurologic conditions.", [["oropharyngeal", "ANATOMY", 89, 102], ["oral cavity", "ANATOMY", 185, 196], ["pharynx", "ANATOMY", 198, 205], ["larynx", "ANATOMY", 207, 213], ["upper esophagealsphincter", "ANATOMY", 218, 243], ["respiratory", "ANATOMY", 313, 324], ["dysphagia", "DISEASE", 103, 112], ["swallowing disorder", "DISEASE", 124, 143], ["patients", "ORGANISM", 6, 14], ["oropharyngeal", "ORGANISM_SUBDIVISION", 89, 102], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 185, 196], ["pharynx", "ORGAN", 198, 205], ["larynx", "ORGAN", 207, 213], ["patients", "SPECIES", 6, 14], ["a frequent complication followingintubation", "TREATMENT", 27, 70], ["extubation", "TREATMENT", 75, 85], ["oropharyngeal dysphagia", "PROBLEM", 89, 112], ["swallowing disorder thatarises", "PROBLEM", 124, 154], ["\u22651 dysfunctions of the oral cavity, pharynx, larynx, or upper esophagealsphincter", "PROBLEM", 162, 243], ["anatomic, respiratory, orneurologic conditions", "PROBLEM", 303, 349], ["oropharyngeal", "ANATOMY", 89, 102], ["dysphagia", "OBSERVATION", 103, 112], ["oral cavity", "ANATOMY", 185, 196], ["pharynx", "ANATOMY", 198, 205], ["larynx", "ANATOMY", 207, 213], ["upper esophagealsphincter", "ANATOMY", 218, 243]]], ["It may be characterized by difficulty initiating a swallow, nasalregurgitation, aspiration into the airway, and/or presence of pharyngeal residue.", [["airway", "ANATOMY", 100, 106], ["pharyngeal", "ANATOMY", 127, 137], ["nasalregurgitation", "DISEASE", 60, 78], ["airway", "MULTI-TISSUE_STRUCTURE", 100, 106], ["pharyngeal", "ORGAN", 127, 137], ["a swallow", "TEST", 49, 58], ["nasalregurgitation", "PROBLEM", 60, 78], ["aspiration into the airway", "PROBLEM", 80, 106], ["pharyngeal residue", "PROBLEM", 127, 145], ["aspiration", "OBSERVATION", 80, 90], ["airway", "ANATOMY", 100, 106], ["pharyngeal", "ANATOMY", 127, 137], ["residue", "OBSERVATION", 138, 145]]], ["In thiscommentary, we highlight the risk and complications of oropharyngeal dysphagia in patientswith COVID-19.", [["oropharyngeal", "ANATOMY", 62, 75], ["oropharyngeal dysphagia", "DISEASE", 62, 85], ["oropharyngeal", "ORGANISM_SUBDIVISION", 62, 75], ["oropharyngeal dysphagia", "PROBLEM", 62, 85], ["COVID", "TEST", 102, 107], ["oropharyngeal", "ANATOMY", 62, 75], ["dysphagia", "OBSERVATION", 76, 85]]], ["Since dysphagia in patients with ARDS affects the overall rehabilitation andrecovery of the patient, we urge medical and rehabilitation professionals to understand therelationship between ARDS and dysphagia so that appropriate referrals may be provided andearly interventions initiated.", [["dysphagia", "DISEASE", 6, 15], ["ARDS", "DISEASE", 33, 37], ["ARDS", "DISEASE", 188, 192], ["dysphagia", "DISEASE", 197, 206], ["patients", "ORGANISM", 19, 27], ["patient", "ORGANISM", 92, 99], ["patients", "SPECIES", 19, 27], ["patient", "SPECIES", 92, 99], ["dysphagia", "PROBLEM", 6, 15], ["ARDS", "PROBLEM", 33, 37], ["rehabilitation professionals", "TREATMENT", 121, 149], ["ARDS", "PROBLEM", 188, 192], ["dysphagia", "PROBLEM", 197, 206], ["interventions", "TREATMENT", 262, 275], ["dysphagia", "OBSERVATION", 6, 15]]]], "e9765c689018a6785d5eb3cc8d24758e5e1ab46b": [["IntroductionOn 20 February 2020, the British Dental Association and Public Health England chaired the first Mental Health and Wellbeing Day bringing together attendees from across the dental profession to discuss the problems with and solutions to stress, burnout and mental ill health among dentists.IntroductionLess than five weeks later, lockdown happened and the dental profession downed tools.", [["burnout", "DISEASE", 256, 263]]], ["Much of the focus then fell on securing the economic livelihoods of those affected -furlough requirements, Business Interruption insurance and business rates relief became (and still are) buzzwords.", [["furlough", "DISEASE", 84, 92]]], ["And while it became clear that economic recovery of the sector and the country were the first and foremost priorities, 'people' were left behind.", [["people", "ORGANISM", 120, 126], ["people", "SPECIES", 120, 126], ["left", "ANATOMY_MODIFIER", 133, 137]]], ["While I am fortunate to have survived with much of my sanity intact, for others the very problems discussed at the Mental Health and Wellbeing Day came to the fore.The stress of uncertaintyAccording to a new poll by the mental health charity Mind, many people who were previously well will develop mental health problems as a 'direct consequence of the pandemic and all that follows' , with the worst yet to come.", [["people", "ORGANISM", 253, 259], ["people", "SPECIES", 253, 259], ["mental health problems", "PROBLEM", 298, 320]]], ["Two out of three adults aged 25 and over and three-quarters of young people aged 13-24 with an existing mental health problem reported worse mental health during the lockdown, its survey found.The stress of uncertaintyOf adults with no previous experience of poor mental health, 22% said that their mental health is poor or very poor.", [["people", "ORGANISM", 69, 75], ["people", "SPECIES", 69, 75], ["poor mental health", "PROBLEM", 259, 277]]], ["Those who were furloughed, changed jobs or lost their job due to coronavirus saw their mental health and wellbeing decline more than those whose employment status did not change, the research revealed.The stress of uncertaintyOf those who tried to access NHS mental health services, 25% were unable to get support, the survey found.", [["coronavirus", "ORGANISM", 65, 76], ["coronavirus", "PROBLEM", 65, 76], ["the survey", "TEST", 315, 325]]], ["A further 32% of adults and 28% of young people did not try to access support because they did not think that their problem was serious enough.David Westgarth Editor, BDJ in PracticeWhile the Mental Health event could not foresee what was around the corner, these issues were brought up.", [["adults", "ORGANISM", 17, 23], ["people", "ORGANISM", 41, 47], ["people", "SPECIES", 41, 47]]], ["Are mental health problems on the increase?", [["mental health problems", "PROBLEM", 4, 26]]], ["There are hills in the marathon, we see them coming and we can and should prepare; for example, buying a practice, starting a family, a parent needing support.", [["hills", "OBSERVATION_MODIFIER", 10, 15]]], ["There are potholes, when we have no chance to prepare and these can be very destabilising, for example a complaint, death of a loved one, and of course a pandemic.David Westgarth Editor, BDJ in Practice'In this pandemic we need to add financial pressures, anxiety about COVID-19 itself and risks of transmission to patients, staff and family, family disruption, the need to manage schooling and caring responsibilities and possibly deal with the grief of losing a loved and cherished member of the family.", [["death", "DISEASE", 116, 121], ["anxiety", "DISEASE", 256, 263], ["patients", "ORGANISM", 315, 323], ["patients", "SPECIES", 315, 323], ["financial pressures", "TREATMENT", 235, 254], ["anxiety", "PROBLEM", 256, 263]]], ["No wonder research for the BDA shows signs of burnout in over 85% in GDPs.David Westgarth Editor, BDJ in Practice'Our early career dentists and students have been real heroes in this pandemic, many being deployed to roles on the front line.", [["BDA", "CHEMICAL", 27, 30], ["burnout", "DISEASE", 46, 53], ["BDA", "SIMPLE_CHEMICAL", 27, 30], ["GDPs", "SIMPLE_CHEMICAL", 69, 73], ["the BDA", "TEST", 23, 30], ["burnout", "PROBLEM", 46, 53], ["burnout", "OBSERVATION", 46, 53]]], ["However they are now returning to the uncertainty of missing time in training, new ways of assessing competency and even 'will there be a job?' .David Westgarth Editor, BDJ in Practice'The anxiety of uncertainty is normal and to be expected.", [["anxiety", "DISEASE", 189, 196], ["normal", "OBSERVATION", 215, 221]]], ["Be sensitive to those in the team who are feeling vulnerable, acknowledge their feelings and ensure they are not experiencing harassment or even bullying.David Westgarth Editor, BDJ in Practice'But above all maintain professional and social networks.", [["bullying", "DISEASE", 145, 153], ["social networks", "MULTI-TISSUE_STRUCTURE", 234, 249]]], ["Regular team meetings in the workplace with effective reflection and twoway communication are very effective.", [["twoway communication", "TREATMENT", 69, 89]]], ["BDA amongst others are organising virtual Branch and Section meetings and online platforms are a good, if imperfect, way to catch up with friends and peers.", [["BDA", "CHEMICAL", 0, 3], ["BDA", "CHEMICAL", 0, 3], ["BDA", "SIMPLE_CHEMICAL", 0, 3], ["Branch", "OBSERVATION_MODIFIER", 42, 48]]], ["Try and separate your home and work life, although that is easier said than done when you go home and the TV is full of news about COVID-19.David Westgarth Editor, BDJ in Practice' Above all, be kind to yourself: eat, sleep, exercise and take some time out of dentistry to do something you enjoy and get satisfaction from.", [["COVID", "TEST", 131, 136]]], ["'David Westgarth Editor, BDJ in PracticeLauren Harrhy, practice owner and founder of Mental Dental, suggested the mental health impact on the profession has been -and will continue to be -profound.David Westgarth Editor, BDJ in Practice'I know from experience colleagues have felt quite downtrodden and powerless, scared and frustrated over this period' , she said.", [["scared", "PROBLEM", 314, 320]]], ["Many have found sourcing PPE a huge challenge and getting used to wearing it yet another massive hurdle.David Westgarth Editor, BDJ in Practice'I know that young dentists in particular have found the mental adjustment to implementing AAA quite difficult.", [["a huge challenge", "TREATMENT", 29, 45], ["AAA", "OBSERVATION", 234, 237]]], ["We are so used to hearing that antibiotics don't cure toothache; it has felt strange and unnatural to prescribe antibiotics over this time.", [["toothache", "DISEASE", 54, 63], ["antibiotics", "TREATMENT", 31, 42], ["toothache", "PROBLEM", 54, 63], ["antibiotics", "TREATMENT", 112, 123]]], ["Many are suffering great moral injury because they have not been able to care for their patients in the way they would like to.", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["great moral injury", "PROBLEM", 19, 37], ["moral injury", "OBSERVATION", 25, 37]]], ["'David Westgarth Editor, BDJ in PracticeDental Core Trainee Alice Duke also found 'the new norm' difficult.David Westgarth Editor, BDJ in Practice'It has been challenging, especially as a dental core trainee where much of the focus is on learning new clinical techniques and gaining clinical experience in new disciplines' , Alice said.", [["challenging", "OBSERVATION_MODIFIER", 159, 170]]], ["'I felt very anxious during the first few weeks and found it difficult to sleep, as did many of my colleagues.", [["very anxious", "PROBLEM", 8, 20]]], ["I had just moved departments from restorative to paediatrics/ orthodontics and found it difficult to adapt to the constantly changing protocols, as well as working alongside new staff.David Westgarth Editor, BDJ in Practice'I spent a few weeks working from home which involved helping to develop new standard operating procedures to be used in the department.", [["new standard operating procedures", "TREATMENT", 296, 329]]], ["I did feel disconnected from the profession during this period and missed the clinical environment.David Westgarth Editor, BDJ in Practice'Dentistry is a profession founded on principles of communication with colleagues/ patients and teamwork, so adapting to working alone in an office environment took some adjustment.", [["patients", "ORGANISM", 221, 229], ["patients", "SPECIES", 221, 229]]], ["'Many hospitals have had to adapt to become urgent dental care hubs during the peak of the pandemic, with both the hospitals I work in beginning to start to resume some ' According to a new poll by the mental health charity Mind, many people who were previously well will develop mental health problems as a 'direct consequence of the pandemic and all that follows', with the worst yet to come.' routine services.", [["people", "ORGANISM", 235, 241], ["people", "SPECIES", 235, 241], ["mental health problems", "PROBLEM", 280, 302]]], ["But the number of patients we have capacity to safely see is dramatically fewer than usual and there is going to be a large backlog of patients to see.", [["patients", "ORGANISM", 18, 26], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 135, 143]]], ["Waiting lists will be affected and in some cases, patient criteria have become much stricter in order to reduce waiting times for priority patients.", [["patient", "ORGANISM", 50, 57], ["patients", "ORGANISM", 139, 147], ["patient", "SPECIES", 50, 57], ["patients", "SPECIES", 139, 147]]], ["Patients who were on waiting lists before the pandemic may now receive letters saying they no longer fit the criteria to be seen in hospital and need to seek care elsewhere.David Westgarth Editor, BDJ in Practice'In this time their oral health may have deteriorated and their needs increased, which is a problem on the horizon the profession will need to tackle.", [["oral", "ANATOMY", 232, 236], ["Patients", "ORGANISM", 0, 8], ["oral", "ORGANISM_SUBDIVISION", 232, 236], ["Patients", "SPECIES", 0, 8]]], ["With disruption to their clinical time with patients, will dental students be ready to hit the ground running?", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52]]], ["'It was worrying reading about the number of dental practices that said they may be forced to close and thinking about the knock-on effects this could have on our cohort in the longer term.Preparedness' Any significant time away from clinic will reduce our confidence in our clinical skills and treatment planning abilities and will require a considerable amount of remediation.", [["treatment planning", "TREATMENT", 295, 313], ["a considerable amount of remediation", "TREATMENT", 341, 377]]], ["We're very lucky at Aberdeen in that we start seeing patients in our first year of study, so we have spent a fair amount of time in clinic already.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61]]], ["Neha added: 'I completely agree.", [["Neha", "CHEMICAL", 0, 4]]], ["However this might not be feasible as we have missed a whole term of teaching and so they are looking at lowering requirements to take finals.", [["a whole term of teaching", "TREATMENT", 53, 77]]], ["This concerns me because upon graduation I might have less clinical exposure and lower skills compared to other students who graduated not being affected by COVID-19.", [["COVID", "TEST", 157, 162]]], ["A full remote replacement for the clinical application of theoretical knowledge and skill has yet to be created.", [["A full remote replacement", "TREATMENT", 0, 25], ["replacement", "OBSERVATION", 14, 25]]], ["Not having patient contact to build relationships and the ability to transfer theory and practical skill is fundamental in the transition from non-clinical to clinical practice.", [["patient", "ORGANISM", 11, 18], ["patient", "SPECIES", 11, 18]]], ["Unique problems such as this require unique solutions and despite the initial stress for staff and students, it is an amazing opportunity to really study and modernise the delivery of a dental curriculum moving forward.", [["Unique problems", "PROBLEM", 0, 15], ["unique solutions", "TREATMENT", 37, 53], ["a dental curriculum", "TREATMENT", 184, 203]]], ["'PreparednessLauren believes the lack of clinical development could be a real issue in the years to come.", [["PreparednessLauren", "TREATMENT", 1, 19]]], ["The need for preparation has increased.", [["preparation", "TREATMENT", 13, 24], ["increased", "OBSERVATION_MODIFIER", 29, 38]]], ["'PreparednessAlice echoed Lauren's concerns about clinical competencies and pointed to some resources that may help to fill the void.Preparedness'Meeting the total requirements for procedures such as molar endodontics and extractions to ensure successful progression to finals is challenging enough as it is' , she told BDJ In Practice.", [["procedures", "TREATMENT", 181, 191], ["molar endodontics", "TREATMENT", 200, 217], ["extractions", "TREATMENT", 222, 233]]], ["'That's why I feel now is the time to capitalise on the advancements made in digital education i.e. e-learning, haptic simulation and distance learning.PreparednessTechnology has advanced rapidly over the last decade and many clinical techniques can now be taught, practiced and assessed virtually or remotely via dental simulators i.e. Moog Simodont Dental Trainer, HapTEL Training System.", [["digital education", "TREATMENT", 77, 94], ["haptic simulation and distance learning", "TREATMENT", 112, 151]]], ["This technology utilises haptic virtual reality simulation for sensorimotor skill acquisition.", [["sensorimotor skill acquisition", "TEST", 63, 93]]], ["As many of these systems do not require an assessor or patient to be present, social distancing guidelines can be followed and clinical skills improved, without risk of transmission.PreparednessI feel there is scope to modify the current techniques used in dental education to make up the shortfall in clinical experience that students have lost as a result of COVID-19.", [["patient", "ORGANISM", 55, 62], ["patient", "SPECIES", 55, 62], ["dental education", "TREATMENT", 257, 273], ["COVID", "TEST", 361, 366]]], ["Natalie added while clinical development was clearly an issue, deeper concerns lie ahead.Preparedness'Besides being an able clinician ready to treat patients, I also worry about their wellbeing.", [["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["Natalie", "TREATMENT", 0, 7]]], ["'Recruitment: what will be left?In April research by the BDA suggested 70% of practices reported that at the time they could only maintain financial viability for a maximum of three months, with those providing predominantly private care worst affected.Recruitment: what will be left?While the NHS side of practices have been offered some support by government, the BDA has warned that if those practices with a greater reliance on private work go under whatever service remains will be unable to meet patient demand.Recruitment: what will be left?In Scotland following confirmation from First Minister Nicola Sturgeon that services would recommence from 22 June, the BDA issued a warning that a combination of higher costs and lower patient numbers could prove fatal for services in Scotland.", [["BDA", "SIMPLE_CHEMICAL", 57, 60], ["BDA", "SIMPLE_CHEMICAL", 366, 369], ["patient", "ORGANISM", 502, 509], ["patient", "ORGANISM", 734, 741], ["patient", "SPECIES", 502, 509], ["patient", "SPECIES", 734, 741], ["left", "ANATOMY_MODIFIER", 27, 31], ["left", "ANATOMY_MODIFIER", 279, 283], ["left", "ANATOMY_MODIFIER", 543, 547]]], ["Shortages of PPE are expected to place limits on patient numbers.", [["patient", "ORGANISM", 49, 56], ["patient", "SPECIES", 49, 56], ["Shortages of PPE", "TREATMENT", 0, 16]]], ["While the authorities recently distributed more than three million individual items of PPE to dental practices, volumes are only sufficient to enable practices to see around 10 patients a day.", [["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 177, 185]]], ["The Assembly Committee for Health in Northern Ireland were warned to expect similar outcomes if government inaction persisted.Recruitment: what will be left?Prior to the pandemic recruitment was already facing a crisis, and there are no doubts this will only serve to elevate concerns for job seekers and recruiters.", [["the pandemic recruitment", "TREATMENT", 166, 190], ["a crisis", "PROBLEM", 210, 218], ["left", "ANATOMY_MODIFIER", 152, 156]]], ["On the other hand, I suspect that with reduced capacity to see patients at the same rate as before COVID-19, there will be a call to work longer hours or on a shift pattern which could increase demand for associates and worsen the recruitment crisis.Recruitment: what will be left?'I think that we need to remain vigilant to the possible risks to our professional careers during this time and in the future; the 'new normal' isn't just going to be isolated to our supermarket trips, but to our working lives and career paths looking into the future. '", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["reduced capacity", "PROBLEM", 39, 55], ["the recruitment crisis", "PROBLEM", 227, 249], ["recruitment crisis", "OBSERVATION", 231, 249], ["left", "ANATOMY_MODIFIER", 276, 280]]], ["'COVID-19 will obviously change the profession -perhaps indefinitely -but we are arguably fortunate that there will always be a need for dentists, even more so now as a result of the backlog of patients not seen due to lockdown.", [["patients", "ORGANISM", 194, 202], ["patients", "SPECIES", 194, 202]]], ["Whether this will be in in a positive or negative way is dependent on how the remuneration system is restructured, the cost/availability of PPE, the capacity for practices to accommodate new patient workflow and the government social distancing guidelines.", [["patient", "ORGANISM", 191, 198], ["patient", "SPECIES", 191, 198], ["PPE", "PROBLEM", 140, 143]]], ["All of these factors are liable to change and by no means an extensive or exhaustive list.Recruitment: what will be left?'It must be acknowledged that the delivery of services, both in the NHS and Private sectors, will need considerable modification.", [["considerable modification", "TREATMENT", 224, 249]]], ["Patient workflow capacity, the UDA remuneration system and provision of elective aerosol generating procedures are particular areas where changes must be made in order to comply with COVID-19 guidelines.", [["Patient", "SPECIES", 0, 7], ["Patient workflow capacity", "TEST", 0, 25], ["elective aerosol generating procedures", "TREATMENT", 72, 110]]], ["The risk of infection to professionals in vulnerable groups i.e. pregnant, underlying health conditions, may deter return to work completely.", [["infection", "DISEASE", 12, 21], ["infection", "PROBLEM", 12, 21], ["infection", "OBSERVATION", 12, 21]]], ["The capacity for practices to accommodate both patients and dentists in a socially distanced environment may force clinicians to seek employment elsewhere, work part-time or between a number of establishments.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55]]], ["The pressures of providing private dentistry may increase treatment prices for patients and/or the variety/modality of elective options available.", [["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["private dentistry", "TREATMENT", 27, 44], ["treatment prices", "TREATMENT", 58, 74], ["elective options", "TREATMENT", 119, 135], ["pressures", "OBSERVATION_MODIFIER", 4, 13]]], ["We may see shifts in recruitment in both primary and secondary dental care, with some individuals opting for the stability of a set salary.", [["secondary dental care", "TREATMENT", 53, 74], ["recruitment", "OBSERVATION_MODIFIER", 21, 32]]], ["I find it almost impossible to predict in the current circumstances, and while that may not sound optimistic, I would encourage young dentists not to be disheartened or concerned, but to embrace the opportunity for change, leadership and integration of new digital technologies into all aspect of the profession as we forge what 'new' will look like.", [["new digital technologies", "TREATMENT", 253, 277]]], ["'Recruitment: what will be left?The watermark of concern runs through Neha and Mairi too.Recruitment: what will be left?Mairi said: 'I imagine if dental practices with VT trainers are forced to close then it's possible that there will be fewer jobs for new graduates.", [["VT trainers", "TREATMENT", 168, 179], ["left", "ANATOMY_MODIFIER", 27, 31], ["left", "ANATOMY_MODIFIER", 115, 119]]], ["I worry that dentists may be forced to reduce their NHS work and increase private work to keep their businesses viable, leaving some of the most vulnerable patients without dental care, and possibly some newly graduated dental students without VT posts.", [["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["dental care", "TREATMENT", 173, 184]]], ["'Recruitment: what will be left?Neha added: 'When I graduate I feel like there will be fewer jobs available.", [["Neha", "CHEMICAL", 32, 36], ["left", "ANATOMY_MODIFIER", 27, 31]]], ["Many surgeries may have fewer dentists as they cannot afford it and therefore this increases the competition for jobs.", [["Many surgeries", "TREATMENT", 0, 14], ["surgeries", "OBSERVATION", 5, 14]]], ["'Recruitment: what will be left?While she understands the concerns of Neha and Mairi, according to Lauren, the enforced break may have provided the opportunity for many to reassess career paths and choices.Recruitment: what will be left?'Yes, in the short term it may seem that there are fewer opportunities for young associates' , she said.", [["left", "ANATOMY_MODIFIER", 27, 31]]], ["'A lack of supportThe mental health event identified that a range of patient-related factors were the main stressors for dentists, but the BDA's research found that, while dissatisfied patients remained the second greatest stressor, fear of complaints and litigation was now the main factor.", [["patient", "ORGANISM", 69, 76], ["BDA", "SIMPLE_CHEMICAL", 139, 142], ["patients", "ORGANISM", 185, 193], ["patient", "SPECIES", 69, 76], ["patients", "SPECIES", 185, 193], ["complaints", "PROBLEM", 241, 251]]], ["The risk of making mistakes, red tape and bureaucracy, and concern about the GDC were also leading causes.A lack of supportIt is without a doubt the situation the world finds itself in, but red tape and bureaucracy are only likely to increase.", [["red tape", "TREATMENT", 29, 37], ["bureaucracy", "PROBLEM", 42, 53], ["red tape", "TREATMENT", 190, 198], ["without", "UNCERTAINTY", 129, 136], ["only likely", "UNCERTAINTY", 219, 230]]], ["Patients will be fearful of catching COVID-19 from their dentist.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["What happens if a patient complains to the GDC that their dentist was responsible for them developing COVID-19?", [["COVID-19", "CHEMICAL", 102, 110], ["patient", "ORGANISM", 18, 25], ["patient", "SPECIES", 18, 25], ["COVID", "TEST", 102, 107]]], ["Which makes you think that during the period of inactivity, the GDC may do something to ease the burden on their financially stretched, hugely stressed registrants.A lack of supportThat did not happen.A lack of supportIn an update to registrants on 20 May, GDC Chair Bill Moyes wrote:A lack of support'The impact of the COVID-19 pandemic continues to have a significant effect on our lives.", [["the COVID", "TREATMENT", 316, 325], ["significant", "OBSERVATION_MODIFIER", 358, 369]]], ["I am very aware that the effect of the suspension of routine dental care and services is severe and that it has prevented you providing the patient treatment and care you want to -and in some cases has caused financial difficulties.", [["patient", "ORGANISM", 140, 147], ["patient", "SPECIES", 140, 147], ["routine dental care", "TREATMENT", 53, 72], ["financial difficulties", "PROBLEM", 209, 231]]], ["We have been ' It is without a doubt the situation the world finds itself in, but red tape and bureaucracy are only likely to increase.", [["red tape", "TREATMENT", 82, 90], ["without", "UNCERTAINTY", 21, 28], ["only likely", "UNCERTAINTY", 111, 122]]], ["Patients will be fearful of catching COVID-19 from their dentist.' asked whether the GDC could respond by making changes to the Annual Retention Fee (ARF) paid by all dental professionals or by introducing an emergency payment by instalments scheme.A lack of supportThe Council has thought carefully about the options available to us, but we have decided not to make changes to the ARF levels or to introduce a payment scheme.", [["ARF", "DISEASE", 382, 385], ["Patients", "ORGANISM", 0, 8], ["ARF", "GENE_OR_GENE_PRODUCT", 382, 385], ["Patients", "SPECIES", 0, 8], ["ARF", "PROBLEM", 150, 153], ["the ARF levels", "PROBLEM", 378, 392], ["a payment scheme", "TREATMENT", 409, 425]]], ["These are not decisions we have taken lightly, and I know they won't be welcomed by some of those we regulate, so I want to be clear about the reasons why we have made them.A lack of supportThe work we have to do, which is laid down in law, has not fundamentally changed.", [["not", "UNCERTAINTY", 245, 248], ["fundamentally", "OBSERVATION_MODIFIER", 249, 262], ["changed", "OBSERVATION", 263, 270]]], ["We are required to remain financially stable and to meet our statutory obligations to ensure the public are protected and confidence in the professions is maintained.A lack of supportNearly all our income comes from the ARF collection.", [["ARF", "DISEASE", 220, 223], ["ARF", "GENE_OR_GENE_PRODUCT", 220, 223], ["our statutory obligations", "TREATMENT", 57, 82], ["the ARF collection", "PROBLEM", 216, 234], ["ARF", "OBSERVATION", 220, 223]]], ["By revising our regulatory approach and increasing our efficiency, we have been able to secure greater value for money and reduce the ARF -and we hope to continue along this path.", [["ARF", "DISEASE", 134, 137], ["ARF", "GENE_OR_GENE_PRODUCT", 134, 137], ["the ARF", "PROBLEM", 130, 137], ["ARF", "OBSERVATION", 134, 137]]], ["But we don't want to make changes now that we can't sustain, and which might lead to inefficiency and increased costs in the future.' 1 As you can imagine, at a time when income had been reduced to zero, this decision was met with universal dismay.", [["inefficiency and increased costs", "PROBLEM", 85, 117]]], ["Yes they did, and yet in a clarification on this, the announcement read: 'That is why Council decided that at present the level of the ARF should not change. ' 2 No mention of the possibility of instalments, which is why in a letter to Moyes, BDA Chair Mick Armstrong stated:A lack of support'It is a great shame that our regulator, who prides itself on making significant improvements to its way of working, wants to work collaboratively with the profession, and whose finances include a significant budget operating surplus and significant reserves, cannot see how positive such a move would have been, and how negative its absence is.A lack of support' As always, the impact will be greatest on the most vulnerable of the profession: new graduates, many of whom have lost their part-time jobs; young dentists leaving dental foundation training and potentially struggling to find their first associateship; and dental care professional colleagues who are significantly affected by the closure of practices and the expected lengthy return to the provision of dentistry over the coming months.A lack of support'It remains a matter of fact that a relatively easy change that is within the GDC's power and would have had a profound positive reaction amongst the professions it regulates -unlike so many other possible positive changes where 'inflexible legislation' is cited as the reason for its lack of agility -is not forthcoming.' 3 It is moves like this that do nothing to improve the patchy relationship the profession has with them.", [["ARF", "DISEASE", 135, 138], ["ARF", "GENE_OR_GENE_PRODUCT", 135, 138], ["the ARF", "PROBLEM", 131, 138], ["a profound positive reaction", "PROBLEM", 1219, 1247], ["positive changes", "PROBLEM", 1316, 1332], ["ARF", "OBSERVATION", 135, 138], ["profound", "OBSERVATION_MODIFIER", 1221, 1229], ["positive", "OBSERVATION", 1230, 1238]]], ["This is on top of the normal anxieties that exist whilst living through a global pandemic.", [["normal", "OBSERVATION", 22, 28]]], ["The GDC must recognise and appreciate that this will inevitably have some influence on our performance as professionals.A lack of support'There have been periods where guidance has not been available, unclear or contradictory, putting clinicians in the impossible situation of trying to work within the best interests of their patients, whilst ensuring the safety of their staff and themselves.", [["patients", "ORGANISM", 327, 335], ["patients", "SPECIES", 327, 335]]], ["After all, we are all human and we do make mistakes. '", [["human", "ORGANISM", 22, 27], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27]]], ["I asked Roz how COVID-19 stresseson top of pre-pandemic stress -would be supported by the BDA and where people can go for support.A lack of support'The Mental Health and Wellbeing report and action plan 4 has just been published and shared with all the attendees.", [["BDA", "SIMPLE_CHEMICAL", 90, 93], ["people", "ORGANISM", 104, 110], ["people", "SPECIES", 104, 110], ["pre-pandemic stress", "PROBLEM", 43, 62]]], ["While the focus has changed to how we support our colleagues at this difficult time, we will return after the acute phase of this pandemic to some of the important long-term objectives in that report.A lack of support'In the meantime, the BDA are doing all we can to support the wellbeing of dentists and their teams by sharing resources, signposting, webinars and of course the offering with the award winning Health-Assured, which is available to all levels of membership, including students.", [["BDA", "SIMPLE_CHEMICAL", 239, 242]]]], "PMC7149677": [["INTRODUCTIONThere is little more ambiguous than words.", [["little more", "OBSERVATION_MODIFIER", 21, 32]]], ["Take retrovirus and evolution that make up the title.", [["retrovirus", "TREATMENT", 5, 15], ["retrovirus", "OBSERVATION", 5, 15]]], ["Once upon a time \u201cretrovirus\u201d was pretty clear and referred to a group of viruses with two copies of polyA+ genomic RNA in the virion.", [["virion", "ANATOMY", 127, 133], ["retrovirus", "ORGANISM", 18, 28], ["polyA", "GENE_OR_GENE_PRODUCT", 101, 106], ["virion", "CELLULAR_COMPONENT", 127, 133], ["polyA+ genomic RNA", "RNA", 101, 119], ["polyA+ genomic RNA in the virion", "PROBLEM", 101, 133], ["genomic RNA", "OBSERVATION", 108, 119], ["virion", "ANATOMY", 127, 133]]], ["Their genetic bauplan was three orfs, gag-pol-env, bounded by two long terminal repeats (LTRs).", [["long terminal repeats", "ANATOMY", 66, 87], ["gag-pol", "GENE_OR_GENE_PRODUCT", 38, 45], ["long terminal repeats", "CELLULAR_COMPONENT", 66, 87], ["orfs", "DNA", 32, 36], ["gag-pol-env", "DNA", 38, 49], ["long terminal repeats", "DNA", 66, 87], ["LTRs", "DNA", 89, 93]]], ["The situation was complicated a little with the identification of endogenous retroviruses in the mid-1970s and thoroughly disjointed by the discoveries in 1982 and 1983 that both hepatitis B virus (HBV) and cauliflower mosaic virus (CaMV) replicate by way of an RNA intermediate.", [["hepatitis B", "DISEASE", 179, 190], ["retroviruses", "ORGANISM", 77, 89], ["hepatitis B virus", "ORGANISM", 179, 196], ["HBV", "ORGANISM", 198, 201], ["cauliflower mosaic virus", "ORGANISM", 207, 231], ["CaMV", "ORGANISM", 233, 237], ["hepatitis B virus", "SPECIES", 179, 196], ["cauliflower mosaic virus", "SPECIES", 207, 231], ["hepatitis B virus", "SPECIES", 179, 196], ["HBV", "SPECIES", 198, 201], ["cauliflower mosaic virus", "SPECIES", 207, 231], ["CaMV", "SPECIES", 233, 237], ["endogenous retroviruses", "PROBLEM", 66, 89], ["hepatitis B virus", "PROBLEM", 179, 196], ["HBV", "PROBLEM", 198, 201], ["cauliflower mosaic virus (CaMV)", "TREATMENT", 207, 238], ["endogenous retroviruses", "OBSERVATION", 66, 89]]], ["The infectious form of both of these viruses is DNA.", [["DNA", "CELLULAR_COMPONENT", 48, 51], ["DNA", "PROBLEM", 48, 51], ["infectious", "OBSERVATION", 4, 14], ["viruses", "OBSERVATION", 37, 44]]], ["However, given that the history of \u201cretroviruses\u201d goes back to the early 1900s, that they induced cancer, while the remarkable phenomenon of reverse transcription that broke \u201cThe Central Dogma\u201d of the day, i.e. DNA makes RNA makes protein, was established using these oncogenic retroviruses, classical \u201cretrovirology\u201d understandably had the advantage of terrain.INTRODUCTIONHBV was referred to as a \u201cpararetrovirus\u201d before becoming the prototype of the \u201chepadnavirus\u201d group.", [["cancer", "ANATOMY", 98, 104], ["cancer", "DISEASE", 98, 104], ["retroviruses", "ORGANISM", 36, 48], ["cancer", "CANCER", 98, 104], ["DNA", "CELLULAR_COMPONENT", 211, 214], ["retroviruses", "ORGANISM", 278, 290], ["hepadnavirus\u201d", "CANCER", 454, 467], ["\u201cretroviruses", "PROBLEM", 35, 48], ["cancer", "PROBLEM", 98, 104], ["reverse transcription", "TREATMENT", 141, 162], ["these oncogenic retroviruses", "PROBLEM", 262, 290], ["cancer", "OBSERVATION", 98, 104], ["Central", "ANATOMY_MODIFIER", 179, 186], ["oncogenic retroviruses", "OBSERVATION", 268, 290]]], ["CaMV lent its name to the caulimovirus group.", [["CaMV", "ORGANISM", 0, 4], ["caulimovirus", "CANCER", 26, 38], ["CaMV", "DNA", 0, 4], ["CaMV", "SPECIES", 0, 4]]], ["Retrovirology has come to be synonymous with classical retroviruses.INTRODUCTIONYet just at this moment, retrovirology was about to be discombobulated once again, and this time by an insider.", [["retroviruses", "ORGANISM", 55, 67], ["classical retroviruses", "PROBLEM", 45, 67], ["retroviruses", "OBSERVATION", 55, 67]]], ["Prior to HIV, the key retroviruses were oncogenic, otherwise known as the avian and murine leukemia viruses (ALV and MLV) and mouse mammary tumor virus (MMTV).", [["avian and murine leukemia viruses", "DISEASE", 74, 107], ["mammary tumor", "DISEASE", 132, 145], ["retroviruses", "ORGANISM", 22, 34], ["avian", "ORGANISM", 74, 79], ["murine leukemia viruses", "ORGANISM", 84, 107], ["ALV", "ORGANISM", 109, 112], ["MLV", "ORGANISM", 117, 120], ["mouse mammary tumor virus", "ORGANISM", 126, 151], ["MMTV", "ORGANISM", 153, 157], ["HIV", "SPECIES", 9, 12], ["avian", "SPECIES", 74, 79], ["murine", "SPECIES", 84, 90], ["mouse", "SPECIES", 126, 131], ["HIV", "SPECIES", 9, 12], ["murine leukemia viruses", "SPECIES", 84, 107], ["ALV", "SPECIES", 109, 112], ["MLV", "SPECIES", 117, 120], ["mouse", "SPECIES", 126, 131], ["MMTV", "SPECIES", 153, 157], ["HIV", "PROBLEM", 9, 12], ["the avian and murine leukemia viruses (ALV and MLV)", "PROBLEM", 70, 121], ["mouse mammary tumor virus", "PROBLEM", 126, 151], ["leukemia viruses", "OBSERVATION", 91, 107], ["mammary", "ANATOMY", 132, 139], ["tumor", "OBSERVATION", 140, 145]]], ["The discovery in 1980 of human T cell leukemia virus (HTLV) associated with adult T cell leukemia virus fitted the bill, so all was well.", [["T cell leukemia", "ANATOMY", 31, 46], ["adult T cell leukemia", "ANATOMY", 76, 97], ["T cell leukemia virus", "DISEASE", 31, 52], ["adult T cell leukemia virus", "DISEASE", 76, 103], ["human T cell leukemia virus", "ORGANISM", 25, 52], ["HTLV", "ORGANISM", 54, 58], ["adult T cell leukemia virus", "ORGANISM", 76, 103], ["human", "SPECIES", 25, 30], ["T cell leukemia virus", "SPECIES", 31, 52], ["human T cell leukemia virus", "SPECIES", 25, 52], ["HTLV", "SPECIES", 54, 58], ["human T cell leukemia virus (HTLV)", "PROBLEM", 25, 59], ["adult T cell leukemia virus", "PROBLEM", 76, 103], ["cell leukemia virus", "OBSERVATION", 33, 52], ["cell leukemia virus", "OBSERVATION", 84, 103]]], ["However, with the isolation of HIV-1, a lentivirus, and a major new disease, AIDS, indeed the infection of a generation, everything changed.", [["AIDS", "DISEASE", 77, 81], ["infection", "DISEASE", 94, 103], ["HIV-1", "ORGANISM", 31, 36], ["lentivirus", "ORGANISM", 40, 50], ["HIV-1", "SPECIES", 31, 36], ["HIV-1", "SPECIES", 31, 36], ["lentivirus", "SPECIES", 40, 50], ["HIV", "PROBLEM", 31, 34], ["a lentivirus", "PROBLEM", 38, 50], ["a major new disease", "PROBLEM", 56, 75], ["AIDS", "PROBLEM", 77, 81], ["the infection", "PROBLEM", 90, 103], ["lentivirus", "OBSERVATION", 40, 50], ["major", "OBSERVATION_MODIFIER", 58, 63], ["new", "OBSERVATION_MODIFIER", 64, 67], ["disease", "OBSERVATION", 68, 75], ["infection", "OBSERVATION", 94, 103]]], ["Within 2 years of isolation detection kits became available, with the first designer antivirals appearing by 1995.", [["isolation detection kits", "TEST", 18, 42]]], ["HIV is the number 1 virus for the Journal of Virology.", [["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV", "PROBLEM", 0, 3]]], ["The younger generations of students know little of ALV, MLV, and MMTV.", [["ALV", "ORGANISM", 51, 54], ["MLV", "ORGANISM", 56, 59], ["MMTV", "ORGANISM", 65, 69], ["ALV", "SPECIES", 51, 54], ["ALV", "ANATOMY", 51, 54]]], ["As ever such a magnet can warp vision, and anything and everything new is tried and tested on HIV, a little like the involvement of every new virus in multiple sclerosis (Vandvik and Norrby, 1989; Winkelmann, 1993; Ablashi et al., 2000).INTRODUCTION\u201cEvolution\u201d has almost as many meanings as researchers working on it.", [["multiple sclerosis", "DISEASE", 151, 169], ["HIV", "ORGANISM", 94, 97], ["HIV", "SPECIES", 94, 97], ["HIV", "PROBLEM", 94, 97], ["every new virus in multiple sclerosis", "PROBLEM", 132, 169], ["multiple", "OBSERVATION_MODIFIER", 151, 159], ["sclerosis", "OBSERVATION", 160, 169]]], ["Outside of a biological setting, evolution actually refers to dy/dx, the change of one parameter with respect to another.", [["dy", "DNA", 62, 64], ["dx", "DNA", 65, 67]]], ["Yet for Darwin the \u201cstuff of evolution\u201d was adaptation, in fact repeated adaptation that over time led to something as wondrously complex as the eye probably 40 times or so.INTRODUCTIONComing to the point, this chapter will deal with the evolution of the classical retroviruses.", [["eye", "ANATOMY", 145, 148], ["eye", "ORGAN", 145, 148], ["retroviruses", "ORGANISM", 265, 277], ["the classical retroviruses", "PROBLEM", 251, 277], ["eye", "ANATOMY", 145, 148], ["retroviruses", "OBSERVATION", 265, 277]]], ["And this is where we will start.GENOME ORGANIZATION AS A STARTING POINTRetroviruses are enveloped viruses composed of a lipid bilayer surrounding a nucleocapsid within which resides the two copies of genomic plus stranded genomic RNA.", [["lipid bilayer", "ANATOMY", 120, 133], ["lipid bilayer", "CELLULAR_COMPONENT", 120, 133], ["genomic plus stranded genomic RNA", "RNA", 200, 233], ["A STARTING POINTRetroviruses", "TREATMENT", 55, 83], ["enveloped viruses", "PROBLEM", 88, 105], ["a lipid bilayer", "PROBLEM", 118, 133], ["a nucleocapsid", "PROBLEM", 146, 160], ["genomic plus stranded genomic RNA", "PROBLEM", 200, 233], ["nucleocapsid", "OBSERVATION", 148, 160], ["stranded genomic RNA", "OBSERVATION", 213, 233]]], ["Understandably the genome must code for capsid and envelope proteins.", [["genome", "CELLULAR_COMPONENT", 19, 25], ["capsid and envelope proteins", "PROTEIN", 40, 68], ["capsid and envelope proteins", "PROBLEM", 40, 68]]], ["Given the provirus, the integrated DNA replication intermediate, a reverse transcriptase and integrase are called for.", [["DNA", "CELLULAR_COMPONENT", 35, 38], ["reverse transcriptase", "PROTEIN", 67, 88], ["the provirus", "PROBLEM", 6, 18], ["a reverse transcriptase", "TREATMENT", 65, 88]]], ["It turns out that three open reading frames (orfs) are sufficient to generate a fully functional retrovirus.", [["retrovirus", "ORGANISM", 97, 107], ["open reading frames", "DNA", 24, 43], ["orfs", "DNA", 45, 49], ["a fully functional retrovirus", "PROBLEM", 78, 107], ["retrovirus", "OBSERVATION", 97, 107]]], ["Retroviral genetic maps are invariably given in the proviral form because it is that of the gene (Figure 13.1).", [["Retroviral", "ORGANISM", 0, 10], ["Retroviral genetic maps", "TEST", 0, 23]]], ["With the signal exception of the spumavirus group of retroviruses, the provirus is a single, multiply spliced gene.", [["retroviruses", "ORGANISM", 53, 65], ["provirus", "ORGANISM", 71, 79], ["retroviruses", "OBSERVATION", 53, 65], ["provirus", "OBSERVATION", 71, 79]]], ["The convention is that genes/orfs are referred to in italics while the corresponding proteins are given in normal type.", [["orfs", "GENE_OR_GENE_PRODUCT", 29, 33], ["orfs", "DNA", 29, 33], ["italics", "DNA", 53, 60], ["genes/orfs", "PROBLEM", 23, 33], ["normal type", "OBSERVATION_MODIFIER", 107, 118]]], ["The gag orf encodes the nucleocapsid proteins in the form of a polyprotein precursor. gag is followed by pol, encoding a large polyprotein incorporating the mature reverse transcriptase; RNase H and integrase proteins.", [["gag", "GENE_OR_GENE_PRODUCT", 4, 7], ["gag", "GENE_OR_GENE_PRODUCT", 86, 89], ["pol", "GENE_OR_GENE_PRODUCT", 105, 108], ["RNase H", "GENE_OR_GENE_PRODUCT", 187, 194], ["gag orf", "DNA", 4, 11], ["nucleocapsid proteins", "PROTEIN", 24, 45], ["polyprotein precursor", "PROTEIN", 63, 84], ["gag", "DNA", 86, 89], ["pol", "PROTEIN", 105, 108], ["mature reverse transcriptase", "PROTEIN", 157, 185], ["RNase H", "PROTEIN", 187, 194], ["integrase proteins", "PROTEIN", 199, 217], ["the nucleocapsid proteins", "PROBLEM", 20, 45], ["a polyprotein precursor", "PROBLEM", 61, 84], ["a large polyprotein", "TREATMENT", 119, 138], ["integrase proteins", "TREATMENT", 199, 217], ["gag orf", "OBSERVATION", 4, 11], ["polyprotein precursor", "OBSERVATION", 63, 84]]], ["Maturation of the polyproteins is the accomplishment of the viral protease that is generally part of pol, but can exist in a separate orf termed pro located between gag and pol.", [["pol", "GENE_OR_GENE_PRODUCT", 101, 104], ["gag", "GENE_OR_GENE_PRODUCT", 165, 168], ["pol", "GENE_OR_GENE_PRODUCT", 173, 176], ["viral protease", "PROTEIN", 60, 74], ["pol", "PROTEIN", 101, 104], ["orf termed pro located between gag and pol", "PROTEIN", 134, 176], ["the polyproteins", "PROBLEM", 14, 30], ["the viral protease", "TREATMENT", 56, 74], ["polyproteins", "OBSERVATION", 18, 30], ["viral protease", "OBSERVATION", 60, 74]]], ["Uniquely for Rous sarcoma virus (RSV) is the protease attached to the C-terminus of the Gag polyprotein.", [["Rous sarcoma", "DISEASE", 13, 25], ["Rous sarcoma virus", "ORGANISM", 13, 31], ["RSV", "ORGANISM", 33, 36], ["Gag", "GENE_OR_GENE_PRODUCT", 88, 91], ["protease", "PROTEIN", 45, 53], ["C-terminus", "PROTEIN", 70, 80], ["Gag polyprotein", "PROTEIN", 88, 103], ["Rous sarcoma virus", "SPECIES", 13, 31], ["Rous sarcoma virus", "SPECIES", 13, 31], ["RSV", "SPECIES", 33, 36], ["Rous sarcoma virus", "PROBLEM", 13, 31], ["the protease", "TREATMENT", 41, 53], ["the Gag polyprotein", "TREATMENT", 84, 103], ["Rous sarcoma", "OBSERVATION", 13, 25], ["Gag polyprotein", "OBSERVATION", 88, 103]]], ["The third orf is env, and encodes a polyprotein envelope precursor that is matured by host cell proteases.", [["cell", "ANATOMY", 91, 95], ["host cell", "CELL", 86, 95], ["polyprotein envelope precursor", "PROTEIN", 36, 66], ["host cell proteases", "PROTEIN", 86, 105], ["a polyprotein envelope precursor", "PROBLEM", 34, 66], ["env", "OBSERVATION", 17, 20], ["host cell proteases", "OBSERVATION", 86, 105]]], ["For ALV, MLV, and MMTV, the historical benchmark retroviruses, gag is always followed by pol which is always followed by env, and gag-pol-env represents the lowest common denominator for retrovirus genome organization.GENOME ORGANIZATION AS A STARTING POINTHowever, as can be seen from Figure 13.1, this effective yet minimalist view of retroviral genomics is far from common.", [["ALV", "ORGANISM", 4, 7], ["MLV", "ORGANISM", 9, 12], ["MMTV", "ORGANISM", 18, 22], ["retroviruses", "ORGANISM", 49, 61], ["gag", "GENE_OR_GENE_PRODUCT", 63, 66], ["pol", "GENE_OR_GENE_PRODUCT", 89, 92], ["env", "GENE_OR_GENE_PRODUCT", 121, 124], ["gag-pol", "GENE_OR_GENE_PRODUCT", 130, 137], ["retrovirus", "ORGANISM", 187, 197], ["retroviral", "ORGANISM", 337, 347], ["gag", "DNA", 63, 66], ["env", "DNA", 121, 124], ["gag-pol", "DNA", 130, 137], ["env", "DNA", 138, 141], ["ALV", "SPECIES", 4, 7], ["MLV", "SPECIES", 9, 12], ["MMTV", "SPECIES", 18, 22], ["retrovirus", "SPECIES", 187, 197], ["ALV, MLV", "TREATMENT", 4, 12], ["gag", "TEST", 130, 133], ["retrovirus genome organization", "PROBLEM", 187, 217], ["MLV", "ANATOMY", 9, 12], ["retrovirus genome", "OBSERVATION", 187, 204], ["retroviral genomics", "OBSERVATION", 337, 356]]], ["The most complex retroviruses bear up to nine distinct orfs encoding 15 mature proteins.", [["retroviruses", "ORGANISM", 17, 29], ["orfs", "GENE_OR_GENE_PRODUCT", 55, 59], ["orfs", "DNA", 55, 59], ["15 mature proteins", "PROTEIN", 69, 87], ["The most complex retroviruses", "PROBLEM", 0, 29], ["most complex", "OBSERVATION_MODIFIER", 4, 16], ["retroviruses", "OBSERVATION", 17, 29], ["15 mature", "OBSERVATION_MODIFIER", 69, 78]]], ["Some orfs are unique to a virus, others common to a cluster.", [["orfs", "GENE_OR_GENE_PRODUCT", 5, 9], ["Some orfs", "PROBLEM", 0, 9], ["a virus", "PROBLEM", 24, 31], ["virus", "OBSERVATION", 26, 31]]], ["Some orfs are apparently analogues even though there is no sequence identity between them.", [["orfs", "GENE_OR_GENE_PRODUCT", 5, 9], ["Some orfs", "PROBLEM", 0, 9], ["orfs", "OBSERVATION", 5, 9]]], ["While the gag-pol-env synteny is never violated, a multitude of orfs can separate pol and env.", [["gag", "GENE_OR_GENE_PRODUCT", 10, 13], ["orfs", "GENE_OR_GENE_PRODUCT", 64, 68], ["pol", "GENE_OR_GENE_PRODUCT", 82, 85], ["env", "GENE_OR_GENE_PRODUCT", 90, 93], ["gag-pol-env synteny", "DNA", 10, 29], ["orfs", "DNA", 64, 68], ["pol", "DNA", 82, 85], ["env", "DNA", 90, 93], ["the gag", "TEST", 6, 13]]], ["Frequently env is followed by 1\u20134 orfs, although an orf preceding gag is rare.GENOME ORGANIZATION AS A STARTING POINTSuch exuberance in terms of genetic organization is probably without precedent among small viral genomes, although coronavirus genome organization shows considerableplasticity.", [["orf preceding gag", "DNA", 52, 69], ["small viral genomes", "DNA", 202, 221], ["A STARTING POINTSuch exuberance", "TREATMENT", 101, 132], ["precedent among small viral genomes", "PROBLEM", 186, 221], ["coronavirus genome organization", "PROBLEM", 232, 263], ["considerableplasticity", "PROBLEM", 270, 292], ["probably without", "UNCERTAINTY", 169, 185], ["small", "OBSERVATION_MODIFIER", 202, 207], ["viral genomes", "OBSERVATION", 208, 221], ["coronavirus genome", "OBSERVATION", 232, 250]]], ["Of course herpesviruses genomes span 119\u2013236 kb while poxvirus genomes vary even more\u2014134\u2013360 kb.", [["herpesviruses", "ORGANISM", 10, 23], ["poxvirus genomes", "DNA", 54, 70], ["poxvirus genomes", "TEST", 54, 70]]], ["By contrast the threefold range in the number of retroviral orfs is accompanied by a relatively modest \u223c50% variation in the size of the coding region.GENOME ORGANIZATION AS A STARTING POINTWhere do all these \u201cextra\u201d genes come from?", [["retroviral", "ORGANISM", 49, 59], ["coding region", "DNA", 137, 150], ["\u201cextra\u201d genes", "DNA", 209, 222], ["a relatively modest \u223c50% variation", "PROBLEM", 83, 117], ["number", "OBSERVATION_MODIFIER", 39, 45], ["retroviral orfs", "OBSERVATION", 49, 64], ["relatively", "OBSERVATION_MODIFIER", 85, 95], ["modest", "OBSERVATION_MODIFIER", 96, 102], ["\u223c", "OBSERVATION_MODIFIER", 103, 104], ["50%", "OBSERVATION_MODIFIER", 104, 107], ["variation", "OBSERVATION_MODIFIER", 108, 117], ["size", "OBSERVATION_MODIFIER", 125, 129]]], ["The origin of the RSV src gene is no secret, it being transduced from the avian genome (Stehelin et al., 1976), while the primate lentiviral vpx gene is arguably derived from a duplication of the vpr gene (Tristem et al., 1990).", [["RSV", "ORGANISM", 18, 21], ["src", "GENE_OR_GENE_PRODUCT", 22, 25], ["lentiviral", "ORGANISM", 130, 140], ["vpx", "GENE_OR_GENE_PRODUCT", 141, 144], ["vpr", "GENE_OR_GENE_PRODUCT", 196, 199], ["RSV src gene", "DNA", 18, 30], ["avian genome", "DNA", 74, 86], ["primate lentiviral vpx gene", "DNA", 122, 149], ["vpr gene", "DNA", 196, 204], ["RSV", "SPECIES", 18, 21], ["secret", "PROBLEM", 37, 43], ["the primate lentiviral vpx gene", "TREATMENT", 118, 149], ["origin", "ANATOMY_MODIFIER", 4, 10], ["RSV src", "OBSERVATION", 18, 25], ["no", "UNCERTAINTY", 34, 36], ["secret", "OBSERVATION", 37, 43], ["lentiviral vpx", "OBSERVATION", 130, 144]]], ["It is possible that many are of cellular origin, however, given the tempo of retroviral mutation (vide infra), all traces have been lost.STABILITY OF GENE ORGANIZATION YET AT LEAST SIX WAYS TO EXPRESS POLApart from gene transduction, the genomic organization of a particular retrovirus is invariant.", [["cellular", "ANATOMY", 32, 40], ["cellular", "CELL", 32, 40], ["retroviral", "ORGANISM", 77, 87], ["retrovirus", "ORGANISM", 275, 285], ["SIX WAYS TO EXPRESS POLApart", "DNA", 181, 209], ["retroviral mutation", "PROBLEM", 77, 96], ["GENE ORGANIZATION", "PROBLEM", 150, 167], ["gene transduction", "TREATMENT", 215, 232], ["cellular origin", "OBSERVATION", 32, 47], ["retroviral mutation", "OBSERVATION", 77, 96], ["GENE ORGANIZATION", "OBSERVATION", 150, 167], ["particular retrovirus", "OBSERVATION", 264, 285], ["invariant", "OBSERVATION_MODIFIER", 289, 298]]], ["While it is possible to isolate viable strains carrying deletions say in env (JDV) or nef (HIV, SIV), deletions are common fare among microorganisms.", [["env (JDV)", "GENE_OR_GENE_PRODUCT", 73, 82], ["SIV", "ORGANISM", 96, 99], ["HIV", "SPECIES", 91, 94], ["SIV", "SPECIES", 96, 99], ["viable strains carrying deletions", "PROBLEM", 32, 65], ["nef (HIV, SIV)", "PROBLEM", 86, 100], ["deletions", "PROBLEM", 102, 111]]], ["As the provirus represents a single gene, large rearrangements and inversions are presumably deleterious.", [["a single gene, large rearrangements and inversions", "PROBLEM", 27, 77], ["deleterious", "PROBLEM", 93, 104], ["provirus", "OBSERVATION", 7, 15], ["large", "OBSERVATION_MODIFIER", 42, 47], ["rearrangements", "OBSERVATION", 48, 62], ["presumably", "UNCERTAINTY", 82, 92], ["deleterious", "OBSERVATION_MODIFIER", 93, 104]]], ["When making retrovirus-wide comparisons of the common gag, pol, and env orfs, the internal order of the major proteins is invariably conserved.", [["retrovirus", "ORGANISM", 12, 22], ["gag", "GENE_OR_GENE_PRODUCT", 54, 57], ["pol", "GENE_OR_GENE_PRODUCT", 59, 62], ["env orfs", "GENE_OR_GENE_PRODUCT", 68, 76], ["common gag, pol, and env orfs", "DNA", 47, 76], ["env orfs", "TREATMENT", 68, 76], ["common gag", "ANATOMY", 47, 57], ["env orfs", "OBSERVATION", 68, 76]]], ["Thus for Gag the order is always matrix antigen, capsid antigen, and nucleic acid binding protein, for Pol the order is protease, reverse transcriptase/RNaseH, integrase while for Env, the order is surface protein, transmembrane protein.STABILITY OF GENE ORGANIZATION YET AT LEAST SIX WAYS TO EXPRESS POLNonetheless, there are a couple of noteworthy cases of reorganization.", [["surface", "ANATOMY", 198, 205], ["nucleic acid", "CHEMICAL", 69, 81], ["Gag", "GENE_OR_GENE_PRODUCT", 9, 12], ["matrix antigen", "GENE_OR_GENE_PRODUCT", 33, 47], ["capsid antigen", "GENE_OR_GENE_PRODUCT", 49, 63], ["Pol", "GENE_OR_GENE_PRODUCT", 103, 106], ["RNaseH", "GENE_OR_GENE_PRODUCT", 152, 158], ["Env", "GENE_OR_GENE_PRODUCT", 180, 183], ["transmembrane", "CELLULAR_COMPONENT", 215, 228], ["Gag", "PROTEIN", 9, 12], ["matrix antigen", "PROTEIN", 33, 47], ["capsid antigen", "PROTEIN", 49, 63], ["nucleic acid binding protein", "PROTEIN", 69, 97], ["Pol", "PROTEIN", 103, 106], ["protease", "PROTEIN", 120, 128], ["reverse transcriptase", "PROTEIN", 130, 151], ["RNaseH", "PROTEIN", 152, 158], ["integrase", "PROTEIN", 160, 169], ["Env", "PROTEIN", 180, 183], ["surface protein", "PROTEIN", 198, 213], ["transmembrane protein", "PROTEIN", 215, 236], ["Gag", "PROBLEM", 9, 12], ["capsid antigen", "TEST", 49, 63], ["nucleic acid binding protein", "TEST", 69, 97], ["Pol", "TREATMENT", 103, 106], ["protease", "TREATMENT", 120, 128], ["reverse transcriptase/RNaseH", "TREATMENT", 130, 158], ["integrase", "TREATMENT", 160, 169], ["transmembrane protein", "TEST", 215, 236], ["GENE ORGANIZATION", "OBSERVATION", 250, 267], ["reorganization", "OBSERVATION", 359, 373]]], ["The first concerns the protease.", [["protease", "PROTEIN", 23, 31], ["the protease", "TREATMENT", 19, 31]]], ["As can be seen, it always precedes the reverse transcriptase/RNaseH (Figure 13.2A).", [["RNaseH", "GENE_OR_GENE_PRODUCT", 61, 67], ["reverse transcriptase", "PROTEIN", 39, 60], ["RNaseH", "PROTEIN", 61, 67], ["Figure 13.2A", "PROTEIN", 69, 81]]], ["However, the coding sequences can be part of gag, pol or in a separate reading frame, called pro.", [["gag", "GENE_OR_GENE_PRODUCT", 45, 48], ["pol", "GENE_OR_GENE_PRODUCT", 50, 53], ["coding sequences", "DNA", 13, 29], ["gag", "DNA", 45, 48], ["pol", "DNA", 50, 53], ["reading frame", "DNA", 71, 84], ["pro", "DNA", 93, 96], ["the coding sequences", "TEST", 9, 29]]], ["In view of this it is not surprising to learn that there are several distinct mechanisms by which these distinct reading frames are connected.", [["reading frames", "DNA", 113, 127], ["several", "OBSERVATION_MODIFIER", 61, 68], ["distinct", "OBSERVATION_MODIFIER", 69, 77]]], ["The mechanisms range from \u20131 ribosomal frameshifting once, twice, splicing, and suppression of a terminator codon.", [["ribosomal", "ANATOMY", 29, 38], ["terminator codon", "DNA", 97, 113], ["\u20131 ribosomal frameshifting", "PROBLEM", 26, 52], ["a terminator codon", "PROBLEM", 95, 113], ["range", "OBSERVATION_MODIFIER", 15, 20], ["ribosomal frameshifting", "OBSERVATION", 29, 52]]], ["If the larger family of retroelements are considered for once, there are two additional Gag-Pol syntenies involving +1 ribosomal frameshifing and the two being part of one long polyprotein precursor.", [["Pol", "GENE_OR_GENE_PRODUCT", 92, 95], ["retroelements", "DNA", 24, 37], ["Gag", "PROTEIN", 88, 91], ["Pol syntenies", "PROTEIN", 92, 105], ["long polyprotein precursor", "PROTEIN", 172, 198], ["one long polyprotein precursor", "PROBLEM", 168, 198], ["larger", "OBSERVATION_MODIFIER", 7, 13]]], ["These examples show that while the gene/orf order may be preserved, there are radical differences underlying their expression.STABILITY OF GENE ORGANIZATION YET AT LEAST SIX WAYS TO EXPRESS POLThe second example concerns the retroviral dUTPase (McGeoch, 1990).", [["retroviral", "ORGANISM", 225, 235], ["retroviral dUTPase", "PROTEIN", 225, 243], ["radical", "OBSERVATION_MODIFIER", 78, 85], ["GENE ORGANIZATION", "OBSERVATION", 139, 156], ["retroviral dUTPase", "OBSERVATION", 225, 243]]], ["Interestingly, only a subset of lentiviruses and the MMTV/SRV group encode such an enzyme and then in two different locations (Figure 13.2B).", [["lentiviruses", "ORGANISM", 32, 44], ["MMTV", "ORGANISM", 53, 57], ["SRV", "GENE_OR_GENE_PRODUCT", 58, 61], ["MMTV/SRV group", "DNA", 53, 67], ["enzyme", "PROTEIN", 83, 89], ["a subset of lentiviruses", "PROBLEM", 20, 44], ["an enzyme", "TEST", 80, 89], ["lentiviruses", "OBSERVATION", 32, 44]]], ["For the lentiviruses, it fits snugly in phase between the RT/RNaseH and integrase coding regions, while for the MMTV/SRV group it is located upstream of the viral protease.", [["lentiviruses", "ORGANISM", 8, 20], ["RNaseH", "GENE_OR_GENE_PRODUCT", 61, 67], ["MMTV", "ORGANISM", 112, 116], ["SRV", "GENE_OR_GENE_PRODUCT", 117, 120], ["RT/RNaseH and integrase coding regions", "DNA", 58, 96], ["MMTV/SRV group", "DNA", 112, 126], ["viral protease", "PROTEIN", 157, 171], ["the lentiviruses", "PROBLEM", 4, 20], ["the RT/RNaseH", "TREATMENT", 54, 67], ["integrase coding regions", "TREATMENT", 72, 96], ["the MMTV/SRV group", "TREATMENT", 108, 126], ["the viral protease", "TREATMENT", 153, 171], ["lentiviruses", "OBSERVATION", 8, 20], ["viral protease", "OBSERVATION", 157, 171]]], ["While phylogenic analysis shows that they cluster together, they do not constitute a robust monophyletic group, meaning that it is not possible to distinguish between a single introduction or independent introductions into each group (McGeoch, 1990).", [["phylogenic analysis", "TEST", 6, 25]]], ["This is the only example of radical change in the synteny of retroviral coding sequences.", [["retroviral", "ORGANISM", 61, 71], ["retroviral coding sequences", "DNA", 61, 88], ["radical change", "PROBLEM", 28, 42], ["radical", "OBSERVATION", 28, 35], ["retroviral coding", "OBSERVATION", 61, 78]]], ["Of course for large DNA viruses, such as the mycophages, marine phaeoviruses, and herpesvirus, to name but three, extensively rearranged genomes are commonplace (Weir, 1998; Delaroque et al., 2003; Pedulla et al., 2003).ERROR AND RECOMBINATIONWhen it comes to making replication errors, DNA and RNA virus differ hugely.", [["DNA", "CELLULAR_COMPONENT", 20, 23], ["marine phaeoviruses", "ORGANISM", 57, 76], ["herpesvirus", "ORGANISM", 82, 93], ["DNA", "CELLULAR_COMPONENT", 287, 290], ["large DNA viruses", "PROBLEM", 14, 31], ["herpesvirus", "PROBLEM", 82, 93], ["replication errors", "PROBLEM", 267, 285], ["DNA and RNA virus", "PROBLEM", 287, 304], ["large", "OBSERVATION_MODIFIER", 14, 19], ["DNA viruses", "OBSERVATION", 20, 31]]], ["RNA viruses are unable to undertake proofreading or mismatch repair while DNA viruses can, either because DNA replication is performed by the host cell or else the genome is large enough to encode the necessary enzymes to undertake high-fidelity replication.", [["cell", "ANATOMY", 147, 151], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["DNA", "CELLULAR_COMPONENT", 106, 109], ["cell", "CELL", 147, 151], ["genome", "CELLULAR_COMPONENT", 164, 170], ["RNA viruses", "PROBLEM", 0, 11], ["mismatch repair", "TREATMENT", 52, 67], ["DNA viruses", "PROBLEM", 74, 85], ["DNA replication", "PROBLEM", 106, 121], ["the necessary enzymes", "TEST", 197, 218], ["viruses", "OBSERVATION", 4, 11], ["mismatch repair", "OBSERVATION", 52, 67]]], ["In this latter context, poxviruses replicating in the cytoplasm is perhaps the most extreme example.", [["cytoplasm", "ANATOMY", 54, 63], ["poxviruses", "ORGANISM", 24, 34], ["cytoplasm", "ORGANISM_SUBSTANCE", 54, 63], ["poxviruses", "PROBLEM", 24, 34], ["poxviruses", "OBSERVATION", 24, 34]]], ["Where do retroviruses, half DNA, half RNA viruses sit when it comes to error?", [["retroviruses", "ORGANISM", 9, 21], ["DNA", "CELLULAR_COMPONENT", 28, 31], ["half DNA", "PROBLEM", 23, 31], ["half RNA viruses sit", "TREATMENT", 33, 53]]], ["Errors made during reverse transcription per se are not corrected whatsoever, while those made during plus-strand synthesis could be proofread when the DNA is translocated to the nucleus.", [["nucleus", "ANATOMY", 179, 186], ["DNA", "CELLULAR_COMPONENT", 152, 155], ["nucleus", "CELLULAR_COMPONENT", 179, 186], ["strand synthesis", "PROBLEM", 107, 123], ["the DNA", "PROBLEM", 148, 155], ["nucleus", "ANATOMY", 179, 186]]], ["It turns out that although retroviral mutation rates are in the range of 0.3\u20130.05 per genome per cycle (Mansky and Temin, 1995; Mansky and Wisniewski, 1998; Mansky, 2000), they are approximately an order of magnitude lower than those for RNA viruses, 1\u20133 per genome per cycle (Drake and Holland, 1999).", [["retroviral", "ORGANISM", 27, 37], ["retroviral mutation rates", "TEST", 27, 52], ["RNA viruses", "PROBLEM", 238, 249], ["retroviral mutation", "OBSERVATION", 27, 46]]], ["While it would be tempting to ascribe this difference to proofreading of mutations of the plus-strand errors, as more errors are made during minus-strand synthesis, it probably reflects some subtle intrinsic difference between the polymerases.ERROR AND RECOMBINATIONAs in almost all polymerases, transitions are produced more readily than transversions, while deletions are more frequent than insertions (essentially duplications).", [["polymerases", "PROTEIN", 231, 242], ["strand errors", "PROBLEM", 95, 108], ["minus-strand synthesis", "TREATMENT", 141, 163], ["some subtle intrinsic difference between the polymerases", "PROBLEM", 186, 242], ["probably reflects", "UNCERTAINTY", 168, 185], ["subtle", "OBSERVATION_MODIFIER", 191, 197], ["intrinsic", "OBSERVATION_MODIFIER", 198, 207], ["difference", "OBSERVATION", 208, 218]]], ["For the HIV reverse transcriptase and presumably the lentiviruses as a whole, deletions arise more frequently than for other RTases.", [["lentiviruses", "ORGANISM", 53, 65], ["RTases", "GENE_OR_GENE_PRODUCT", 125, 131], ["HIV reverse transcriptase", "PROTEIN", 8, 33], ["HIV", "SPECIES", 8, 11], ["the HIV reverse transcriptase", "TREATMENT", 4, 33], ["the lentiviruses", "PROBLEM", 49, 65], ["lentiviruses", "OBSERVATION", 53, 65]]], ["Being diploid viruses, recombination is to be reckoned with.", [["diploid viruses", "PROBLEM", 6, 21], ["diploid viruses", "OBSERVATION", 6, 21]]], ["Retroviral recombination goes back to 1971 (Vogt, 1971; Kawai and Hanafusa, 1972; Weiss et al., 1973) just one year following the description of reverse transcription.", [["Retroviral", "ORGANISM", 0, 10], ["Retroviral recombination", "PROBLEM", 0, 24], ["reverse transcription", "TREATMENT", 145, 166]]], ["Precise recombination rates have been worked out for two retroviruses, HIV-1 and MLV, the values being 3\u20134 per virus per cycle respectively for both viruses, despite an initially lower rate for MLV (Jetzt et al., 2000; Zhuang et al., 2006).", [["retroviruses", "ORGANISM", 57, 69], ["HIV-1", "ORGANISM", 71, 76], ["MLV", "ORGANISM", 81, 84], ["MLV", "ORGANISM", 194, 197], ["HIV-1", "SPECIES", 71, 76], ["HIV-1", "SPECIES", 71, 76], ["MLV", "SPECIES", 81, 84], ["MLV", "SPECIES", 194, 197], ["two retroviruses", "PROBLEM", 53, 69], ["HIV", "TEST", 71, 74], ["MLV", "PROBLEM", 81, 84], ["the values", "TEST", 86, 96], ["both viruses", "PROBLEM", 144, 156]]], ["Importantly, these values are \u223c10\u2013100\u00d7 the point mutation rate for both retroviruses.", [["retroviruses", "ORGANISM", 72, 84], ["these values", "TEST", 13, 25], ["mutation rate", "TEST", 49, 62], ["retroviruses", "OBSERVATION", 72, 84]]], ["This means that as soon as a point mutation is made it will be recombined in the following round.ERROR AND RECOMBINATIONThere are a couple of conditions to be met before concluding that everything is recombined for a retrovirus.", [["retrovirus", "ORGANISM", 217, 227], ["a point mutation", "PROBLEM", 27, 43], ["a retrovirus", "PROBLEM", 215, 227]]], ["First, infected cells have to be multiply infected, meaning that they must harbor multiple proviruses.", [["cells", "ANATOMY", 16, 21], ["cells", "CELL", 16, 21], ["infected cells", "CELL_TYPE", 7, 21], ["infected cells", "PROBLEM", 7, 21], ["infected cells", "OBSERVATION", 7, 21], ["multiply", "OBSERVATION_MODIFIER", 33, 41], ["infected", "OBSERVATION", 42, 50], ["multiple", "OBSERVATION_MODIFIER", 82, 90], ["proviruses", "OBSERVATION", 91, 101]]], ["Second, the proviruses must be genetically distinct.", [["proviruses", "ORGANISM", 12, 22], ["the proviruses", "PROBLEM", 8, 22], ["proviruses", "OBSERVATION", 12, 22], ["distinct", "OBSERVATION_MODIFIER", 43, 51]]], ["If, for example, a multiple infected cell received all its HIV content from a productively infected neighboring cell that harbored a single provirus, then recombination would proceed but effectively produce the parental virus despite recombination.", [["cell", "ANATOMY", 37, 41], ["cell", "ANATOMY", 112, 116], ["cell", "CELL", 37, 41], ["HIV", "ORGANISM", 59, 62], ["cell", "CELL", 112, 116], ["HIV", "SPECIES", 59, 62], ["a multiple infected cell", "PROBLEM", 17, 41], ["all its HIV content", "PROBLEM", 51, 70], ["a productively infected neighboring cell", "PROBLEM", 76, 116], ["a single provirus", "PROBLEM", 131, 148], ["the parental virus", "PROBLEM", 207, 225], ["multiple", "OBSERVATION_MODIFIER", 19, 27], ["infected", "OBSERVATION", 28, 36], ["infected", "OBSERVATION_MODIFIER", 91, 99], ["neighboring cell", "OBSERVATION", 100, 116]]], ["So does multi-infection occur and are the proviruses divergent in vivo?ERROR AND RECOMBINATIONWe have only the beginnings of an answer to these questions and then only for HIV-1.", [["HIV-1", "ORGANISM", 172, 177], ["HIV", "SPECIES", 172, 175], ["HIV-1", "SPECIES", 172, 177], ["HIV", "PROBLEM", 172, 175]]], ["Using fluorescent in situ hybridization (FISH) a single report showed that for two patients, one with high and one with low plasma viremia, the average proviral copy number in splenic mononuclear cells was 3\u20134 with a range of 1\u20138 (Jung et al., 2002).", [["plasma", "ANATOMY", 124, 130], ["splenic mononuclear cells", "ANATOMY", 176, 201], ["viremia", "DISEASE", 131, 138], ["patients", "ORGANISM", 83, 91], ["plasma", "ORGANISM_SUBSTANCE", 124, 130], ["splenic mononuclear cells", "CELL", 176, 201], ["splenic mononuclear cells", "CELL_TYPE", 176, 201], ["patients", "SPECIES", 83, 91], ["low plasma viremia", "PROBLEM", 120, 138], ["splenic mononuclear cells", "TEST", 176, 201], ["viremia", "OBSERVATION", 131, 138], ["splenic", "ANATOMY", 176, 183], ["mononuclear cells", "OBSERVATION", 184, 201]]], ["The majority of cells (\u223c72%) were multiply infected.", [["cells", "ANATOMY", 16, 21], ["cells", "CELL", 16, 21], ["cells", "TEST", 16, 21], ["infected", "OBSERVATION", 43, 51]]], ["Laser microdissection of the FISH positive nuclei and transfer to PCR tubes allowed amplification and sequencing of the HIV-1 DNA.", [["nuclei", "ANATOMY", 43, 49], ["nuclei", "CELLULAR_COMPONENT", 43, 49], ["HIV-1", "ORGANISM", 120, 125], ["DNA", "CELLULAR_COMPONENT", 126, 129], ["PCR tubes", "DNA", 66, 75], ["HIV-1 DNA", "DNA", 120, 129], ["HIV-1", "SPECIES", 120, 125], ["HIV-1", "SPECIES", 120, 125], ["Laser microdissection", "TREATMENT", 0, 21], ["the FISH positive nuclei", "PROBLEM", 25, 49], ["PCR tubes", "TREATMENT", 66, 75], ["the HIV", "TEST", 116, 123], ["microdissection", "OBSERVATION", 6, 21], ["FISH", "ANATOMY", 29, 33], ["positive nuclei", "OBSERVATION", 34, 49]]], ["The sequence complexity of the V1V2 hypervariable regions analyzed, probably the most sensitive indicator of Env variation, was stunning.", [["Env", "GENE_OR_GENE_PRODUCT", 109, 112], ["V1V2 hypervariable regions", "DNA", 31, 57], ["stunning", "PROBLEM", 128, 136], ["Env variation", "OBSERVATION", 109, 122]]], ["Up to 28% amino acid variation was found within a single nucleus.", [["nucleus", "ANATOMY", 57, 64], ["amino acid", "CHEMICAL", 10, 20], ["amino acid", "CHEMICAL", 10, 20], ["amino acid", "AMINO_ACID", 10, 20], ["nucleus", "CELLULAR_COMPONENT", 57, 64], ["amino acid variation", "TEST", 10, 30]]], ["This is greater than the average protein variation between humans and birds!", [["humans", "ORGANISM", 59, 65], ["humans", "SPECIES", 59, 65], ["humans", "SPECIES", 59, 65], ["greater", "OBSERVATION_MODIFIER", 8, 15]]], ["To add to a complex situation, numerous distinct recombinants were also found within the same nucleus.ERROR AND RECOMBINATIONWhat does this mean?", [["nucleus", "ANATOMY", 94, 101], ["nucleus", "CELLULAR_COMPONENT", 94, 101], ["numerous distinct recombinants", "PROBLEM", 31, 61], ["distinct", "OBSERVATION_MODIFIER", 40, 48], ["recombinants", "OBSERVATION", 49, 61], ["same nucleus", "ANATOMY", 89, 101]]], ["First, it indicates that phenotypic mixing is possible, generating heterogeneous virions (Figure 13.3B).", [["phenotypic mixing", "PROBLEM", 25, 42], ["heterogeneous virions", "PROBLEM", 67, 88], ["phenotypic mixing", "OBSERVATION", 25, 42], ["heterogeneous", "OBSERVATION_MODIFIER", 67, 80], ["virions", "OBSERVATION", 81, 88]]], ["Second, it means that HIV virions are non-clonal objects.", [["HIV", "ORGANISM", 22, 25], ["HIV", "SPECIES", 22, 25], ["HIV", "SPECIES", 22, 25], ["HIV virions", "PROBLEM", 22, 33]]], ["Worse, these non-clonal structures are ephemeral as production, infection and reverse transcription involving recombination are a matter of 10\u201318 hours (Figure 13.3).", [["non-clonal structures", "ANATOMY", 13, 34], ["infection", "DISEASE", 64, 73], ["infection", "PROBLEM", 64, 73], ["reverse transcription", "PROBLEM", 78, 99], ["Figure", "TEST", 153, 159], ["ephemeral", "OBSERVATION_MODIFIER", 39, 48], ["infection", "OBSERVATION", 64, 73]]], ["Such complexity inside a single nucleus (synonymous here with boundary or discrete volume) indeed conjures up the quasispecies.", [["nucleus", "ANATOMY", 32, 39], ["nucleus", "CELLULAR_COMPONENT", 32, 39]]], ["The population of genomes is of course limited to two or at most eight functional genomes, which can produce a rich variety of heterokaryons.", [["heterokaryons", "ANATOMY", 127, 140], ["heterokaryons", "CELL", 127, 140], ["heterokaryons", "CELL_LINE", 127, 140], ["genomes", "OBSERVATION", 18, 25], ["heterokaryons", "OBSERVATION", 127, 140]]], ["However, they will recombine in the next round of infection producing a new ensemble of recombinant genomes.", [["infection", "DISEASE", 50, 59], ["recombinant genomes", "DNA", 88, 107], ["infection", "PROBLEM", 50, 59], ["infection", "OBSERVATION", 50, 59], ["new", "OBSERVATION_MODIFIER", 72, 75], ["recombinant genomes", "OBSERVATION", 88, 107]]], ["However, when recombinants of HIV and SIV are made the resulting \u201cSHIV\u201d that is eventually recovered invariably carries \u201cadditional\u201d substitutions as though the jump in sequence space made by the molecular virologist landed the SHIV in a relatively unfit region.", [["HIV", "ORGANISM", 30, 33], ["SIV", "ORGANISM", 38, 41], ["SHIV", "ORGANISM", 66, 70], ["SHIV", "ORGANISM", 228, 232], ["HIV", "SPECIES", 30, 33], ["HIV", "SPECIES", 30, 33], ["SIV", "SPECIES", 38, 41], ["SHIV", "SPECIES", 66, 70], ["HIV", "PROBLEM", 30, 33], ["additional\u201d substitutions", "PROBLEM", 121, 146], ["the jump in sequence space", "PROBLEM", 157, 183], ["SHIV", "OBSERVATION", 228, 232]]], ["It seems possible that most recombinants may in fact reduce fitness.", [["seems possible", "UNCERTAINTY", 3, 17]]], ["Certainly, it seems logical given that functional sequence space can represent only a small fraction of total sequence space.", [["functional sequence space", "PROBLEM", 39, 64], ["a small fraction of total sequence space", "PROBLEM", 84, 124], ["small", "OBSERVATION_MODIFIER", 86, 91]]], ["Could the retroviral Red Queen be constantly running to make up for the devastating effects of recombination?", [["retroviral", "ORGANISM", 10, 20], ["retroviral Red", "OBSERVATION", 10, 24]]], ["Could this be the major driving force leading to the relentless accumulation of point mutations for HIV, no matter the multiplicity of infection, the disease stage, or the nature of existing immune responses?ERROR AND RECOMBINATIONAt the more macroscopic level, recombinants are found at all levels of HIV and SIV\u2014intrapatient recombinants, those among different strains of the same clade, the ever-expanding number of circulating recombinant forms (CRFs) worldwide that can be readily shown to be mixes of the original founder clade viruses, recombinants of CRFs, intergroup recombinants, e.g. HIV-1 M-O (Peeters et al., 1999), and a plethora of recombinants between HIV-1 precursor viruses with SIVs of chimpanzees (Bibollet-Ruche et al., 2004).", [["infection", "DISEASE", 135, 144], ["HIV", "ORGANISM", 302, 305], ["SIV", "ORGANISM", 310, 313], ["founder clade viruses", "ORGANISM", 520, 541], ["HIV-1", "ORGANISM", 595, 600], ["HIV-1 precursor viruses", "ORGANISM", 668, 691], ["SIVs", "CANCER", 697, 701], ["chimpanzees", "ORGANISM", 705, 716], ["circulating recombinant forms", "PROTEIN", 419, 448], ["CRFs", "PROTEIN", 450, 454], ["HIV", "SPECIES", 302, 305], ["HIV-1", "SPECIES", 595, 600], ["HIV-1", "SPECIES", 668, 673], ["HIV", "SPECIES", 100, 103], ["HIV", "SPECIES", 302, 305], ["SIV", "SPECIES", 310, 313], ["HIV-1", "SPECIES", 595, 600], ["HIV-1", "SPECIES", 668, 673], ["point mutations", "PROBLEM", 80, 95], ["HIV", "PROBLEM", 100, 103], ["infection", "PROBLEM", 135, 144], ["the disease stage", "PROBLEM", 146, 163], ["HIV", "PROBLEM", 302, 305], ["SIV\u2014intrapatient recombinants", "TREATMENT", 310, 339], ["CRFs", "PROBLEM", 559, 563], ["HIV", "PROBLEM", 668, 671], ["infection", "OBSERVATION", 135, 144], ["clade viruses", "OBSERVATION", 528, 541]]], ["Many of the diverse SIVs from small equatorial monkeys are demonstrably recombinants (Jin et al., 1994).", [["SIVs", "GENE_OR_GENE_PRODUCT", 20, 24], ["monkeys", "ORGANISM", 47, 54], ["SIVs", "DNA", 20, 24], ["diverse", "OBSERVATION_MODIFIER", 12, 19], ["SIVs", "OBSERVATION", 20, 24], ["small", "OBSERVATION_MODIFIER", 30, 35], ["equatorial monkeys", "OBSERVATION", 36, 54]]], ["Indeed we are probably at a level where the null hypothesis should be that everything is recombinant unless shown otherwise.ERROR AND RECOMBINATIONOne of the hottest topics in retrovirus variation right now is APOBEC3-mediated hypermutation, which is extensively treated in the excellent chapter by Warner Greene (Chapter 8).", [["retrovirus", "ORGANISM", 176, 186], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 210, 217], ["APOBEC3", "PROTEIN", 210, 217], ["the null hypothesis", "PROBLEM", 40, 59], ["APOBEC3", "PROBLEM", 210, 217], ["mediated hypermutation", "PROBLEM", 218, 240], ["retrovirus variation", "OBSERVATION", 176, 196], ["APOBEC3", "OBSERVATION", 210, 217], ["hypermutation", "OBSERVATION", 227, 240]]], ["Briefly, these are cellular cytidine deaminases that if packaged into the virion can edit hundreds of cytidine residues, leaving behind uracil.", [["cellular", "ANATOMY", 19, 27], ["cytidine", "CHEMICAL", 28, 36], ["cytidine", "CHEMICAL", 102, 110], ["uracil", "CHEMICAL", 136, 142], ["cytidine", "CHEMICAL", 28, 36], ["cytidine", "CHEMICAL", 102, 110], ["uracil", "CHEMICAL", 136, 142], ["cellular", "CELL", 19, 27], ["virion", "CELLULAR_COMPONENT", 74, 80], ["cytidine", "SIMPLE_CHEMICAL", 102, 110], ["uracil", "SIMPLE_CHEMICAL", 136, 142], ["cellular cytidine deaminases", "TREATMENT", 19, 47], ["cytidine residues", "TREATMENT", 102, 119], ["cellular", "OBSERVATION", 19, 27], ["cytidine deaminases", "OBSERVATION", 28, 47], ["cytidine residues", "OBSERVATION", 102, 119]]], ["This is tantamount to a host restriction system.", [["a host restriction system", "TREATMENT", 22, 47]]], ["It is particularly a problem for the lentiviruses to the point that they have evolved the vif gene that prevents APOBEC3 incorporation (Sheehy et al., 2002).", [["lentiviruses", "ORGANISM", 37, 49], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 113, 120], ["vif gene", "DNA", 90, 98], ["APOBEC3", "PROTEIN", 113, 120], ["the lentiviruses", "PROBLEM", 33, 49], ["APOBEC3 incorporation", "OBSERVATION", 113, 134]]], ["While other retroviruses including HBV do undergo editing in vitro and in vivo (Mahieux et al., 2005; Suspene et al., 2005; Delebecque et al., 2006), there is no evidence that this seriously impacts their replication.", [["retroviruses", "ORGANISM", 12, 24], ["HBV", "ORGANISM", 35, 38], ["HBV", "SPECIES", 35, 38], ["HBV", "PROBLEM", 35, 38], ["retroviruses", "OBSERVATION", 12, 24], ["no evidence that", "UNCERTAINTY", 159, 175]]], ["For the mouse there is a single APOBEC3 gene and knockout mice are both viable and fertile, which suggests that it does not restrict the transposition of endogenous retroviruses (Mikl et al., 2005).", [["mouse", "ORGANISM", 8, 13], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 32, 39], ["mice", "ORGANISM", 58, 62], ["retroviruses", "ORGANISM", 165, 177], ["APOBEC3 gene", "DNA", 32, 44], ["mouse", "SPECIES", 8, 13], ["mice", "SPECIES", 58, 62], ["mouse", "SPECIES", 8, 13], ["mice", "SPECIES", 58, 62], ["endogenous retroviruses", "PROBLEM", 154, 177], ["endogenous retroviruses", "OBSERVATION", 154, 177]]], ["This fits in well with the fact that although the bird genome carries a plethora of endogenous retroviruses, there is no APOBEC3 counterpart (Harris and Liddament, 2004).", [["retroviruses", "ORGANISM", 95, 107], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 121, 128], ["bird genome", "DNA", 50, 61], ["endogenous retroviruses", "PROBLEM", 84, 107], ["endogenous retroviruses", "OBSERVATION", 84, 107], ["no", "UNCERTAINTY", 118, 120], ["APOBEC3 counterpart", "OBSERVATION", 121, 140]]], ["Might a little APOBEC3 editing help the lentiviruses evolve?", [["APOBEC3", "GENE_OR_GENE_PRODUCT", 15, 22], ["lentiviruses", "ORGANISM", 40, 52], ["APOBEC3", "PROTEIN", 15, 22], ["a little APOBEC3 editing", "PROBLEM", 6, 30], ["little", "OBSERVATION_MODIFIER", 8, 14], ["APOBEC3", "OBSERVATION", 15, 22], ["lentiviruses", "OBSERVATION", 40, 52]]], ["Could it occasionally act as the equivalent of a bacterial mutator?", [["a bacterial mutator", "PROBLEM", 47, 66], ["bacterial mutator", "OBSERVATION", 49, 66]]], ["As is frequently the case, speculation is understandably inversely proportional to the amount of data.RETROVIRAL FIXATION RATES VARY HUGELYIt comes as no surprise to any virologist that fixation rates vary with the protein under study\u2014the flu paradigm is known to all.", [["RETROVIRAL FIXATION", "TREATMENT", 102, 121], ["fixation rates", "TEST", 186, 200], ["the protein under study", "TEST", 211, 234], ["the flu paradigm", "PROBLEM", 235, 251], ["FIXATION", "OBSERVATION", 113, 121]]], ["To get this quickly out of the way, the retroviral surface envelope protein is generally the most variable, although some of the small accessory proteins fix mutations at a comparable rate.", [["retroviral", "ORGANISM", 40, 50], ["retroviral surface envelope protein", "PROTEIN", 40, 75], ["small accessory proteins", "PROTEIN", 129, 153], ["the retroviral surface envelope protein", "TEST", 36, 75], ["the small accessory proteins fix mutations", "PROBLEM", 125, 167], ["retroviral", "OBSERVATION", 40, 50], ["protein", "OBSERVATION", 68, 75], ["most variable", "OBSERVATION_MODIFIER", 93, 106], ["small", "OBSERVATION_MODIFIER", 129, 134], ["accessory proteins", "OBSERVATION", 135, 153], ["fix mutations", "OBSERVATION", 154, 167]]], ["The nucleocapsid Gag proteins are understandably less tolerant of change only in the temporal sense, while the enzymes that make up Pol bring up the rear.", [["Pol", "GENE_OR_GENE_PRODUCT", 132, 135], ["nucleocapsid Gag proteins", "PROTEIN", 4, 29], ["enzymes", "PROTEIN", 111, 118], ["Pol", "PROTEIN", 132, 135], ["the enzymes", "TEST", 107, 118], ["Gag proteins", "OBSERVATION", 17, 29]]], ["The retroviral integrase has the lowest amino acid fixation rate and so it not a surprise that this region is invariably used to perform retrovirus-wide phylogenic analyses.", [["amino acid", "CHEMICAL", 40, 50], ["amino acid", "CHEMICAL", 40, 50], ["retroviral", "ORGANISM", 4, 14], ["amino acid", "AMINO_ACID", 40, 50], ["The retroviral integrase", "TREATMENT", 0, 24], ["the lowest amino acid fixation rate", "TREATMENT", 29, 64], ["retrovirus", "TEST", 137, 147], ["retroviral integrase", "OBSERVATION", 4, 24], ["acid fixation", "OBSERVATION", 46, 59]]], ["A typical phylogenic tree based on the integrase gene is shown in Figure 13.4A.RETROVIRAL FIXATION RATES VARY HUGELY", [["integrase gene", "DNA", 39, 53], ["A typical phylogenic tree", "PROBLEM", 0, 25], ["RETROVIRAL FIXATION", "TREATMENT", 79, 98], ["phylogenic tree", "OBSERVATION", 10, 25], ["FIXATION", "OBSERVATION", 90, 98]]]], "23626bb7670a90301705f9d2ac9bb5238a8b215f": [["We note that there are many similarities between the surgical responses in Italy and the UK.", [["UK", "GENE_OR_GENE_PRODUCT", 89, 91], ["surgical", "OBSERVATION", 53, 61]]], ["The halt of elective surgery, although necessary, quite reasonably, is a concern with over 2 million elective operations scheduled in the third quarter of 2019 2,3 .", [["elective surgery", "TREATMENT", 12, 28], ["2 million elective operations", "TREATMENT", 91, 120]]], ["The authors also quite rightly highlight likely missed diagnoses due to reduced outpatient appointments or screening; not to mention disease and co-morbidities that may have progressed beyond our operable window.", [["screening", "TEST", 107, 116], ["disease", "PROBLEM", 133, 140], ["co-morbidities", "PROBLEM", 145, 159]]]], "fe7a98fe0cff2975b555ecb6dd618da8243fb924": [["1 In many countries, the politics surrounding climate change has constrained mitigation action.", [["climate change", "OBSERVATION", 46, 60]]]], "91276b1c72c7bff1b7b796b8efaa9215519289a1": [["IntroductionRather than existing as independent organisms, multi-cellular hosts together with their inhabiting microbial cells have been viewed as \"metaorganisms\" (also termed superorganisms or holobionts) [1] .", [["cells", "ANATOMY", 121, 126], ["microbial cells", "CELL", 111, 126], ["microbial cells", "CELL_TYPE", 111, 126], ["IntroductionRather", "TREATMENT", 0, 18], ["multi-cellular hosts", "TREATMENT", 59, 79], ["their inhabiting microbial cells", "PROBLEM", 94, 126]]], ["Millions of commensals, symbiotic, and pathogenic microorganisms colonize our body.", [["body", "ANATOMY", 78, 82], ["body", "ORGANISM_SUBDIVISION", 78, 82], ["symbiotic", "PROBLEM", 24, 33], ["pathogenic microorganisms colonize our body", "PROBLEM", 39, 82], ["symbiotic", "OBSERVATION_MODIFIER", 24, 33]]], ["Microbiota are indispensable for the host, as they contribute to the functioning of essential physiological processes including immunity and metabolism.", [["essential physiological processes", "PROBLEM", 84, 117]]], ["Microbiota immune system development.", [["immune system", "ANATOMY", 11, 24]]], ["The immune system recognizes antigens of microorganisms e.g. DNA, RNA, cell wall components, and many others, through pattern recognition receptors, such as Toll-like receptors (TLRs) and downstream intracellular signaling circuitries are activated to generate immune responses [4] .", [["cell wall", "ANATOMY", 71, 80], ["intracellular", "ANATOMY", 199, 212], ["DNA", "CELLULAR_COMPONENT", 61, 64], ["cell wall", "CELLULAR_COMPONENT", 71, 80], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 157, 176], ["TLRs", "GENE_OR_GENE_PRODUCT", 178, 182], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 199, 212], ["pattern recognition receptors", "PROTEIN", 118, 147], ["Toll-like receptors", "PROTEIN", 157, 176], ["TLRs", "PROTEIN", 178, 182], ["microorganisms", "PROBLEM", 41, 55], ["DNA", "PROBLEM", 61, 64], ["RNA, cell wall components", "TEST", 66, 91], ["downstream intracellular signaling circuitries", "TREATMENT", 188, 234], ["cell wall", "OBSERVATION_MODIFIER", 71, 80], ["components", "OBSERVATION_MODIFIER", 81, 91]]], ["However, like self-antigens, antigens from commensal microbiota are tolerated with no consequent inflammatory responses.", [["antigens", "PROTEIN", 29, 37], ["consequent inflammatory responses", "PROBLEM", 86, 119], ["inflammatory", "OBSERVATION", 97, 109]]], ["This makes gut microbiota accepted as \"extended-self\" [5] .", [["gut microbiota", "ANATOMY", 11, 25], ["gut", "ORGANISM_SUBDIVISION", 11, 14]]], ["For example, Staphylococcus aureus [6] or Candida albicans [7] are commensals of human, but in \"susceptible\" hosts, they can undergo commensal-to-pathogen transition.", [["Staphylococcus aureus", "DISEASE", 13, 34], ["Staphylococcus aureus [6]", "ORGANISM", 13, 38], ["Candida albicans", "ORGANISM", 42, 58], ["human", "ORGANISM", 81, 86], ["Staphylococcus aureus", "SPECIES", 13, 34], ["Candida albicans", "SPECIES", 42, 58], ["human", "SPECIES", 81, 86], ["Staphylococcus aureus", "SPECIES", 13, 34], ["Candida albicans", "SPECIES", 42, 58], ["human", "SPECIES", 81, 86], ["Staphylococcus aureus", "PROBLEM", 13, 34], ["Candida albicans", "PROBLEM", 42, 58], ["Staphylococcus aureus", "OBSERVATION", 13, 34]]], ["Thus, identifying microorganisms that reside in the host, and within these, those that are responsible for distinct host phenotypes, and the host pathways through which they act are significant goals in host-microbiota research.", [["microorganisms", "PROBLEM", 18, 32], ["distinct host phenotypes", "PROBLEM", 107, 131], ["microorganisms", "OBSERVATION", 18, 32], ["host phenotypes", "OBSERVATION", 116, 131], ["significant", "OBSERVATION_MODIFIER", 182, 193]]], ["Microbiota survival strategies within the host are likely to be limited.", [["Microbiota survival strategies", "TREATMENT", 0, 30], ["likely to be", "UNCERTAINTY", 51, 63]]], ["Analysis of their repertoire may reveal core modules, thereby helping in classification, mechanistic elucidation and profile prediction.", [["Analysis of their repertoire", "TEST", 0, 28], ["core modules", "PROBLEM", 40, 52], ["core modules", "OBSERVATION", 40, 52]]], ["Here we provide an overview of structural host-microbiota interaction networks from this standpoint.The host-microbiota interactions in the metaorganismThe host interacts with microbiota through proteins, metabolites, small molecules and nucleic acids [8, 9] .", [["metaorganism", "ANATOMY", 140, 152], ["nucleic acids", "CHEMICAL", 238, 251], ["nucleic acids", "SIMPLE_CHEMICAL", 238, 251], ["nucleic acids", "TEST", 238, 251], ["microbiota interactions", "OBSERVATION", 109, 132], ["small", "OBSERVATION_MODIFIER", 218, 223], ["nucleic acids", "OBSERVATION", 238, 251]]], ["The microbiota employs a range of effectors to modulate host cellular functions and immune responses.", [["cellular", "ANATOMY", 61, 69], ["cellular", "CELL", 61, 69]]], ["Most proteins of bacterial and eukaryotic pathogens are not accessible to bind to host proteins; but some of their proteins either bind to host surface receptors [11] or enter the host cell and interact with host cytoplasmic proteins.", [["surface", "ANATOMY", 144, 151], ["cell", "ANATOMY", 185, 189], ["cytoplasmic", "ANATOMY", 213, 224], ["cell", "CELL", 185, 189], ["cytoplasmic", "ORGANISM_SUBSTANCE", 213, 224], ["host proteins", "PROTEIN", 82, 95], ["host surface receptors", "PROTEIN", 139, 161], ["host cytoplasmic proteins", "PROTEIN", 208, 233], ["bacterial and eukaryotic pathogens", "PROBLEM", 17, 51], ["host proteins", "TEST", 82, 95], ["host cytoplasmic proteins", "TEST", 208, 233], ["bacterial", "OBSERVATION_MODIFIER", 17, 26], ["eukaryotic pathogens", "OBSERVATION", 31, 51], ["host cell", "OBSERVATION", 180, 189]]], ["Various bacterial species have a secretion system-a syringe-like apparatus-through which they inject the bacterial effectors directly into the host cell cytoplasm [12] .", [["cell cytoplasm", "ANATOMY", 148, 162], ["cytoplasm", "ORGANISM_SUBSTANCE", 153, 162], ["bacterial effectors", "PROTEIN", 105, 124], ["Various bacterial species", "PROBLEM", 0, 25], ["a secretion system", "PROBLEM", 31, 49], ["a syringe", "TREATMENT", 50, 59], ["the bacterial effectors", "PROBLEM", 101, 124], ["bacterial species", "OBSERVATION", 8, 25], ["secretion system", "OBSERVATION", 33, 49], ["bacterial effectors", "OBSERVATION", 105, 124], ["host cell cytoplasm", "OBSERVATION", 143, 162]]], ["Via HMIs, they specifically hone in on key pathways, alter host physiological signaling, evade the host immune system, modify the cytoskeletal organization [13, 14] , alter membrane and vesicular trafficking [2, 11, 13] , promote pathogen entry into the host, shift the cell cycle [15, 16] , and modulate apoptosis [17] .", [["cytoskeletal", "ANATOMY", 130, 142], ["membrane", "ANATOMY", 173, 181], ["vesicular", "ANATOMY", 186, 195], ["cell", "ANATOMY", 270, 274], ["cytoskeletal", "CELLULAR_COMPONENT", 130, 142], ["membrane", "CELLULAR_COMPONENT", 173, 181], ["vesicular", "MULTI-TISSUE_STRUCTURE", 186, 195], ["cell", "CELL", 270, 274], ["the cytoskeletal organization", "TEST", 126, 155], ["the cell cycle", "TEST", 266, 280]]], ["Host signaling pathways that are targeted by microbiota and turned on or off may change the cell fate.", [["cell", "ANATOMY", 92, 96], ["cell", "CELL", 92, 96], ["the cell fate", "TREATMENT", 88, 101]]], ["Unraveling the HMIs for both commensals and pathogens can elucidate how they repurpose the host signaling pathways and help develop new therapeutic approaches.The host-microbiota interactions in the metaorganismHMIs have complex and dynamic profiles.", [["HMIs", "GENE_OR_GENE_PRODUCT", 15, 19], ["metaorganismHMIs", "GENE_OR_GENE_PRODUCT", 199, 215], ["pathogens", "PROBLEM", 44, 53], ["host", "OBSERVATION_MODIFIER", 163, 167], ["microbiota interactions", "OBSERVATION", 168, 191]]], ["Studies often focus on individual protein interactions and try to explain the pathogenicity of a microorganism with a single interaction.", [["Studies", "TEST", 0, 7], ["individual protein interactions", "PROBLEM", 23, 54], ["a microorganism", "PROBLEM", 95, 110]]], ["For instance, replication of vaccinia virus necessitates the establishment of a complex protein interaction network [19] and hence focusing on only one HMI is incomplete and may be misleading.", [["vaccinia virus", "ORGANISM", 29, 43], ["HMI", "CANCER", 152, 155], ["vaccinia virus", "SPECIES", 29, 43], ["vaccinia virus", "TREATMENT", 29, 43], ["a complex protein interaction network", "TREATMENT", 78, 115], ["may be", "UNCERTAINTY", 174, 180]]], ["At any given time, hundreds of different species reside in the gut.", [["gut", "ANATOMY", 63, 66], ["gut", "ORGANISM_SUBDIVISION", 63, 66], ["different species", "PROBLEM", 31, 48], ["different species", "OBSERVATION", 31, 48], ["gut", "ANATOMY", 63, 66]]], ["Different microbial compositions and hence effector protein combinations from these microbial species may have additive (cross-activation) or subtractive (cross-inhibition) [4] impacts on the host pathways, which lead to signal amplification or inhibition, respectively (Fig 1) .The host-microbiota interactions in the metaorganismSince numerous bacteria will be sensed by the host immune system at any given time, more than one signaling cascade will be active in a cell.", [["cell", "ANATOMY", 467, 471], ["immune system", "ANATOMICAL_SYSTEM", 382, 395], ["cell", "CELL", 467, 471], ["Different microbial compositions", "TREATMENT", 0, 32], ["hence effector protein combinations", "TREATMENT", 37, 72], ["these microbial species", "PROBLEM", 78, 101], ["additive (cross-activation)", "PROBLEM", 111, 138], ["subtractive (cross-inhibition)", "PROBLEM", 142, 172], ["signal amplification", "TEST", 221, 241], ["the metaorganismSince numerous bacteria", "PROBLEM", 315, 354], ["microbial compositions", "OBSERVATION", 10, 32], ["host", "OBSERVATION_MODIFIER", 283, 287], ["-microbiota", "OBSERVATION_MODIFIER", 287, 298], ["active", "OBSERVATION_MODIFIER", 455, 461]]], ["Communication and crosstalk among active, or active and inhibited, pathways determine the ultimate cellular outcome [4] : to survive, die, or elicit immune responses.", [["cellular", "ANATOMY", 99, 107], ["cellular", "CELL", 99, 107]]], ["The combinatorial ramifications of all active (or suppressed) host pathways and HMIs will be integrated to shape the type and magnitude of the response, and thus the cell state.", [["cell", "ANATOMY", 166, 170], ["HMIs", "SIMPLE_CHEMICAL", 80, 84], ["cell", "CELL", 166, 170], ["all active (or suppressed) host pathways", "TREATMENT", 35, 75], ["HMIs", "TREATMENT", 80, 84], ["active", "OBSERVATION_MODIFIER", 39, 45]]], ["To tackle the pathogenicity challenge, it is reasonable to concomitantly consider all host pathways and HMIs.", [["pathogenicity", "OBSERVATION", 14, 27]]], ["The transkingdom (metaorganism) network analysis is a robust research framework that considers host and microbiota as a whole [1] .", [["The transkingdom (metaorganism)", "TREATMENT", 0, 31]]], ["Systems biology approaches that integrate the HMIs with host endogenous protein interaction networks reveal the systematic trends in virulence strategies of pathogens.Host-microbiota network core modulesHere we ask how interspecies (superorganism) networks can facilitate the understanding of the role of microbiota in disease and health.", [["HMIs", "GENE_OR_GENE_PRODUCT", 46, 50], ["microbiota network", "MULTI-TISSUE_STRUCTURE", 172, 190], ["host endogenous protein interaction networks", "TREATMENT", 56, 100], ["pathogens", "PROBLEM", 157, 166], ["pathogens", "OBSERVATION", 157, 166]]], ["We focus on host-microbiota protein interaction networks since many bacteria or virus-induced pathological processes require physical interactions of host and microbial proteins [20] .", [["microbial proteins", "PROTEIN", 159, 177], ["host-microbiota protein interaction networks", "TREATMENT", 12, 56], ["many bacteria", "PROBLEM", 63, 76], ["virus", "PROBLEM", 80, 85], ["induced pathological processes", "PROBLEM", 86, 116]]], ["The availability of genome-wide high throughput omics data makes it possible to associate microbiota with certain host phenotypes at multiple levels and construct host-pathogen interaction networks at the transcriptome [21], proteome Combinatorial effects of microbial effectors and the active host pathways determine the cell response. (a) Composition1 has certain microorganisms that secrete effector protein combination1.", [["cell", "ANATOMY", 322, 326], ["cell", "CELL", 322, 326], ["microbial effectors", "PROTEIN", 259, 278], ["effector protein combination1", "PROTEIN", 394, 423], ["certain host phenotypes", "PROBLEM", 106, 129], ["microbial effectors", "TREATMENT", 259, 278], ["certain microorganisms", "PROBLEM", 358, 380], ["microbial effectors", "OBSERVATION", 259, 278]]], ["These effectors activate pathway1 in the host, which produces pro-inflammatory cytokines. (b) Composition2 secretes effector combination2 and activates pathway2 in addition to pathway1.", [["pathway1", "GENE_OR_GENE_PRODUCT", 25, 33], ["pathway2", "GENE_OR_GENE_PRODUCT", 152, 160], ["pathway1", "PROTEIN", 25, 33], ["pro-inflammatory cytokines", "PROTEIN", 62, 88], ["Composition2", "PROTEIN", 94, 106], ["effector combination2", "PROTEIN", 116, 137], ["pathway2", "PROTEIN", 152, 160], ["pathway1", "PROTEIN", 176, 184], ["pro-inflammatory cytokines", "PROBLEM", 62, 88], ["pro-inflammatory cytokines", "OBSERVATION", 62, 88]]], ["Additive effects of these two pathways amplifies the signal and promotes inflammation (cross-activation). (c) Microbial composition3 utilize effector combination3 to activate both pathway 1 and 3, which have opposing outcomes.", [["inflammation", "DISEASE", 73, 85], ["3", "GENE_OR_GENE_PRODUCT", 194, 195], ["promotes inflammation", "PROBLEM", 64, 85], ["Microbial composition3 utilize effector", "TREATMENT", 110, 149], ["inflammation", "OBSERVATION", 73, 85]]], ["Subtractive effects of these pathways result in no inflammation (cross-inhibition).Host-microbiota network core moduleshttps://doi.org/10.1371/journal.pcbi.1005579.g001Host-microbiota network core modules[22], and metabolome levels [23] .", [["inflammation", "DISEASE", 51, 63], ["these pathways", "TEST", 23, 37], ["inflammation", "PROBLEM", 51, 63], ["metabolome levels", "TEST", 214, 231], ["no", "UNCERTAINTY", 48, 50], ["inflammation", "OBSERVATION", 51, 63]]], ["Steps toward the construction of host-microbiota networks of gene [1] , mRNA [24], protein-protein interaction (PPI) [25] [26] [27] [28] , and metabolic networks [29] have already been taken.", [["26] [27] [28]", "SIMPLE_CHEMICAL", 123, 136], ["mRNA", "RNA", 72, 76], ["mRNA", "TEST", 72, 76], ["protein-protein interaction", "TEST", 83, 110], ["PPI", "TEST", 112, 115], ["metabolic networks", "TEST", 143, 161]]], ["Within this framework we highlight molecular mimicry, a common strategy that microorganisms exploit to bind to host proteins and perturb its physiological signaling.", [["host proteins", "PROTEIN", 111, 124], ["molecular mimicry", "OBSERVATION", 35, 52]]], ["Mimicry of interactions of critical regulatory nodes in core network modules in the immune system, may be a major way through which pathogens adversely subvert-and commensal microbiota may beneficially modulate-the host cell.Molecular mimicryMicrobiota developed several strategies to interact with host proteins and modulate its pathways.", [["immune system", "ANATOMY", 84, 97], ["cell", "ANATOMY", 220, 224], ["host cell", "CELL", 215, 224], ["host proteins", "PROTEIN", 299, 312], ["critical regulatory nodes", "PROBLEM", 27, 52], ["critical", "OBSERVATION_MODIFIER", 27, 35], ["regulatory nodes", "OBSERVATION", 36, 52], ["immune system", "ANATOMY", 84, 97], ["host cell", "OBSERVATION", 215, 224]]], ["One efficient way is molecular mimicry, which has been extensively reviewed in our recent study [9] .", [["molecular mimicry", "OBSERVATION", 21, 38]]], ["Molecular mimicry can take place at four levels: mimicking (i) both sequence and 3D structure of a protein, (ii) only structure without sequence similarity, (iii) sequence of a short motif-motif mimicry, and (iv) structure of a binding surface without sequence similarity-interface mimicry.", [["surface", "ANATOMY", 236, 243], ["a short motif-motif mimicry", "PROBLEM", 175, 202]]], ["Interface mimicry (protein binding surface similarity) seems to be the most common type of molecular mimicry.", [["most common", "OBSERVATION_MODIFIER", 71, 82], ["molecular mimicry", "OBSERVATION", 91, 108]]], ["Global structural similarity is much rarer than interface similarity both within and across species.", [["Global structural similarity", "PROBLEM", 0, 28], ["structural similarity", "OBSERVATION", 7, 28], ["species", "OBSERVATION_MODIFIER", 92, 99]]], ["Thus, employing interface mimicry instead of full-length sequence or structural homology allows microbes to target more host proteins.", [["host proteins", "PROTEIN", 120, 133], ["full-length sequence", "TREATMENT", 45, 65]]], ["Molecular mimicry follows the principle suggested over two decades ago that proteins with different global structures can interact in similar ways [30] [31] [32] .Molecular mimicryInterface mimicry is frequently observed within intra-[33-35] and inter-species [18, 36] (Fig 2) (intra-species interface mimicry: distinct proteins from the same species having the same/similar interfaces; inter-species interface mimicry: proteins from different species hijack the same interface architectures).", [["Fig", "TEST", 270, 273], ["distinct proteins", "PROBLEM", 311, 328]]], ["If an interface is formed between proteins from the same species, it is an 'endogenous interface'.", [["interface", "OBSERVATION", 6, 15], ["endogenous interface", "OBSERVATION", 76, 96]]], ["If it is formed by proteins from two different species, it is an 'exogenous interface' [18, 36] .", [["two different", "OBSERVATION_MODIFIER", 33, 46], ["species", "OBSERVATION_MODIFIER", 47, 54]]], ["Endogenous (intra-species) interfaces mimic each other [33] [34] [35] , and exogenous (inter-species) interfaces mimic endogenous interfaces (Fig 2) [18, 36].", [["[33] [34] [35]", "SIMPLE_CHEMICAL", 55, 69], ["endogenous interfaces", "OBSERVATION", 119, 140]]], ["By mimicking endogenous interfaces, exogenous interfaces enable pathogenic proteins to compete with their host counterparts and hence rewire host signaling pathways for their own advantage [9] .", [["pathogenic proteins", "PROTEIN", 64, 83], ["endogenous interfaces", "OBSERVATION", 13, 34]]], ["For example, the Helicobacter pylori secreted protein CagA interacts with human tumor suppressor TP53BP2, inhibits apoptosis and allows survival of infected host cells [37] .", [["tumor", "ANATOMY", 80, 85], ["cells", "ANATOMY", 162, 167], ["tumor", "DISEASE", 80, 85], ["Helicobacter pylori", "ORGANISM", 17, 36], ["CagA", "GENE_OR_GENE_PRODUCT", 54, 58], ["human", "ORGANISM", 74, 79], ["tumor", "CANCER", 80, 85], ["TP53BP2", "GENE_OR_GENE_PRODUCT", 97, 104], ["host cells", "CELL", 157, 167], ["Helicobacter pylori secreted protein CagA", "PROTEIN", 17, 58], ["TP53BP2", "PROTEIN", 97, 104], ["infected host cells", "CELL_TYPE", 148, 167], ["Helicobacter pylori", "SPECIES", 17, 36], ["human", "SPECIES", 74, 79], ["Helicobacter pylori", "SPECIES", 17, 36], ["human", "SPECIES", 74, 79], ["the Helicobacter pylori secreted protein CagA", "TREATMENT", 13, 58], ["human tumor suppressor TP53BP2", "TREATMENT", 74, 104], ["apoptosis", "PROBLEM", 115, 124], ["infected host cells", "PROBLEM", 148, 167]]], ["However, Map protein of E. coli and SopE protein of Salmonella bacteria bind and activate human Cdc42, a Rho GTPase, and trigger actin reorganization in the host cell, facilitating bacterial entry into the host [38].An example of microbial subversion of a major pattern recognition receptor family: TLR familyOne of the most significant pattern recognition receptor families in the innate immune system is the TLR family.", [["cell", "ANATOMY", 162, 166], ["Map protein", "GENE_OR_GENE_PRODUCT", 9, 20], ["E. coli", "ORGANISM", 24, 31], ["SopE", "GENE_OR_GENE_PRODUCT", 36, 40], ["Salmonella bacteria", "ORGANISM", 52, 71], ["human", "ORGANISM", 90, 95], ["Cdc42", "GENE_OR_GENE_PRODUCT", 96, 101], ["Rho", "GENE_OR_GENE_PRODUCT", 105, 108], ["actin", "GENE_OR_GENE_PRODUCT", 129, 134], ["host cell", "CELL", 157, 166], ["TLR", "GENE_OR_GENE_PRODUCT", 299, 302], ["TLR", "GENE_OR_GENE_PRODUCT", 410, 413], ["Map protein", "PROTEIN", 9, 20], ["SopE protein", "PROTEIN", 36, 48], ["human Cdc42", "PROTEIN", 90, 101], ["Rho GTPase", "PROTEIN", 105, 115], ["actin", "PROTEIN", 129, 134], ["host cell", "CELL_TYPE", 157, 166], ["major pattern recognition receptor family", "PROTEIN", 256, 297], ["TLR family", "PROTEIN", 299, 309], ["pattern recognition receptor families", "PROTEIN", 337, 374], ["TLR family", "PROTEIN", 410, 420], ["E. coli", "SPECIES", 24, 31], ["human", "SPECIES", 90, 95], ["E. coli", "SPECIES", 24, 31], ["Salmonella", "SPECIES", 52, 62], ["human", "SPECIES", 90, 95], ["Map protein", "TEST", 9, 20], ["E. coli", "PROBLEM", 24, 31], ["SopE protein", "PROBLEM", 36, 48], ["Salmonella bacteria bind", "PROBLEM", 52, 76], ["human Cdc42", "TEST", 90, 101], ["a Rho GTPase", "TEST", 103, 115], ["E. coli", "OBSERVATION", 24, 31], ["host cell", "OBSERVATION", 157, 166], ["microbial subversion", "OBSERVATION", 230, 250], ["most significant", "OBSERVATION_MODIFIER", 320, 336]]], ["Its members detect diverse bacterial compounds, like peptidoglycan, lipopolysaccharide, and nucleic acids of bacteria and viruses.", [["lipopolysaccharide", "CHEMICAL", 68, 86], ["nucleic acids", "CHEMICAL", 92, 105], ["peptidoglycan", "SIMPLE_CHEMICAL", 53, 66], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 68, 86], ["nucleic acids", "SIMPLE_CHEMICAL", 92, 105], ["diverse bacterial compounds", "PROBLEM", 19, 46], ["peptidoglycan", "TREATMENT", 53, 66], ["lipopolysaccharide", "TREATMENT", 68, 86], ["nucleic acids of bacteria", "PROBLEM", 92, 117], ["viruses", "PROBLEM", 122, 129], ["diverse", "OBSERVATION_MODIFIER", 19, 26], ["bacterial compounds", "OBSERVATION", 27, 46]]], ["They induce pro-inflammatory or anti-viral responses.", [["pro-inflammatory", "OBSERVATION_MODIFIER", 12, 28]]], ["Once activated, they recruit other TIR-containing proteins such as Mal and MyD88 or TRAM and TRIF through their cytoplasmic TIR domains, forming the MyD88-and TRIF-dependent TIR domain signalosomes, respectively [39].", [["cytoplasmic", "ANATOMY", 112, 123], ["Mal", "GENE_OR_GENE_PRODUCT", 67, 70], ["MyD88", "GENE_OR_GENE_PRODUCT", 75, 80], ["TRAM", "GENE_OR_GENE_PRODUCT", 84, 88], ["TRIF", "GENE_OR_GENE_PRODUCT", 93, 97], ["cytoplasmic", "ORGANISM_SUBSTANCE", 112, 123], ["MyD88", "GENE_OR_GENE_PRODUCT", 149, 154], ["TRIF", "GENE_OR_GENE_PRODUCT", 159, 163], ["TIR-containing proteins", "PROTEIN", 35, 58], ["Mal", "PROTEIN", 67, 70], ["MyD88", "PROTEIN", 75, 80], ["TRAM", "PROTEIN", 84, 88], ["TRIF", "PROTEIN", 93, 97], ["cytoplasmic TIR domains", "PROTEIN", 112, 135], ["MyD88", "PROTEIN", 149, 154], ["TRIF", "PROTEIN", 159, 163], ["TIR domain signalosomes", "PROTEIN", 174, 197], ["Mal and MyD88", "TREATMENT", 67, 80], ["TRAM", "TREATMENT", 84, 88], ["TRIF", "TREATMENT", 93, 97], ["their cytoplasmic TIR domains", "TEST", 106, 135], ["the MyD88", "TEST", 145, 154]]], ["MyD88 also assembles into a Myddosome structure through its death domain together with IRAK4 and IRAK1/2 death domains.", [["death", "DISEASE", 60, 65], ["death", "DISEASE", 105, 110], ["MyD88", "GENE_OR_GENE_PRODUCT", 0, 5], ["IRAK4", "GENE_OR_GENE_PRODUCT", 87, 92], ["IRAK1", "GENE_OR_GENE_PRODUCT", 97, 102], ["MyD88", "PROTEIN", 0, 5], ["Myddosome structure", "PROTEIN", 28, 47], ["death domain", "PROTEIN", 60, 72], ["IRAK4", "PROTEIN", 87, 92], ["IRAK1/2 death domains", "PROTEIN", 97, 118], ["IRAK4", "TREATMENT", 87, 92], ["IRAK1/2 death domains", "TREATMENT", 97, 118]]], ["The myddosome then recruits E3 ubiquitin ligases-either TRAF6 or TRAF3 -to catalyze the addition of K63-linked ubiquitin chains to themselves, which serve as a docking platform for other proteins to bind, such as TAK1.", [["E3", "GENE_OR_GENE_PRODUCT", 28, 30], ["TRAF6", "GENE_OR_GENE_PRODUCT", 56, 61], ["TRAF3", "GENE_OR_GENE_PRODUCT", 65, 70], ["K63", "SIMPLE_CHEMICAL", 100, 103], ["TAK1", "GENE_OR_GENE_PRODUCT", 213, 217], ["E3 ubiquitin ligases", "PROTEIN", 28, 48], ["TRAF6", "PROTEIN", 56, 61], ["TRAF3", "PROTEIN", 65, 70], ["K63", "PROTEIN", 100, 103], ["ubiquitin chains", "PROTEIN", 111, 127], ["TAK1", "PROTEIN", 213, 217], ["E3 ubiquitin ligases", "TREATMENT", 28, 48], ["TRAF6", "TREATMENT", 56, 61], ["TRAF3", "TREATMENT", 65, 70], ["K63-linked ubiquitin chains", "TREATMENT", 100, 127]]], ["Subsequently, NF-\u03baB and MAPK pathways are activated.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 14, 19], ["MAPK", "GENE_OR_GENE_PRODUCT", 24, 28], ["NF-\u03baB", "PROTEIN", 14, 19], ["MAPK", "PROTEIN", 24, 28], ["NF", "TEST", 14, 16]]], ["In the NF-\u03baB pathway, TAK1 phosphorylates and activates IKK.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 7, 12], ["TAK1", "GENE_OR_GENE_PRODUCT", 22, 26], ["IKK", "GENE_OR_GENE_PRODUCT", 56, 59], ["NF-\u03baB", "PROTEIN", 7, 12], ["TAK1", "PROTEIN", 22, 26], ["IKK", "PROTEIN", 56, 59], ["TAK1 phosphorylates", "TREATMENT", 22, 41]]], ["Activated IKK in turn phosphorylates I\u03baB, which is the inhibitor of NF-\u03baB.", [["IKK", "GENE_OR_GENE_PRODUCT", 10, 13], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 37, 40], ["NF-\u03baB.", "GENE_OR_GENE_PRODUCT", 68, 74], ["IKK", "PROTEIN", 10, 13], ["I\u03baB", "PROTEIN", 37, 40], ["NF-\u03baB.", "PROTEIN", 68, 74]]], ["Phosphorylated I\u03baB is then ubiquitylated by other E3 ubiquitin ligases (K48-linked ubiquitin chain) and targeted for proteosomal degradation.", [["I\u03baB", "GENE_OR_GENE_PRODUCT", 15, 18], ["E3", "GENE_OR_GENE_PRODUCT", 50, 52], ["K48-linked ubiquitin chain", "GENE_OR_GENE_PRODUCT", 72, 98], ["I\u03baB", "PROTEIN", 15, 18], ["E3 ubiquitin ligases", "PROTEIN", 50, 70], ["K48", "PROTEIN", 72, 75], ["ubiquitin chain", "PROTEIN", 83, 98], ["Phosphorylated I\u03baB", "TREATMENT", 0, 18], ["K48-linked ubiquitin chain", "TREATMENT", 72, 98], ["proteosomal degradation", "PROBLEM", 117, 140], ["ubiquitin ligases", "OBSERVATION", 53, 70]]], ["This liberates the p65 subunit of NF-\u03baB to translocate to nucleus and initiate transcription.", [["nucleus", "ANATOMY", 58, 65], ["p65", "GENE_OR_GENE_PRODUCT", 19, 22], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 34, 39], ["nucleus", "CELLULAR_COMPONENT", 58, 65], ["p65 subunit", "PROTEIN", 19, 30], ["NF-\u03baB", "PROTEIN", 34, 39]]], ["In the MAPK pathway, TAK1 serves as a MAP3K that activates ERK1/2, p38 and JNK pathways.", [["MAPK", "GENE_OR_GENE_PRODUCT", 7, 11], ["TAK1", "GENE_OR_GENE_PRODUCT", 21, 25], ["MAP3K", "GENE_OR_GENE_PRODUCT", 38, 43], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 59, 65], ["p38", "GENE_OR_GENE_PRODUCT", 67, 70], ["JNK", "GENE_OR_GENE_PRODUCT", 75, 78], ["MAPK", "PROTEIN", 7, 11], ["TAK1", "PROTEIN", 21, 25], ["MAP3K", "PROTEIN", 38, 43], ["ERK1", "PROTEIN", 59, 63], ["p38", "PROTEIN", 67, 70], ["JNK", "PROTEIN", 75, 78], ["a MAP3K", "TEST", 36, 43], ["ERK1", "TEST", 59, 63], ["p38", "TEST", 67, 70], ["JNK pathways", "TEST", 75, 87]]], ["The TRIF-dependent downstream path of TLRs recruits TRAF3 and leads to activation of interferon regulatory factors (IRFs) and production of key antiviral cytokines, interferons (IFNs).An example of microbial subversion of a major pattern recognition receptor family: TLR familyThe TLR pathway is regulated by several endogenous negative regulators to prevent excess inflammation [40] .", [["inflammation", "DISEASE", 366, 378], ["TRIF", "GENE_OR_GENE_PRODUCT", 4, 8], ["TLRs", "GENE_OR_GENE_PRODUCT", 38, 42], ["TRAF3", "GENE_OR_GENE_PRODUCT", 52, 57], ["interferon regulatory factors", "GENE_OR_GENE_PRODUCT", 85, 114], ["IRFs", "GENE_OR_GENE_PRODUCT", 116, 120], ["interferons", "GENE_OR_GENE_PRODUCT", 165, 176], ["IFNs", "GENE_OR_GENE_PRODUCT", 178, 182], ["TLR", "GENE_OR_GENE_PRODUCT", 267, 270], ["TLR", "GENE_OR_GENE_PRODUCT", 281, 284], ["TRIF", "PROTEIN", 4, 8], ["TLRs", "PROTEIN", 38, 42], ["TRAF3", "PROTEIN", 52, 57], ["interferon regulatory factors", "PROTEIN", 85, 114], ["IRFs", "PROTEIN", 116, 120], ["antiviral cytokines", "PROTEIN", 144, 163], ["interferons", "PROTEIN", 165, 176], ["IFNs", "PROTEIN", 178, 182], ["major pattern recognition receptor family", "PROTEIN", 224, 265], ["TLR family", "PROTEIN", 267, 277], ["TLR", "PROTEIN", 281, 284], ["endogenous negative regulators", "PROTEIN", 317, 347], ["The TRIF", "TREATMENT", 0, 8], ["TLRs recruits TRAF3", "TREATMENT", 38, 57], ["interferon regulatory factors", "TREATMENT", 85, 114], ["key antiviral cytokines", "TREATMENT", 140, 163], ["interferons (IFNs)", "TREATMENT", 165, 183], ["excess inflammation", "PROBLEM", 359, 378], ["antiviral cytokines", "OBSERVATION", 144, 163], ["microbial subversion", "OBSERVATION", 198, 218], ["excess", "OBSERVATION_MODIFIER", 359, 365], ["inflammation", "OBSERVATION", 366, 378]]], ["Since this is one of the major immune pathways, its signaling is targeted by diverse microorganisms at various steps (Fig 3) , compete with endogenous TIR-containing proteins and interfere with the assembly of the TIR-domain signalosome and prevent downstream signaling.", [["TIR-containing proteins", "GENE_OR_GENE_PRODUCT", 151, 174], ["endogenous TIR-containing proteins", "PROTEIN", 140, 174], ["TIR-domain signalosome", "PROTEIN", 214, 236], ["diverse microorganisms", "PROBLEM", 77, 99], ["endogenous TIR-containing proteins", "TREATMENT", 140, 174], ["the TIR-domain signalosome", "TREATMENT", 210, 236], ["downstream signaling", "PROBLEM", 249, 269], ["diverse", "OBSERVATION_MODIFIER", 77, 84], ["microorganisms", "OBSERVATION", 85, 99], ["prevent", "UNCERTAINTY", 241, 248], ["downstream signaling", "OBSERVATION", 249, 269]]], ["Since these microbial proteins do not enzymatically modify the endogenous proteins, elucidation of their inhibition mechanism requires structural information.", [["microbial proteins", "PROTEIN", 12, 30], ["endogenous proteins", "PROTEIN", 63, 82], ["these microbial proteins", "TEST", 6, 30], ["the endogenous proteins", "PROBLEM", 59, 82], ["endogenous proteins", "OBSERVATION", 63, 82]]], ["The availability of the structures of their complexes with the orchestrators of the TLR pathway can clarify how they inhibit downstream signaling.", [["TLR", "GENE_OR_GENE_PRODUCT", 84, 87], ["TLR", "PROTEIN", 84, 87]]], ["Microbial proteases prevent both TLR-induced MAPK and NF-\u03baB signaling and lead to proteosomal degradation of the key orchestrators in these pathways: NleD of E. coli cleaves JNK and p38, inhibiting MAPK pathway; and NleC cleaves p65, inhibiting NF-\u03baB [46] .", [["TLR", "GENE_OR_GENE_PRODUCT", 33, 36], ["MAPK", "GENE_OR_GENE_PRODUCT", 45, 49], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 54, 59], ["NleD", "GENE_OR_GENE_PRODUCT", 150, 154], ["E. coli", "ORGANISM", 158, 165], ["JNK", "GENE_OR_GENE_PRODUCT", 174, 177], ["p38", "GENE_OR_GENE_PRODUCT", 182, 185], ["MAPK", "GENE_OR_GENE_PRODUCT", 198, 202], ["NleC", "GENE_OR_GENE_PRODUCT", 216, 220], ["p65", "GENE_OR_GENE_PRODUCT", 229, 232], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 245, 250], ["Microbial proteases", "PROTEIN", 0, 19], ["TLR", "PROTEIN", 33, 36], ["MAPK", "PROTEIN", 45, 49], ["\u03baB", "PROTEIN", 57, 59], ["NleD", "PROTEIN", 150, 154], ["JNK", "PROTEIN", 174, 177], ["p38", "PROTEIN", 182, 185], ["MAPK", "PROTEIN", 198, 202], ["NleC", "PROTEIN", 216, 220], ["p65", "PROTEIN", 229, 232], ["NF-\u03baB", "PROTEIN", 245, 250], ["E. coli", "SPECIES", 158, 165], ["E. coli", "SPECIES", 158, 165], ["Microbial proteases", "TREATMENT", 0, 19], ["MAPK", "TEST", 45, 49], ["NF", "PROBLEM", 54, 56], ["B signaling", "PROBLEM", 58, 69], ["proteosomal degradation", "PROBLEM", 82, 105], ["E. coli", "TEST", 158, 165], ["JNK", "TEST", 174, 177], ["p38", "TEST", 182, 185], ["inhibiting MAPK pathway", "TEST", 187, 210]]], ["There are also bacterial acetyltransferases ( [57, 58] inhibit this protein to limit IFN production [59] .An example of microbial subversion of a major pattern recognition receptor family: TLR familyHere, we listed only a couple of microbial proteins targeting TLR pathway as examples.", [["IFN", "GENE_OR_GENE_PRODUCT", 85, 88], ["TLR", "GENE_OR_GENE_PRODUCT", 189, 192], ["TLR", "GENE_OR_GENE_PRODUCT", 261, 264], ["bacterial acetyltransferases", "PROTEIN", 15, 43], ["IFN", "PROTEIN", 85, 88], ["major pattern recognition receptor family", "PROTEIN", 146, 187], ["TLR family", "PROTEIN", 189, 199], ["microbial proteins", "PROTEIN", 232, 250], ["TLR", "PROTEIN", 261, 264], ["bacterial acetyltransferases", "PROBLEM", 15, 43], ["this protein", "TEST", 63, 75], ["IFN production", "TEST", 85, 99], ["microbial proteins", "TREATMENT", 232, 250], ["bacterial acetyltransferases", "OBSERVATION", 15, 43], ["microbial subversion", "OBSERVATION", 120, 140]]], ["There are many others.", [["many", "OBSERVATION_MODIFIER", 10, 14], ["others", "OBSERVATION_MODIFIER", 15, 21]]], ["The TLR pathway does not constitute the whole innate immune system; other immune pathways also need to be considered as well as how these microbial proteins affect them as a whole.", [["TLR", "GENE_OR_GENE_PRODUCT", 4, 7], ["TLR", "PROTEIN", 4, 7], ["microbial proteins", "PROTEIN", 138, 156], ["other immune pathways", "PROBLEM", 68, 89], ["does not constitute", "UNCERTAINTY", 16, 35]]], ["This can help foreseeing what kind of responses the coordinated actions of these pathways together with TLRs would generate.PPI networks and their topological propertiesMost cellular processes are elicited by proteins and their interactions.", [["cellular", "ANATOMY", 174, 182], ["TLRs", "GENE_OR_GENE_PRODUCT", 104, 108], ["cellular", "CELL", 174, 182], ["TLRs", "PROTEIN", 104, 108], ["TLRs", "TREATMENT", 104, 108], ["PPI networks", "TREATMENT", 124, 136], ["their topological properties", "TREATMENT", 141, 169], ["Most cellular processes", "PROBLEM", 169, 192], ["cellular processes", "OBSERVATION", 174, 192]]], ["Graph representations of PPI networks, where proteins are the nodes and their interactions are edges, are helpful for delineating the global behavior of the network.", [["PPI networks", "TREATMENT", 25, 37], ["PPI networks", "OBSERVATION", 25, 37], ["nodes", "OBSERVATION", 62, 67]]], ["Topological features of networks, such as degree (number of edges), betweenness-centrality (how a node affects the communication between two nodes), lethality-centrality, hubs (proteins with high node-degree, i.e. severalEndogenous (intra-species) and exogenous (inter-species) interface mimicry. (a)A, B, C, D are host proteins and P is pathogenic protein.", [["node", "ANATOMY", 98, 102], ["node", "ANATOMY", 196, 200], ["(a)A, B, C, D", "CHEMICAL", 297, 310], ["B, C, D", "SIMPLE_CHEMICAL", 303, 310], ["P", "PROTEIN", 333, 334], ["pathogenic protein", "PROTEIN", 338, 356], ["lethality", "PROBLEM", 149, 158], ["high node-degree", "PROBLEM", 191, 207], ["Endogenous (intra-species", "PROBLEM", 221, 246], ["pathogenic protein", "PROBLEM", 338, 356], ["edges", "OBSERVATION_MODIFIER", 60, 65], ["node", "OBSERVATION", 98, 102], ["high node", "OBSERVATION", 191, 200], ["intra-species", "OBSERVATION_MODIFIER", 233, 246]]], ["Protein A has two interfaces: through blue interface it binds to B and through grey interface it binds to C and D. C and D proteins employ similar interfaces to bind to A. So, endogenous interfaces mimic each other.", [["Protein A", "GENE_OR_GENE_PRODUCT", 0, 9], ["B", "GENE_OR_GENE_PRODUCT", 65, 66], ["D proteins", "GENE_OR_GENE_PRODUCT", 121, 131], ["Protein A", "PROTEIN", 0, 9], ["B", "PROTEIN", 65, 66], ["C and D. C and D proteins", "PROTEIN", 106, 131]]], ["Pathogenic protein P has similar interface as B and competes to bind to the blue interface on A. In this case, an exogenous interface mimics an endogenous interface. (b) The F1L protein of variola virus interacts with human BID protein (5ajj:AB.pdb) and inhibits apoptosis in the host cell by hijacking the interface between human BID-BCLXL (4qve:AB.pdb): an exogenous interface mimicking an endogenous one.", [["cell", "ANATOMY", 285, 289], ["F1L", "GENE_OR_GENE_PRODUCT", 174, 177], ["variola virus", "ORGANISM", 189, 202], ["human", "ORGANISM", 218, 223], ["BID", "GENE_OR_GENE_PRODUCT", 224, 227], ["5ajj:AB.pdb", "GENE_OR_GENE_PRODUCT", 237, 248], ["host cell", "CELL", 280, 289], ["human", "ORGANISM", 325, 330], ["BID-BCLXL", "GENE_OR_GENE_PRODUCT", 331, 340], ["4qve:AB.pdb", "GENE_OR_GENE_PRODUCT", 342, 353], ["Pathogenic protein P", "PROTEIN", 0, 20], ["B", "PROTEIN", 46, 47], ["F1L protein", "PROTEIN", 174, 185], ["human BID protein", "PROTEIN", 218, 235], ["5ajj:AB.pdb", "PROTEIN", 237, 248], ["host cell", "CELL_TYPE", 280, 289], ["human BID", "PROTEIN", 325, 334], ["BCLXL", "PROTEIN", 335, 340], ["4qve:AB.pdb", "PROTEIN", 342, 353], ["human", "SPECIES", 218, 223], ["human", "SPECIES", 325, 330], ["variola virus", "SPECIES", 189, 202], ["human", "SPECIES", 218, 223], ["human", "SPECIES", 325, 330], ["The F1L protein", "TREATMENT", 170, 185], ["variola virus", "PROBLEM", 189, 202], ["human BID protein", "TREATMENT", 218, 235], ["apoptosis", "PROBLEM", 263, 272], ["an exogenous interface", "PROBLEM", 356, 378], ["endogenous interface", "OBSERVATION", 144, 164], ["variola virus", "OBSERVATION", 189, 202], ["host cell", "OBSERVATION", 280, 289], ["exogenous interface", "OBSERVATION", 359, 378], ["endogenous one", "OBSERVATION", 392, 406]]], ["Human MCL1 protein binds to human BID (5c3f:AB.pdb) in a very similar fashion that BCLXL does: endogenous interfaces mimicking each other.Endogenous (intra-species) and exogenous (inter-species) interface mimicry. (a)https://doi.org/10.1371/journal.pcbi.1005579.g002 interaction partners), non-hubs (with only a few partners), and bottlenecks (nodes with high betweenness-centrality) help characterization of the importance of the nodes, i.e. the contribution of the node to network integrity [60, 61] .", [["nodes", "ANATOMY", 431, 436], ["node", "ANATOMY", 467, 471], ["Human", "ORGANISM", 0, 5], ["MCL1", "GENE_OR_GENE_PRODUCT", 6, 10], ["human", "ORGANISM", 28, 33], ["BID", "GENE_OR_GENE_PRODUCT", 34, 37], ["BCLXL", "GENE_OR_GENE_PRODUCT", 83, 88], ["node", "MULTI-TISSUE_STRUCTURE", 467, 471], ["Human MCL1 protein", "PROTEIN", 0, 18], ["human BID", "PROTEIN", 28, 37], ["5c3f:AB.pdb", "PROTEIN", 39, 50], ["BCLXL", "PROTEIN", 83, 88], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 28, 33], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 28, 33], ["Human MCL1 protein binds", "TREATMENT", 0, 24], ["Endogenous (intra-species", "PROBLEM", 138, 163], ["intra-species", "OBSERVATION_MODIFIER", 150, 163], ["nodes", "OBSERVATION", 431, 436], ["node", "OBSERVATION", 467, 471]]], ["To infer whether a hub is party or date hub, structural information (interface residues) [62] or gene expression data (co-expressed proteins have higher chances of interacting with each other) [63] were used.", [["co-expressed proteins", "PROTEIN", 119, 140], ["gene expression data", "TEST", 97, 117]]], ["Among the reasons were the many examples where a protein node can serve concomitantly as a party and date hub.", [["node", "ANATOMY", 57, 61], ["a protein node", "PROBLEM", 47, 61], ["node", "OBSERVATION", 57, 61]]], ["Large assemblies typically fall into this category.Endogenous (intra-species) and exogenous (inter-species) interface mimicry. (a)Biological networks are often scale-free, with many non-hubs and fewer hubs [64, 65] .", [["Large assemblies", "PROBLEM", 0, 16], ["Endogenous (intra-species", "PROBLEM", 51, 76], ["intra-species", "OBSERVATION_MODIFIER", 63, 76]]], ["Not all nodes have the same effect on the network: random node attacks do not harm the network as much as removing hubs from scale-free networks [66] .", [["node", "ANATOMY", 58, 62], ["nodes", "MULTI-TISSUE_STRUCTURE", 8, 13], ["node", "MULTI-TISSUE_STRUCTURE", 58, 62], ["all nodes", "PROBLEM", 4, 13], ["random node attacks", "PROBLEM", 51, 70], ["nodes", "OBSERVATION", 8, 13], ["node", "OBSERVATION", 58, 62]]], ["Degree and betweenness-centrality are measures of the contribution of nodes to network integrity.", [["network", "TISSUE", 79, 86], ["betweenness", "OBSERVATION_MODIFIER", 11, 22], ["centrality", "OBSERVATION_MODIFIER", 23, 33], ["nodes", "OBSERVATION", 70, 75]]], ["There are also \"essential\" nodes, knock-out of which leads to lethality: a feature also known as \"lethality-centrality\".", [["nodes", "ANATOMY", 27, 32], ["essential\" nodes", "PROBLEM", 16, 32], ["lethality", "PROBLEM", 62, 71], ["lethality", "PROBLEM", 98, 107], ["essential", "OBSERVATION_MODIFIER", 16, 25], ["\"", "OBSERVATION_MODIFIER", 25, 26], ["nodes", "OBSERVATION", 27, 32], ["lethality", "OBSERVATION", 62, 71]]], ["Attack of a hub by microbiota is likely to influence the cell, either resulting in lethality, or in beneficial modulation.", [["cell", "ANATOMY", 57, 61], ["cell", "CELL", 57, 61], ["lethality", "PROBLEM", 83, 92]]], ["Thus, integrated superorganism interaction networks may suggest candidate host and microbial node targets.", [["node", "ANATOMY", 93, 97], ["microbial node", "MULTI-TISSUE_STRUCTURE", 83, 97], ["microbial node targets", "TREATMENT", 83, 105], ["node", "OBSERVATION", 93, 97]]], ["Structural interspecies networks and their topological features can shed light on how microbiota alter the host signaling and what will the outcome in different settings be.Structural metaorganism networksAvailable HMI networks demonstrate that different bacteria often hijack the same host pathway in distinct ways [12] , like the TLR pathway subversion by numerous microbial species (Fig 3) .", [["HMI networks", "MULTI-TISSUE_STRUCTURE", 215, 227], ["TLR", "GENE_OR_GENE_PRODUCT", 332, 335], ["HMI networks", "PROTEIN", 215, 227], ["TLR", "PROTEIN", 332, 335], ["different bacteria", "PROBLEM", 245, 263], ["numerous microbial species", "PROBLEM", 358, 384], ["numerous", "OBSERVATION_MODIFIER", 358, 366], ["microbial species", "OBSERVATION", 367, 384]]], ["However, importantly, the same host pathway is often targeted at several nodes, which was suggested to guarantee modulation of cellular function [12] .", [["nodes", "ANATOMY", 73, 78], ["cellular", "ANATOMY", 127, 135], ["cellular", "CELL", 127, 135], ["nodes", "OBSERVATION", 73, 78]]], ["Although there are a number of examples of constructed networks of host-pathogen superorganism interactions [12, 19, [67] [68] [69] [70] [71] [72] [73] [74] [75] , there are many fewer attempts of integrating 3D structural data with the HMI networks [18] .", [["superorganism", "SIMPLE_CHEMICAL", 81, 94], ["69] [70] [71] [72] [73] [74] [75]", "SIMPLE_CHEMICAL", 128, 161]]], ["Traditional network representation has low resolution, missing important details.", [["low resolution", "OBSERVATION_MODIFIER", 39, 53]]], ["The potential of structural networks in unraveling signaling pathways was demonstrated earlier [39, 40, 76, 77] .", [["structural networks", "OBSERVATION", 17, 36]]], ["They are essential to fully grasp the mechanisms exerted by pathogens to divert the host cell signaling and attenuate immune responses.", [["cell", "ANATOMY", 89, 93], ["cell", "CELL", 89, 93], ["host cell", "OBSERVATION", 84, 93]]], ["Fig 4 displays an example of a structural HMI network, showing how host PPIs can be affected by HMIs.", [["HMI network", "MULTI-TISSUE_STRUCTURE", 42, 53], ["host PPIs", "TREATMENT", 67, 76]]], ["Structures can detail which endogenous host PPIs are disrupted by the HMIs, possible consequences of mutations on either host proteins or pathogenic proteins, and whether variants of a virulence factor in different strains of the same species have distinct HMIs.", [["HMIs", "GENE_OR_GENE_PRODUCT", 70, 74], ["HMIs", "CANCER", 257, 261], ["host proteins", "PROTEIN", 121, 134], ["pathogenic proteins", "PROTEIN", 138, 157], ["virulence factor", "PROTEIN", 185, 201], ["endogenous host PPIs", "TREATMENT", 28, 48], ["mutations", "PROBLEM", 101, 110], ["pathogenic proteins", "PROBLEM", 138, 157], ["a virulence factor", "PROBLEM", 183, 201], ["different strains", "PROBLEM", 205, 222], ["the same species", "PROBLEM", 226, 242], ["host PPIs", "OBSERVATION", 39, 48]]], ["For instance, the pro-35 residue on HIV accessory protein Vpr is at the interface with human CypA and its mutation to Alanine abrogates the interaction [78] .", [["Alanine", "CHEMICAL", 118, 125], ["Alanine", "CHEMICAL", 118, 125], ["pro-35", "GENE_OR_GENE_PRODUCT", 18, 24], ["Vpr", "GENE_OR_GENE_PRODUCT", 58, 61], ["human", "ORGANISM", 87, 92], ["CypA", "GENE_OR_GENE_PRODUCT", 93, 97], ["Alanine", "AMINO_ACID", 118, 125], ["HIV accessory protein", "PROTEIN", 36, 57], ["Vpr", "PROTEIN", 58, 61], ["human CypA", "PROTEIN", 87, 97], ["human", "SPECIES", 87, 92], ["HIV", "SPECIES", 36, 39], ["human", "SPECIES", 87, 92], ["the pro-35 residue", "PROBLEM", 14, 32], ["HIV accessory protein Vpr", "TREATMENT", 36, 61], ["human CypA", "TREATMENT", 87, 97]]], ["The structure of the CypA-Vpr complex shows that pro-35 is at the interface.", [["CypA", "GENE_OR_GENE_PRODUCT", 21, 25], ["Vpr", "GENE_OR_GENE_PRODUCT", 26, 29], ["pro-35", "GENE_OR_GENE_PRODUCT", 49, 55], ["CypA", "PROTEIN", 21, 25], ["Vpr complex", "PROTEIN", 26, 37], ["pro-35", "DNA", 49, 55], ["CypA", "OBSERVATION", 21, 25]]], ["If the structure of the Vpr-CypA complex was unknown, it would have been difficult to understand why, or how, this mutation disrupts the PPI.Structural metaorganism networksPreviously built structural HMI networks demonstrated that endogenous interfaces that are hijacked by pathogens are involved in multiple transient interactions [18, 36] .", [["Vpr-CypA", "GENE_OR_GENE_PRODUCT", 24, 32], ["Vpr-CypA complex", "PROTEIN", 24, 40], ["HMI networks", "PROTEIN", 201, 213], ["this mutation", "PROBLEM", 110, 123], ["the PPI", "TREATMENT", 133, 140], ["endogenous interfaces", "PROBLEM", 232, 253], ["pathogens", "PROBLEM", 275, 284], ["endogenous interfaces", "OBSERVATION", 232, 253], ["multiple", "OBSERVATION_MODIFIER", 301, 309], ["transient", "OBSERVATION_MODIFIER", 310, 319]]], ["These endogenous interfaces exhibit 'date-like' features, i.e. they are involved in interactions with several endogenous proteins at different times [18, 36] .", [["endogenous proteins", "PROTEIN", 110, 129], ["several endogenous proteins", "PROBLEM", 102, 129]]], ["Hub and bottleneck proteins at the crossroads of several host pathways were suggested to be the major targets of viral and bacterial proteins [26, 28] and interface mimics allow transient interactions with the hub [79] .", [["Hub", "GENE_OR_GENE_PRODUCT", 0, 3], ["Hub", "PROTEIN", 0, 3], ["bottleneck proteins", "PROTEIN", 8, 27], ["viral and bacterial proteins", "PROTEIN", 113, 141], ["bottleneck proteins", "PROBLEM", 8, 27], ["viral and bacterial proteins", "PROBLEM", 113, 141]]], ["This allows them to interfere with multiple endogenous PPIs.", [["multiple endogenous PPIs", "TREATMENT", 35, 59], ["endogenous PPIs", "OBSERVATION", 44, 59]]], ["It was proposed that microorganisms causing acute infections, which are dramatic for the host, are likely to interfere with the hubs, whereas others that lead to persistent infections tend to target non-hubs [80] .", [["infections", "DISEASE", 50, 60], ["infections", "DISEASE", 173, 183], ["microorganisms", "PROBLEM", 21, 35], ["acute infections", "PROBLEM", 44, 60], ["persistent infections", "PROBLEM", 162, 183], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["infections", "OBSERVATION", 50, 60], ["persistent", "OBSERVATION_MODIFIER", 162, 172], ["infections", "OBSERVATION", 173, 183]]], ["During acute infection, pathogens replicate very quickly and are transmitted to new hosts.", [["acute infection", "DISEASE", 7, 22], ["acute infection", "PROBLEM", 7, 22], ["pathogens", "PROBLEM", 24, 33], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["infection", "OBSERVATION", 13, 22]]], ["However, during chronic infections, they adapt to the host environment, which allows them to reside there for a long period of time.", [["infections", "DISEASE", 24, 34], ["chronic infections", "PROBLEM", 16, 34], ["chronic", "OBSERVATION_MODIFIER", 16, 23], ["infections", "OBSERVATION", 24, 34]]], ["Thus, how microbiota target certain proteins and pathways at the molecular level is of paramount importance.Structural metaorganism networksDetecting the HMIs, mapping them onto networks and determining their 3D structures as a complex are the major steps to construct structural HMI networks.", [["HMI networks", "MULTI-TISSUE_STRUCTURE", 280, 292], ["HMIs", "DNA", 154, 158], ["HMI networks", "PROTEIN", 280, 292], ["the HMIs", "PROBLEM", 150, 158]]], ["Despite the progress in experimental techniques, it is still challenging to determine structures of PPI complexes, particularly HMIs.", [["PPI", "SIMPLE_CHEMICAL", 100, 103], ["HMIs", "PATHOLOGICAL_FORMATION", 128, 132], ["PPI complexes", "PROTEIN", 100, 113], ["experimental techniques", "TREATMENT", 24, 47], ["PPI complexes", "PROBLEM", 100, 113], ["HMIs", "PROBLEM", 128, 132], ["PPI complexes", "OBSERVATION", 100, 113]]], ["Since large-scale experimental characterization of host-pathogen PPIs is difficult, time consuming, and costly, experimentally verified HMI data is scarce.", [["host-pathogen PPIs", "TREATMENT", 51, 69], ["large", "OBSERVATION_MODIFIER", 6, 11], ["-scale", "OBSERVATION_MODIFIER", 11, 17]]], ["It is important to note that available endogenous protein structures are biased towards permanent, rather than transient interactions.", [["endogenous protein structures", "PROBLEM", 39, 68]]], ["If majority of the HMIs are transient, this presents another hurdle since they will be under-represented in the structural space.", [["HMIs", "DISEASE", 19, 23], ["HMIs", "CANCER", 19, 23], ["transient", "OBSERVATION_MODIFIER", 28, 37]]], ["Several HMI databases have been developed, such as PHISTO [81] , HPIDB [82] , Proteopathogen [83] , PATRIC [84] , PHI-base [85] , PHIDIAS [86] , HoPaCI-DB [87] , VirHostNet [88] , ViRBase [89] , VirusMentha [90] , HCVpro [91] , and likely some others as well.", [["Several HMI databases", "TEST", 0, 21], ["HPIDB", "TEST", 65, 70], ["Proteopathogen", "TEST", 78, 92], ["PATRIC", "TEST", 100, 106], ["PHI-base", "TEST", 114, 122], ["PHIDIAS", "TEST", 130, 137], ["HoPaCI", "TEST", 145, 151], ["DB", "TEST", 152, 154], ["VirHostNet", "TEST", 162, 172], ["ViRBase", "TEST", 180, 187], ["VirusMentha", "TEST", 195, 206], ["HCVpro", "TEST", 214, 220], ["base", "ANATOMY_MODIFIER", 118, 122]]], ["However, these databases cover only a limited number of pathogens and their interactions.", [["pathogens", "PROBLEM", 56, 65]]], ["Given that thousands of species residing in the host, thousands of HMIs are yet to be identified.", [["HMIs", "GENE_OR_GENE_PRODUCT", 67, 71], ["species", "PROBLEM", 24, 31], ["HMIs", "PROBLEM", 67, 71], ["species", "OBSERVATION_MODIFIER", 24, 31]]], ["Computational approaches are becoming increasingly important in prioritizing putative HMIs and complementing experiments.", [["HMIs", "CANCER", 86, 90]]], ["Hence, construction of comprehensive metaorganism networks and increasing the coverage of the host-microbiota interactome will still mostly rely on computational models in the near future [92] .", [["metaorganism networks", "MULTI-TISSUE_STRUCTURE", 37, 58], ["comprehensive metaorganism networks", "TREATMENT", 23, 58]]], ["Computational modeling of intra-species interactions is a well-established area; detection of inter-species interactions is relatively new.", [["inter-species interactions", "PROBLEM", 94, 120], ["new", "OBSERVATION_MODIFIER", 135, 138]]], ["Current methods mostly depend on global sequence and structure homology.", [["Current methods", "TREATMENT", 0, 15]]], ["Sequence-based methods focus only on orthologs of host proteins.", [["host proteins", "PROTEIN", 50, 63], ["Sequence", "TEST", 0, 8]]], ["However, sequence by itself is insufficient to detect the targets of pathogenic proteins because several virulence factors do not have any sequence homologs in human.", [["human", "ORGANISM", 160, 165], ["pathogenic proteins", "PROTEIN", 69, 88], ["virulence factors", "PROTEIN", 105, 122], ["human", "SPECIES", 160, 165], ["human", "SPECIES", 160, 165], ["pathogenic proteins", "PROBLEM", 69, 88], ["several virulence factors", "PROBLEM", 97, 122]]], ["For instance, the VacA protein of Helicobacter pylori, the most dominant species in gastric microbiota, has a unique sequence that does not resemble any human protein [94] .", [["gastric microbiota", "ANATOMY", 84, 102], ["Helicobacter pylori", "DISEASE", 34, 53], ["VacA", "GENE_OR_GENE_PRODUCT", 18, 22], ["Helicobacter pylori", "ORGANISM", 34, 53], ["gastric microbiota", "MULTI-TISSUE_STRUCTURE", 84, 102], ["human", "ORGANISM", 153, 158], ["VacA protein", "PROTEIN", 18, 30], ["Helicobacter pylori", "SPECIES", 34, 53], ["human", "SPECIES", 153, 158], ["Helicobacter pylori", "SPECIES", 34, 53], ["human", "SPECIES", 153, 158], ["the VacA protein", "TEST", 14, 30], ["Helicobacter pylori", "PROBLEM", 34, 53], ["the most dominant species in gastric microbiota", "PROBLEM", 55, 102], ["Helicobacter pylori", "OBSERVATION", 34, 53], ["most dominant", "OBSERVATION_MODIFIER", 59, 72], ["species", "OBSERVATION", 73, 80], ["gastric microbiota", "ANATOMY", 84, 102]]], ["With sequence-based methods, it is impossible to find HMIs for VacA.", [["HMIs", "GENE_OR_GENE_PRODUCT", 54, 58], ["VacA", "GENE_OR_GENE_PRODUCT", 63, 67], ["VacA", "PROTEIN", 63, 67], ["VacA", "PROBLEM", 63, 67]]], ["As noted above, global structural mimicry is much rarer than interface mimicry.", [["structural mimicry", "OBSERVATION", 23, 41]]], ["Hence, utilizing interface similarity, rather than global structural similarity in a computational approach would generate a more enriched set of HMI data together with atomic details [9] .Structural metaorganism networksSeveral studies suggested that the available interface structures are diverse enough to cover most human PPIs [96] [97] [98] [99] .", [["human", "ORGANISM", 320, 325], ["human", "SPECIES", 320, 325], ["human", "SPECIES", 320, 325], ["Several studies", "TEST", 221, 236], ["the available interface structures", "PROBLEM", 252, 286]]], ["Therefore, success of template-based methods for prediction of human PPIs is very high [34] .", [["human", "ORGANISM", 63, 68], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["template-based methods", "TREATMENT", 22, 44], ["human PPIs", "TREATMENT", 63, 73]]], ["Since exogenous interfaces mimic endogenous ones, both available endogenous and exogenous interface structures can be used as templates to detect novel HMIs.", [["HMIs", "CANCER", 152, 156], ["exogenous interfaces mimic endogenous ones", "PROBLEM", 6, 48], ["novel HMIs", "PROBLEM", 146, 156], ["endogenous ones", "OBSERVATION", 33, 48]]], ["Thanks to the rapid increase in the number of resolved 3D structures of human-pathogen PPIs in recent years [100] and advances in structural and computational biology, the performance of interface-based methods is expected to increase.Structural metaorganism networksBoth experimental and computational approaches have false-positives and false-negatives with varying rates depending on the approach.", [["human", "ORGANISM", 72, 77], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77], ["pathogen PPIs", "TREATMENT", 78, 91], ["false-negatives", "PROBLEM", 339, 354], ["varying rates", "PROBLEM", 360, 373], ["rapid", "OBSERVATION_MODIFIER", 14, 19], ["increase", "OBSERVATION_MODIFIER", 20, 28]]], ["Although the coverage of interface-based methods is higher, their false-positive rate is also higher.", [["higher", "OBSERVATION_MODIFIER", 52, 58], ["positive rate", "OBSERVATION", 72, 85], ["higher", "OBSERVATION_MODIFIER", 94, 100]]], ["Despite this, attempts to complete the host-microbiota interactome will improve our knowledge of microbiota and their roles in health and disease.ConclusionsAdvances in host-microbiota research will revolutionize the understanding of the connection between health and a broad range of diseases.", [["disease", "PROBLEM", 138, 145], ["diseases", "PROBLEM", 285, 293]]], ["Building the rewired host-microbiota multiorganism interaction network, along with its structural details, is vital for figuring out the molecular mechanisms underlying host immune modulation by microbiota.", [["host immune modulation", "OBSERVATION", 169, 191]]], ["Identification of the HMIs will also help drug discovery and integrated superorganism networks would suggest how inhibition of an HMI can influence the whole system.ConclusionsHere we highlighted the importance of building structural HMI networks.", [["superorganism networks", "MULTI-TISSUE_STRUCTURE", 72, 94], ["HMI", "GENE_OR_GENE_PRODUCT", 130, 133], ["HMI networks", "MULTI-TISSUE_STRUCTURE", 234, 246], ["HMI networks", "PROTEIN", 234, 246], ["the HMIs", "PROBLEM", 18, 26], ["integrated superorganism networks", "TREATMENT", 61, 94]]], ["However, not only HMIs are important; although to date data are scant, crosstalk among microorganisms is also emerging as critical.", [["HMIs", "GENE_OR_GENE_PRODUCT", 18, 22], ["scant, crosstalk among microorganisms", "PROBLEM", 64, 101]]], ["Alterations in their population dynamics may lead to dysbiosis.", [["dysbiosis", "DISEASE", 53, 62], ["dysbiosis", "PROBLEM", 53, 62]]], ["Signals from gut microbiota resulting from population shifts can affect profoundly several tissues, including the central nervous system.", [["gut microbiota", "ANATOMY", 13, 27], ["tissues", "ANATOMY", 91, 98], ["central nervous system", "ANATOMY", 114, 136], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 13, 27], ["tissues", "TISSUE", 91, 98], ["central nervous system", "ANATOMICAL_SYSTEM", 114, 136], ["profoundly several tissues", "PROBLEM", 72, 98], ["several tissues", "OBSERVATION_MODIFIER", 83, 98], ["central", "ANATOMY_MODIFIER", 114, 121], ["nervous system", "ANATOMY", 122, 136]]], ["Dysbiosis of microbiota is involved in several diseases, such as inflammatory bowel disease [101] , autoimmune diseases (e.g. multiple sclerosis) [102] , neurodegenerative diseases (e.g. Parkinson's) [103] , and cancer [104, 105] .", [["bowel", "ANATOMY", 78, 83], ["cancer", "ANATOMY", 212, 218], ["inflammatory bowel disease", "DISEASE", 65, 91], ["autoimmune diseases", "DISEASE", 100, 119], ["multiple sclerosis", "DISEASE", 126, 144], ["neurodegenerative diseases", "DISEASE", 154, 180], ["Parkinson's) [103]", "DISEASE", 187, 205], ["cancer", "DISEASE", 212, 218], ["bowel", "ORGAN", 78, 83], ["cancer", "CANCER", 212, 218], ["Dysbiosis of microbiota", "PROBLEM", 0, 23], ["several diseases", "PROBLEM", 39, 55], ["inflammatory bowel disease", "PROBLEM", 65, 91], ["autoimmune diseases", "PROBLEM", 100, 119], ["multiple sclerosis)", "PROBLEM", 126, 145], ["neurodegenerative diseases", "PROBLEM", 154, 180], ["Parkinson's)", "PROBLEM", 187, 199], ["cancer", "PROBLEM", 212, 218], ["microbiota", "OBSERVATION", 13, 23], ["several", "OBSERVATION_MODIFIER", 39, 46], ["diseases", "OBSERVATION", 47, 55], ["inflammatory", "OBSERVATION_MODIFIER", 65, 77], ["bowel", "ANATOMY", 78, 83], ["disease", "OBSERVATION", 84, 91], ["multiple", "OBSERVATION_MODIFIER", 126, 134], ["sclerosis", "OBSERVATION", 135, 144], ["neurodegenerative", "OBSERVATION_MODIFIER", 154, 171], ["diseases", "OBSERVATION", 172, 180], ["cancer", "OBSERVATION", 212, 218]]], ["Identifying bacterial effectors, or effector combinations, which are responsible for specific phenotypes, is challenging.", [["bacterial effectors", "PROTEIN", 12, 31], ["bacterial effectors", "PROBLEM", 12, 31], ["bacterial effectors", "OBSERVATION", 12, 31]]], ["In line with this, recently, Parkinson's disease (PD) patients are found to have altered gut microbiota composition [106, 107] .", [["gut", "ANATOMY", 89, 92], ["Parkinson's disease", "DISEASE", 29, 48], ["PD", "DISEASE", 50, 52], ["Parkinson's disease", "CANCER", 29, 48], ["patients", "ORGANISM", 54, 62], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 89, 103], ["patients", "SPECIES", 54, 62], ["Parkinson's disease", "PROBLEM", 29, 48], ["altered gut microbiota composition", "PROBLEM", 81, 115]]], ["Transplanted microbiota from PD patients, but not from healthy controls, induce motor dysfunction and trigger PD in mice.", [["PD", "DISEASE", 29, 31], ["motor dysfunction", "DISEASE", 80, 97], ["PD", "DISEASE", 110, 112], ["patients", "ORGANISM", 32, 40], ["mice", "ORGANISM", 116, 120], ["patients", "SPECIES", 32, 40], ["mice", "SPECIES", 116, 120], ["mice", "SPECIES", 116, 120], ["motor dysfunction", "PROBLEM", 80, 97], ["motor dysfunction", "OBSERVATION", 80, 97]]], ["It is not clear however whether dysbiosis triggers PD or it arises as a consequence of the disease [103] .ConclusionsThe role of microbiota in host health and disease might be even more complex than thought: Commensals once being benign can convert to disease-causing pathogens; different compositions of microbial communities trigger different phenotypes; more than one host pathway is targeted by more than one effector; the same microbial effector/antigen is sensed by several pattern recognition receptors (back-up mechanism, compensatory microbial sensing [4] ) and genetic variation in hosts results in different responses (i.e. some commensals transition to pathogen only in \"susceptible\" individuals).", [["communities", "ANATOMY", 315, 326], ["dysbiosis", "DISEASE", 32, 41], ["PD", "DISEASE", 51, 53], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 480, 509], ["microbial effector", "PROTEIN", 432, 450], ["pattern recognition receptors", "PROTEIN", 480, 509], ["dysbiosis triggers PD", "PROBLEM", 32, 53], ["the disease", "PROBLEM", 87, 98], ["disease", "PROBLEM", 159, 166], ["disease", "PROBLEM", 252, 259], ["pathogens", "PROBLEM", 268, 277], ["different phenotypes", "PROBLEM", 335, 355], ["compensatory microbial sensing", "PROBLEM", 530, 560], ["genetic variation in hosts", "PROBLEM", 571, 597], ["pathogen", "PROBLEM", 665, 673], ["not", "UNCERTAINTY", 6, 9], ["clear", "OBSERVATION", 10, 15]]]], "4771213f28390566698deebf717cdc2259140903": [["To the Editor-Italy has been hard hit by coronavirus disease 2019 , mostly in the northern regions, 1 while the Lazio region was partially spared.", [["coronavirus disease", "DISEASE", 41, 60], ["coronavirus disease", "PROBLEM", 41, 60], ["coronavirus disease", "OBSERVATION", 41, 60], ["spared", "OBSERVATION", 139, 145]]], ["Although no evidence thus far has shown vertical transmission, 2, 3 neonatologists are concerned about preventing the spread of infection-related disease (COVID-19) in infants and healthcare workers (HCWs) of neonatal intensive care units (NICUs).", [["infection", "DISEASE", 128, 137], ["COVID-19", "CHEMICAL", 155, 163], ["infants", "ORGANISM", 168, 175], ["infants", "SPECIES", 168, 175], ["infection", "PROBLEM", 128, 137], ["disease", "PROBLEM", 146, 153], ["no evidence", "UNCERTAINTY", 9, 20], ["vertical", "OBSERVATION_MODIFIER", 40, 48], ["infection", "OBSERVATION", 128, 137]]], ["4 Here, we report our NICU's reorganization during the COVID-19 pandemic.MethodsThis observational study focused on infants admitted to our tertiary-care-level NICU during the COVID-19 outbreak in Italy from March 15 to May 15, 2020.", [["infants", "ORGANISM", 116, 123], ["infants", "SPECIES", 116, 123], ["the COVID", "TEST", 51, 60], ["pandemic", "PROBLEM", 64, 72], ["observational study", "TEST", 85, 104]]], ["Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) was ruled out by nasopharyngeal swab in all infants before NICU admission.", [["nasopharyngeal swab", "ANATOMY", 75, 94], ["acute respiratory coronavirus virus 2", "ORGANISM", 7, 44], ["SARS-CoV-2", "ORGANISM", 46, 56], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 75, 94], ["infants", "ORGANISM", 102, 109], ["respiratory coronavirus virus", "SPECIES", 13, 42], ["infants", "SPECIES", 102, 109], ["Severe acute respiratory coronavirus virus", "SPECIES", 0, 42], ["SARS-CoV-2", "SPECIES", 46, 56], ["Severe acute respiratory coronavirus virus", "PROBLEM", 0, 42], ["SARS-CoV", "TEST", 46, 54], ["nasopharyngeal swab", "TEST", 75, 94], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory coronavirus virus", "OBSERVATION", 13, 42], ["nasopharyngeal", "ANATOMY", 75, 89], ["swab", "OBSERVATION", 90, 94]]], ["Detection of SARS-CoV-2 was performed using the Allplex 2019-nCoV assay (Seegene, Seoul, South Korea) as previously described.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 13, 23], ["SARS-CoV", "SPECIES", 13, 21], ["SARS-CoV", "TEST", 13, 21]]], ["5 Nasopharyngeal swabbing was performed at referring center in stable neonates.", [["Nasopharyngeal", "ANATOMY", 2, 16], ["neonates", "ORGANISM", 70, 78], ["Nasopharyngeal swabbing", "TEST", 2, 25], ["Nasopharyngeal", "ANATOMY", 2, 16], ["stable", "OBSERVATION_MODIFIER", 63, 69]]], ["SARS-CoV-2-positive neonates were managed in a dedicated pediatric COVID-19 unit.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["neonates", "ORGANISM", 20, 28], ["COVID-19 unit", "DNA", 67, 80], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["positive neonates", "PROBLEM", 11, 28]]], ["If the swab test was negative, the newborn was referred to our non-COVID-19 NICU as usual by neonatal emergency transport service (NETS) staff.", [["swab", "ANATOMY", 7, 11], ["the swab test", "TEST", 3, 16]]], ["For untested babies, accurate telephone contacts between spoke and hub centers were crucial to assuring the safest pathway for admission.", [["babies", "ORGANISM", 13, 19]]], ["Newborns were managed by HCWs wearing surgical masks (when COVID-19 was not suspected and/or mothers were negative within 24 hours of life) or N95 masks (in case of suspected or confirmed SARS-CoV-2-positive newborns), gloves, eye protection, and gowns.", [["eye", "ANATOMY", 227, 230], ["SARS", "DISEASE", 188, 192], ["Newborns", "ORGANISM", 0, 8], ["newborns", "ORGANISM", 208, 216], ["eye", "ORGAN", 227, 230], ["Newborns", "SPECIES", 0, 8], ["surgical masks", "TREATMENT", 38, 52], ["N95 masks", "TREATMENT", 143, 152], ["SARS", "TEST", 188, 192], ["CoV", "TEST", 193, 196], ["gloves", "TREATMENT", 219, 225], ["eye", "ANATOMY", 227, 230], ["gowns", "OBSERVATION", 247, 252]]], ["Upon arrival at our hospital, newborns were isolated and temporarily managed by an NETS dedicated neonatologist and nurse in a separate pavilion.", [["newborns", "ORGANISM", 30, 38]]], ["The staff were equipped with personal protective equipment until the negative result of the nasopharyngeal swab for SARS-CoV-2 arrived.", [["nasopharyngeal swab", "ANATOMY", 92, 111], ["SARS", "DISEASE", 116, 120], ["nasopharyngeal swab", "ORGAN", 92, 111], ["SARS-CoV", "SPECIES", 116, 124], ["personal protective equipment", "TREATMENT", 29, 58], ["the nasopharyngeal swab", "TEST", 88, 111], ["SARS", "PROBLEM", 116, 120], ["nasopharyngeal", "ANATOMY", 92, 106]]], ["Thereafter, the neonate could be hospitalized in our NICU in a room with other infants.MethodsInfants admitted to the emergency department (ED) were tested for SARS-CoV-2 on arrival and remained there until the negative result was available prior to NICU admission.MethodsIn the NICU, disposable surgical masks were always required for HCWs; body temperature was measured every day for all HCWs.", [["body", "ANATOMY", 342, 346], ["neonate", "ORGANISM", 16, 23], ["infants", "ORGANISM", 79, 86], ["body", "ORGANISM_SUBDIVISION", 342, 346], ["infants", "SPECIES", 79, 86], ["SARS-CoV", "SPECIES", 160, 168], ["SARS", "PROBLEM", 160, 164], ["CoV", "TEST", 165, 168], ["disposable surgical masks", "TREATMENT", 285, 310], ["body temperature", "TEST", 342, 358]]], ["Parental visits are still restricted to 6 hours each day, and only 1 parent is allowed for each baby, after signing a selfcertification regarding fever, symptoms, and contacts.", [["fever", "DISEASE", 146, 151], ["fever", "PROBLEM", 146, 151], ["symptoms", "PROBLEM", 153, 161]]], ["All parents are required to wear masks, gloves, and disposable clothing.", [["masks", "TREATMENT", 33, 38], ["gloves", "TREATMENT", 40, 46]]], ["If they have fever or respiratory symptoms the visit to the baby is forbidden, as reported in Veneto.", [["respiratory", "ANATOMY", 22, 33], ["fever", "DISEASE", 13, 18], ["respiratory symptoms", "DISEASE", 22, 42], ["fever", "PROBLEM", 13, 18], ["respiratory symptoms", "PROBLEM", 22, 42]]], ["As nasopharyngeal swab was requested by the health directorate of our institution, and no approval from our institution's ethical committee was required for this study.ResultsDuring the study period, 101 newborns required NICU admission; of these, 71 newborns were referred from other institutions and 30 infants who were firstly discharged from other institutions and then required rehospitalization were admitted from the ED ( Table 1) .ResultsNo newborns referred from other institutions tested positive for SARS-CoV-2.ResultsAmong infants admitted from the ED, only 1 neonate (3.3% of infants admitted from the ED), who required hospitalization because of urinary tract infection, tested positive via nasopharyngeal swab test for SARS-CoV-2.", [["nasopharyngeal swab", "ANATOMY", 3, 22], ["urinary tract", "ANATOMY", 660, 673], ["nasopharyngeal swab", "ANATOMY", 705, 724], ["SARS", "DISEASE", 511, 515], ["urinary tract infection", "DISEASE", 660, 683], ["SARS", "DISEASE", 734, 738], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 3, 22], ["newborns", "ORGANISM", 204, 212], ["newborns", "ORGANISM", 251, 259], ["infants", "ORGANISM", 305, 312], ["newborns", "ORGANISM", 449, 457], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 511, 521], ["infants", "ORGANISM", 535, 542], ["infants", "ORGANISM", 589, 596], ["urinary tract", "ORGANISM_SUBDIVISION", 660, 673], ["infants", "SPECIES", 305, 312], ["infants", "SPECIES", 535, 542], ["infants", "SPECIES", 589, 596], ["SARS-CoV", "SPECIES", 511, 519], ["SARS-CoV", "SPECIES", 734, 742], ["nasopharyngeal swab", "TEST", 3, 22], ["this study", "TEST", 157, 167], ["SARS", "PROBLEM", 511, 515], ["CoV", "TEST", 516, 519], ["urinary tract infection", "PROBLEM", 660, 683], ["nasopharyngeal swab test", "TEST", 705, 729], ["SARS", "PROBLEM", 734, 738], ["CoV", "TEST", 739, 742], ["urinary tract", "ANATOMY", 660, 673], ["infection", "OBSERVATION", 674, 683]]], ["Considering his stable conditions, the infant was hospitalized in the dedicated pediatric COVID-19 unit and not in NICU; a neonatologist gave requested advices for the appropriate management.", [["infant", "ORGANISM", 39, 45], ["infant", "SPECIES", 39, 45], ["the appropriate management", "TREATMENT", 164, 190], ["stable", "OBSERVATION_MODIFIER", 16, 22]]], ["No COVID-19 cases wereDiscussionOne of the lessons learned from the COVID-19 pandemic in Italy is that hospital overcrowding was a serious mistake that led hospitals to become the first places to spread the infection.", [["infection", "DISEASE", 207, 216], ["COVID", "TEST", 3, 8], ["the infection", "PROBLEM", 203, 216], ["infection", "OBSERVATION", 207, 216]]], ["1 Although concern about COVID-19 severity is less in children, 7 the amount of SARS-CoV-2 viral material that could be potentially harmful in neonates remains unknown, especially in preterm infants.", [["SARS", "DISEASE", 80, 84], ["COVID-19", "GENE_OR_GENE_PRODUCT", 25, 33], ["children", "ORGANISM", 54, 62], ["SARS-CoV-2", "ORGANISM", 80, 90], ["neonates", "ORGANISM", 143, 151], ["infants", "ORGANISM", 191, 198], ["children", "SPECIES", 54, 62], ["infants", "SPECIES", 191, 198], ["COVID", "TEST", 25, 30], ["SARS", "PROBLEM", 80, 84], ["CoV-2 viral material", "PROBLEM", 85, 105], ["harmful in neonates", "PROBLEM", 132, 151]]], ["2 Therefore, strict preventive measures should be adopted in all NICUs.", [["strict preventive measures", "TREATMENT", 13, 39]]], ["The relative ease of horizontal transmission, even within a controlled NICU, has been highlighted.", [["ease", "OBSERVATION_MODIFIER", 13, 17], ["horizontal", "OBSERVATION_MODIFIER", 21, 31]]], ["8 Our NICU is a referral care center for severely ill neonates, with a delivery room only for highly selected patients.", [["neonates", "ORGANISM", 54, 62], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["severely ill neonates", "PROBLEM", 41, 62]]], ["Therefore, almost all babies are referred from Rome and Lazio, and other regions either as a planned or an emergency admission because of a variety of high-risk conditions: surgical emergencies, congenital heart defects, perinatal asphyxia, prematurity, genetic syndromes, infections, metabolic disorders, etc. NETS play a key role in minimizing the risk of contamination from one institution to another, 9 which is especially important in an outborn NICU such as ours.", [["heart", "ANATOMY", 206, 211], ["congenital heart defects", "DISEASE", 195, 219], ["perinatal asphyxia", "DISEASE", 221, 239], ["prematurity", "DISEASE", 241, 252], ["genetic syndromes", "DISEASE", 254, 271], ["infections", "DISEASE", 273, 283], ["metabolic disorders", "DISEASE", 285, 304], ["NETS", "CHEMICAL", 311, 315], ["babies", "ORGANISM", 22, 28], ["heart", "ORGAN", 206, 211], ["surgical emergencies", "TREATMENT", 173, 193], ["congenital heart defects", "PROBLEM", 195, 219], ["perinatal asphyxia", "PROBLEM", 221, 239], ["prematurity", "PROBLEM", 241, 252], ["genetic syndromes", "PROBLEM", 254, 271], ["infections", "PROBLEM", 273, 283], ["metabolic disorders", "PROBLEM", 285, 304], ["heart", "ANATOMY", 206, 211], ["defects", "OBSERVATION", 212, 219], ["perinatal asphyxia", "OBSERVATION", 221, 239], ["prematurity", "OBSERVATION", 241, 252], ["metabolic disorders", "OBSERVATION", 285, 304]]], ["However, none of the infants referred from other institutions tested positive for SARS-CoV-2 during the study period.", [["SARS", "DISEASE", 82, 86], ["infants", "ORGANISM", 21, 28], ["SARS-CoV-2", "ORGANISM", 82, 92], ["infants", "SPECIES", 21, 28], ["SARS-CoV", "SPECIES", 82, 90], ["SARS", "PROBLEM", 82, 86], ["CoV", "TEST", 87, 90], ["the study", "TEST", 100, 109]]], ["On the contrary, infants admitted from the ED, including the sole neonate who screened positive for SARS-CoV-2, had a higher age at admission and thus they had potentially been more exposed to the community.", [["SARS", "DISEASE", 100, 104], ["infants", "ORGANISM", 17, 24], ["neonate", "ORGANISM", 66, 73], ["infants", "SPECIES", 17, 24], ["SARS-CoV", "SPECIES", 100, 108], ["SARS", "PROBLEM", 100, 104]]], ["Differences between the 2 groups were not calculated because of the small sample size and a sole neonate who tested positive.", [["neonate", "ORGANISM", 97, 104], ["the small sample size", "PROBLEM", 64, 85], ["small", "OBSERVATION_MODIFIER", 68, 73], ["size", "OBSERVATION_MODIFIER", 81, 85]]], ["The main limitation of our study was the single center site in a medium-risk region, and 70% of these cases were registered in northern Italy.", [["our study", "TEST", 23, 32], ["main", "OBSERVATION_MODIFIER", 4, 8], ["limitation", "OBSERVATION_MODIFIER", 9, 19]]], ["However, the procedures outlined here allowed us to ensure continuity of care in the NICU, with limited risks of infection for newborns and HCWs.", [["infection", "DISEASE", 113, 122], ["newborns", "ORGANISM", 127, 135], ["infection", "PROBLEM", 113, 122], ["infection", "OBSERVATION", 113, 122]]], ["Although no newborns screened positive among NICU patients in the higher-risk Veneto region, 6 by testing all newborns before admission, we could have separated a positive neonate from other fragile infants, avoiding life-threatening risks for them and the incalculable costs of spreading the virus to the unit.", [["newborns", "ORGANISM", 12, 20], ["patients", "ORGANISM", 50, 58], ["newborns", "ORGANISM", 110, 118], ["infants", "ORGANISM", 199, 206], ["patients", "SPECIES", 50, 58], ["infants", "SPECIES", 199, 206], ["a positive neonate", "PROBLEM", 161, 179], ["no", "UNCERTAINTY", 9, 11]]], ["The fight against the COVID-19 pandemic should not affect the quality of the assistance to high-risk infants.", [["infants", "ORGANISM", 101, 108], ["infants", "SPECIES", 101, 108]]], ["Therefore, we conclude that all newborns should be tested for SARS-CoV-2 before being admitted to NICUs, especially if admitted from an ED.", [["SARS", "DISEASE", 62, 66], ["newborns", "ORGANISM", 32, 40], ["SARS-CoV-2", "ORGANISM", 62, 72], ["SARS-CoV", "SPECIES", 62, 70], ["SARS", "PROBLEM", 62, 66]]]]}